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Abstract 
 
Resorcin[4]arenes and their rigid structures “cavitands” offer a unique molecular structure 
scaffolds suitable for attaching and orienting multi-ligands on their upper rims. Their remarkable 
structure properties, the relative ease of chemical modification on their either rims or through the 
multiple phenolic hydroxyl (-OH) groups, manipulating their cavity size and the role of spatial 
directionality provided by their cores, led synthetic chemist to explore their utilities in the synthesis 
of valuable resorcin[4]arene/cavitand assemblies with wide range of applications in many research 
areas such as supramolecular chemistry, host-guest chemistry, glycoconjugates, polymer 
chemistry, host-guest chemistry, micro-reactors in chemical catalysis and others. In particular, in 
the field of glycoconjugates, the synthesis of multi-directional glycoresorcin[4]arenes have found 
valuable uses in glycobiology, i.e. lectins and cells recognitions. Recently, the spatial directionality 
of β-D-glucopyranoside based on the resorcin[4]arene rigid structure “cavitand” was first 
described by our group in the synthesis of resorcin[4]arene cavitand glycoconjugates (RCGs). The 
efficacy of RCGs was established as phase catalysts in order to evaluate their abilities catalyzing 
different organic transformations in aqueous environment as a green approach in organic 
syntheses. RCGs showed a variety of advantages such as low catalytic loading and faster 
conversions for water-insoluble hydrophobic substrates in aqueous media. 
This dissertation consists of four chapters. Chapter 1 describes the design and the synthesis 
of a family of spatially directional resorcin[4]arene cavitand glycoconjugates (RCGs) by coupling 
β-D-glucopyranose moieties on the resorcin[4]arene cavitand upper rims via multiple 1,4-
xviii 
 
disubstituted 1,2,3-triazolethe linkages achieved from the well-known click reaction, the Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC). The multiple directional β-D-glucopyranoside 
units on the cavitand cores are capable of multiple H-bond interactions resulting in a significant 
molecular host system, i.e. “pseudo-saccharide cavity” capable of accommodating different guest 
molecules, especially hydrophobic organic species, in aqueous environment raising the advantages 
of these amphiphilies for appreciable applications as molecular vessels and micro-reactors in an 
ideal atmosphere “water”. 
In Chapter 2, the utility of RCGs as efficient phase transfer catalysts for thiocyanation and 
thiazole formation in water is described. The catalytic activity (1 mol% loading) of RCGs 
enhancing the formation of both thiocyanate and thioazole species in aqueous media is a direct 
evidence of their capability acting as micro-reactors in water. Also, the recoverability and the 
reusability of RCGs for thiocyanation and thizaole formation have been examined. Additionally, 
the influence of the flexibility/rigidity and the orientation of the multiple β-D-glucopyranose 
moieties on the RCGs’ catalytic efficciency in thiocyanation and thiazole formation has been 
investigated. 
In Chapter 3, the design and the synthesis of an octopus-like structure resorcin[4]arene 
glycoconjugate (RG) is described. RG consists of eight β-D-glucopyranoside units attached to a 
flexible open system resorcin[4]arene core. The flexibility of the resorcin[4]arene assembly and 
the presence of the multiple β-D-glucopyranosides provides a wider-type of pseudo-saccharide 
bucket capable of encapsulating larger molecules in aqueous environment. RG was evaluated for 
catalyzing the CuAAC in water without the use of any added organic solvent. RG was remarkably 
efficient in catalyzing the CuAAC reactions in aqueous atmosphere for a variety of small/bulky 
and hydrophilic/hydrophobic azido and alkyne substrates. 
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In Chapter 4, the construction of resorcin[4]arene cavitand based-carcerands (RCCs) via 
tandem CuAAC reactions is described. The CuAAC reaction was utilized as an efficient coupling 
method for the complimentary azido- and alkyne-cavitand halves via multiple 1,4-disubstituted 
1,2,3-triazole linkers. Unlike the most reports of covalently linked carcerand synthesis, which are 
accomplished at very dilute concentration, the fast kinetics of the CuAAC reaction enabled 
carcerand synthesis at much higher concentration and in high yield. 
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Chapter 1 
Design and the Synthesis of Spatially Directional Resorcin[4]arene Cavitand 
Glycoconjugates (RCGs) 
 
1.1. Resorcin[4]arenes 
Resorcin[4]arenes1 (Figure 1.1) are attractive macrocyclic tetramer that consist of four 
resorcinol units providing a high π-electron rich cavity systems with multiple phenolic hydroxyl 
(-OH) groups on their upper rims and hydrophobic lower regions. 
 
Figure 1.1. General structure of resorcin[4]arenes in 3D and top view. 
 
The construction of the first resorcin[4]arene was achieved from the seminal work done by 
Adolf Von Baeyer2 in 1872 upon the reaction of an ethanolic solution of resorcinol with 
benzaldehyde in the presence of concentrated sulfuric acid. Baeyer observed that the solution color 
changed from light yellow to dark red with a precipitated compound obtained from the reaction 
mixture (Scheme 1.1). 
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Scheme 1.1. Synthesis of the first resorcin[4]arene by Adolf Von Baeyer. 
 
In 1883, Michael determined that the solid precipitate was formed from an equal number 
of resorcinol and benzaldehyde with the loss of water molecules.3 Consequently, Vogel and 
Niederl4 in 1940, proposed the correct structure of the crystalline product reported by Baeyer by 
synthesizing the same cyclic oligomer and its acetylated version and upon the data gained by the 
molecular weight determination, the ratio between the resorcinol and benzaldehyde was 
established to be 4:4 with the loss of four water molecules in the synthesis of a single octa-hydroxy 
resorcin[4]arene. In 1968, the structure of resorcin[4]arene was confirmed by Erdtman and 
coworkers using x-ray diffraction method.5  Accordingly, resorcin[4]arenes now can be readily 
achieved in gram quantities via the acid-catalyzed cyclocondensation reaction of resorcinol or 2-
methyl resorcinol with various of aliphatic or aromatic aldehydes (Scheme 1.2). 
 
Scheme 1.2. Synthesis of octa-hydroxy resorcin[4]arene. 
 
Resorcin[4]arenes are known to have five different conformational structures, namely; 
crown (C4v, rccc), boat (C2v, rccc), chair (C2h, rcctt), saddle (D2d, rtct) and diamond (Cs, rcct) 
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(Figure 1.2). The first four isomeric structures were introduced by Hogberg,6 while the fifth 
conformer, the diamond (Cs, rcct), was observed by Abis et. al.
7 However, it was found that only 
the crown (C4v) and chair (C2h) conformations can be formed as major products in the formation 
of resorcin[4]arenes.5,6 The conformational preference is dependent upon the sterics of the 
substituent on the resorcin[4]arene lower rim, for example, if the substituents on the lower rim are 
small such as hydrogens or short/long linear aliphatic alkane chains, the thermodynamically stable 
crown (C4v) conformation is preferred. On the other hand, if the substituents on the lower rim are 
bulky, i.e. benzene or substituted benzene, the product would be in the chair (C2h) conformer. 
 
Figure 1.2. Resorcin[4]arene conformational structures. 
 
The conformational changes can be determined using NMR analysis or from the crystal 
structure obtained using x-ray diffraction methodology. In the 1H-NMR spectrum, for example 
(Figure 1.3), two different resorcin[4]arene conformations, i.e. the crown (C4v) and the chair (C2h) 
conformers are observed. From their backbone structures, the resorcinol units in the crown (C4v) 
structure are oriented at the same direction, thus, all protons within the resorcinol units, i.e. 
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benzylic (Ha), phenolic (Hc) and the aromatic (Hd) are equivalent and show one set of singlets in 
their 1H-NMR spectrum. On the other hand, in the chair (C2h) conformer, the protons (Ha, Hc & 
Hd) are no longer equivalent due to its asymmetric structure and two sets of singlets are observed 
in their 1H-NMR spectrum. 
 
 
Figure 1.3. Resorcin[4]arene in the (a) crown (C4v) and (b) chair (C2h) conformations. 
 
Moreover, resorcin[4]arenes, especially in their crown (C4v) conformation, are known to 
form a stable cone-shape structure stabilized by the multiple intramolecular H-bonding interactions 
between the adjacent phenolic (-OH) groups on the resorcinol aromatic rings. The resulting well-
defined molecular cavities are recognized as host-guest systems that are capable of encapsulating 
ionic and neutral guest molecules (Figure 1.4).8,9 In basic environment, half of the phenols (-OHs) 
are deprotonated and the obtained bowl-shaped assembly has a high affinity for alkylammonium 
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cations and other guest ions.8 Also, in their neutral forms, they have the ability to bind polar organic 
substrates such as D-ribose, dicarboxylic acids and other guests through H-bond interactions.9 
 
Figure 1.4. Resorcin[4]arenes as host-guest molecules. 
 
In the field of supramolecular chemistry, resorcin[4]arenes are known to form self-
assemble supramolecular structures through their phenolic groups (-OHs) via donor/acceptor 
hydrogen bonding with water molecules.10-12 In 1985, Donald Cram reported the synthesis of the 
first resorcin[4]arene based-dimeric capsule by joining two resorcin[4]arene subunits through their 
upper rims via non-covalent bridges.10 In 1992, Aoyama and coworkers described the formation 
of resorcin[4]arene cage complexes with methyl and octyl β-glucopyranoside moieties.11 Also, 
dimeric complexes in the presence of cationic species have been reported (Figure 1.5).12 
 
Figure 1.5. Self-assemble H-bonding resorcin[4]arenes dimer. 
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As well, they are capable of forming self-assembled hydrogen bonded dimers in the 
presence of appropriate H-bond acceptor organic bridges such as terpyridine, 4,4’-bipyridine and 
2-aminopyridine.13 In addition, MacGillivray and Atwood, described the formation of an 
impressive supramolecular hexamer consisting of six resorcin[4]arene subunits held together by 
eight water molecules through sixty H-bonds. The resulted hexameric assembly had a spherical-
shape with an internal volume of approximate 1375 Å3 (Figure 1.6).14 
 
Figure 1.6. Self-assemble H-bonding resorcin[4]arene (a) dimer and (b) hexamer. 
 
1.2. Cavitands 
Resorcin[4]arenes are used as starting materials in the synthesis of cavitands generated by 
covalently linking the adjacent phenolic hydroxyls (-OHs) on the corresponding resorcin[4]arenes. 
Cavitands (Figure 1.7) were originally defined by Donald Cram as “synthetic organic compounds 
with enforced cavities large enough to complex complementary organic compounds and ions”.15 
Their distinct cavities can be manipulated by varying the size of the linkers between the 
neighboring hydroxyl (-OH) groups. Hence, many cavitands have been reported in literature by 
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locking the resorcin[4]arene system with different covalent bridges including methylene, ethylene, 
propylene, di-alkylsilicon, phosphoryl, phosphonate, quinoxaline, ethylenedioxy, etc.16-22 
 
Figure 1.7. General structure of resorcin[4]arene cavitands. 
 
Cavitands have been recognized as fruitful platform for attaching different interesting 
molecules. More importantly, the spatial directionality provided by their rigid cores gives these 
molecular assemblies the advantage as preferred scaffolds for directing and orienting multi-ligands 
on their upper rims.23 The concept of spatial directionality was first established by Bisht and 
coworkers in 2009 in the synthesis of multi-arm poly-(ε-caprolactone) based on the 
resorcin[4]arene rigid structure “cavitand” (Scheme 1.3).24 It was found that the polymer based on 
the cavitand core had a higher thermal stability than their linear counterpart which was a direct 
evidence of the importance of the cavitand orienting and directing the poly-(ε-caprolactone) on its 
upper rim.24 
        
Scheme 1.3. Synthesis of multi-arm poly-(ε-caprolactone) resorcin[4]arene cavitand. 
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1.3. Cyclodextrins (CDs) 
Cyclodextrins25 (CDs) (Figure 1.8) which were first discovered by Villiers26 in 1891 are 
cyclic oligosaccharide composed of multiple glycopyranose units connected to each other in a 
cyclic-type of structure through the α-(1,4) linkage. They are produced from the enzymatic process 
of starch by cyclodextrin glycosyltransferase (CGTase).27 The most common and known 
cyclodextrins are the α, β and γ which consist of six, seven and eight α-(1,4)-linked glycosyl units, 
respectively (Figure 1.9).28 The structure of both α- and β-cyclodextrins were confirmed by x-ray 
crystallography in 1942,29 while the γ-cyclodextrin structure was established later in 1948.30  
 
Figure 1.8. General structure of cyclodextrins (CDs). 
 
 
Figure 1.9. General structures of α-, β- and ϒ-cyclodextrin analogs. 
β α γ 
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The structure of cyclodextrins is composed of two hydrophilic outer rims in the primary 
and the secondary phases and a hydrophobic inside cavity. Their substantial interior cavities are 
known to host a variety of hydrophobic guests in aqueous media.31 They are well-known to 
catalyze organic transformations with enzymes-like specificity and have been widely applied as 
phase transfer catalysts in aqueous environment (Figure 1.10).32 
 
Figure 1.10. Cyclodextrins as phase transfer catalysts. 
 
1.4. Resorcin[4]arene/cavitand glycoconjugates 
The syntheses of multi-valent glycoconjugates have received a great interest in the field of 
glycobiology due to their notable activities in the formation of multi-interactions for cell–cell, cell 
adhesion and cell–virus recognition which are otherwise weak when considered independently.33 
Thus, various synthetic mimics have been prepared and studied for biomolecular targets such as 
lectins.34 The use of glycoconjugates firmly anchored to a calix- or resorcin[4]arene due to their 
significant molecular structures that can undergo into multiple-glycosylation processes in one-step 
chemical reaction for the synthesis of multi-directional saccharides.35-38 Many synthesized 
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glycocalix[4]arenes have been reported in literature,35 while examples of glycoresorcin[4]arenes 
are limited.36,37 From 1997 to 2006, numbers of octa-(mono-, tri-, tetra, penta-, hexa- and hepta)-
saccharide coupled on the resorcin[4]arene skeleton via amide linker have been exclusively 
reported by Prof. Aoyama and coworkers in Japan (Figure 1.11).36 
 
Figure 1.11. Octa-valent resorcin[4]arene glycoconjugate. 
 
In 2011, Matthews and coworkers have reported the synthesis of two tetra-valent 
resorcin[4]arene clusters in both boat (C2v) and chair (C2h) conformations using the Cu(I)-catalyzed 
azide-alkyne cycloaddition (CuAAC)39 methodology by coupling azido-galactose and azido-
lactose moieites on propargyl functionalized resorcin[4]arene backbones (Figure 1.12).37 These 
type of glycoresorcin[4]arenes were found to have an exclusively recognition of lectins and cells. 
 
Figure 1.12. Tetra-valent resorcin[4]arene clusters. 
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Recently, in 2016, the concept of spatial directionality of multi-directional β-D-
glucopyranoside units based on the rigid structure of resorcin[4]arene “cavitand” was reported by 
our group in the synthesis of resorcin[4]arene cavitand glycoconjugates (RCGs).38 The advantages 
of these glycocavitands have been established as phase transfer catalysts in order to evaluate their 
ability catalyzing different organic reactions in aqueous media, namely; thiocyanation, thiazole 
formation, the CuAAC and Mannich-type reaction (Figure 1.13).38 
 
Figure 1.13. Organic reactions catalyzed by RCGs. 
 
Present work 
Herein, I would like to describe in detail the design and the synthesis of resorcin[4]arene 
cavitand glycoconjugates (RCGs) using the CuAAC methodology. RCG structures consist of four 
β-D-glucopyranosyl units constructed on the aromatic C-2 position on the resorcin[4]arene 
cavitand upper rim via multiple 1,4-disubstituted 1,2,3-triazole linkages achieved from the well-
known click reaction, the CuAAC. The spatial directionality provided by the resorcin[4]arene 
cavitand cores results in pseudo-β-D-glucopyranoside cavities that provide suitable host-guest 
environments capable of accommodating different hydrophobic organic species in aqueous 
environment, enabling the advantages of these amphiphilies for appreciable applications as 
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molecular vessels and micro-reactors in an ideal green atmosphere “water”. The presence of a rigid 
directional cavitand core and placement of polar β-D-glucopyranose moieties, which are capable 
of multiple hydrogen bonds formation bear a close resemblance to well-known class of molecular 
hosts, the cyclodextrins (CDs) (Figure 1.14). 
 
Figure 1.14. General structures of RCGs and cyclodextrins (CDs). 
 
1.5. Design and the synthesis of RCGs 
1.5.1. The design strategy of RCGs 
Conformationally rigid, bowl-shaped resorcin[4]arene cavitands provide a robust cavity 
bearing framework upon which covalent modifications on the upper rims can be achieved without 
compromising the structural integrity of the inner cavity. Therefore, they offer an ideal core 
platform for interrogation of the effect of spatial directionality of the multi-valent glycoconjugates. 
For evaluating the role of spatial directionality of the cavitand core and the resulting pseudo-
saccharide cavity, five RCG models were synthesized (Figure 1.15). RCG1-3 consist of four β-
D-glucose moieties differed in the length of flexible aliphatic β-D-glucose linkers, while RCG4 
had a rigid aromatic linker that places the β-D-glucose units further away from the cavitand core. 
On the other hand, the β-D-glucose in RCG5 are oriented sideway from the cavitand backbone. 
RCG5 was designed as a control in order to investigate the influence of the glycoside moiety on 
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the formation of the pseudo-β-D-glucopyranoside cavity system. The placement of the multiple β-
D-glucopyranose units on the upper rim of the cavitand core facilitates extensive intramolecular 
hydrogen bonding and lead to a pseudo-saccharide cavity, a binding pocket, capable of substrate 
inclusion and catalysis. 
 
Figure 1.15. Pseudo-saccharide cavity provided by the resorcin[4]arene cavitand core. 
 
Also designed, as a control, was compound X which lacks the rigid spatially directionality 
of the cavitand core but is rather based on a non-directional pentaerythritol backbone which does 
not deliver any cavity system due to its flexible structure; as a result, no directionality control 
would be provided and no host-guest arrangement would exist (Figure 1.16). 
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Figure 1.16. The concept of the spatial directionality by RCGs and compound X. 
 
Since the crown (C4v) conformation provides spatial directionally and can be easily locked 
in a rigid form by bridging the adjacent phenolic (-OH) groups. Thus, the formation of RCGs was 
accomplished when first octa-hydroxy resorcin[4]arene 138 was synthesized. Resorcin[4]arene 1 
was obtained as a pale yellow solid in 80 % upon the condensation reaction of 2-methyl resorcinol 
with heptaldehyde in presence of diluted HCl (37 %) in refluxed ethanol (Scheme 1.4). 
 
Scheme 1.4. Synthesis of octa-hydroxy resorcin[4]arene 1. 
 
The crown conformation (C4v) of compound 1 was established from its 
1H-NMR spectrum 
(250 MHz, DMSO-d6), i.e. the presence of the benzylic (-CH3, Ha), the aromatic benzene 
(aromatic, Hd) and the phenolic (-OH, Hc) protons as one set of singlets at 1.99 ppm, 7.23 ppm 
and 8.69 ppm, respectively. Also, the aliphatic protons (-(CH2)4-, CH2’s) and the terminal aliphatic 
protons (-CH3-, CH3’s) were found in the region between 0.50-1.50 ppm, while the bridge protons 
(-CH-, Hb) were shown as a triplet (J = 7.3 Hz) at 4.24 ppm. In its 13C-NMR spectrum (62.5 MHz, 
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DMSO-d6), the benzylic carbons (-CH3, Ca) were found at 10.1 ppm and the benzene carbons 
(aromatic, Cd) were at 120.9 ppm (Figure 1.17). 
 
Figure 1.17. Full 1H- and 13C-NMR spectra of resorcin[4]arene 1. 
 
1.5.2. Synthesis of resorcin[4]arene cavitand intermediates 
Octa-hydroxy resorcin[4]arene 1 was then locked in the rigid form structure cavitand by 
bridging the adjacent phenols (-OHs) with methylene linker upon the reaction with 
dibromomethane in the existence of potassium carbonate in DMF at 70 0C to obtain cavitand 238 
in 89 % yield. Free-radical bromination on the benzylic C-2 position of cavitand 2 using NBS and 
AIBN in hot benzene (80 0C) afforded the tetra-bromo cavitand 338 in 93 % yield. For different 
saccharide arm length ligands, compound 3 was subjected to nucleophilic substitution reaction 
with sodium azide, propargyl alcohol, 2-azidoethanol, 4- and 2-azidophenol in the synthesis of 
cavitand intermediates 4-8, respectively. The short arm ligand cavitand 438 was achieved by 
treating compound 3 with NaN3 in DMF at room temperature (isolated yield, 98 %), while the 
flexible ligand tetra-alkyne 5 and tetra-azido 6 intermediates were obtained from the reaction of 
bromo-cavitand 3 with propargyl alcohol and 2-azidoethanol in the presence of NaH (60 %) in dry 
THF to obtain both cavitands 538 and 6 in 92 %. The bulkier phenyl ligand intermediate 738 (91 %) 
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and 8 (87 %) were achieved from the reaction of cavitand 3 with 4- and 2-azidophenol in the 
presence of potassium carbonate in refluxed acetone (Scheme 1.5). All compounds 2-8 were fully 
characterized from their respective NMR spectral data. 
 
Scheme 1.5. Synthesis of cavitand intermediates 4-8. 
 
In the 1H-NMR spectrum (250 MHz, CDCl3) of cavitand 2, the methylene bridge protons 
(-OCH2O-, Hc,c’) were observed as two set of doublets (J = 7.0 Hz) at 4.28 ppm and 5.90 ppm, 
respectively. In its 13C-NMR spectrum (62.5 MHz, CDCl3), the methylene carbons (-OCH2O-, Cc) 
were detected at 98.5 ppm (Figure 1.18). The presence of the methylene bridge protons (Hc & 
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Hc’) as two set of doublets can be explained by the rigidity of cavitand 2 structure in which Hc and 
Hc’ are in different chemical environment, i.e. the Hc protons are pointing toward the cavitand 
cavity and are shielded by the magnetic field of the aromatic system and hence appear upfield, 
while the Hc’ protons are pointing outside the and appear downfield in the 1H-NMR spectrum. 
 
 
Figure 1.18. Full 1H- and 13C-NMR spectra of cavitand 2. 
 
In the 1H-NMR spectrum (250 MHz, CDCl3) of cavitand 3, it was observed the shift of the 
benzylic (-CH2Br, Ha) downfield from 1.98 ppm to 4.42 ppm. Also, the benzylic carbons (-CH2Br, 
Ca) were shifted downfield from 10.1 ppm to 23.2 ppm in its 13C-NMR spectrum (62.5 MHz, 
CDCl3) (Figure 1.19). 
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Figure 1.19. Full 1H- and 13C-NMR spectra of tetra-bromo cavitand 3. 
 
In the 1H-NMR spectrum (250 MHz, CDCl3) and 
13C-NMR spectrum (62.5 MHz, CDCl3) 
of tetra-azido intermediate 4, the benzylic protons (-CH2N3, Ha) were slightly shifted upfield from 
4.42 ppm to 4.34 ppm, while the benzylic carbons (-CH2N3, Ca) were at 44.9 ppm (Figure 1.20). 
 
Figure 1.20. Partial 1H- and 13C-NMR spectra of tetra-azido cavitand 4. 
 
In the 1H-NMR spectrum (250 MHz, CDCl3) of cavitnad 5 the benzylic protons (-
CH2OCH2CCH, Ha) were at 4.45 ppm and the terminal alkyne protons (-CCH, Hf) showed as a 
triplet at 2.45 ppm (J = 2.2 Hz), while the methyleneoxy protons (-CH2OCH2CCH, He) were a 
doublet at 4.13 ppm (J = 2.4 Hz). In its 13C-NMR spectrum (62.5 MHz, CDCl3), the alkyne carbons 
19 
 
Cf and Cg were at 74.4 and 80.0 ppm, respectively, while the propargyl methylene carbons (-
CH2OCH2CCH, Ce) were at 57.7 ppm (Figure 1.21). 
 
Figure 1.21. Partial 1H- and 13C-NMR spectra of tetra-alkyne cavitand 5. 
 
In the 1H-NMR spectrum (400 MHz, CDCl3)  and 
13C-NMR spectra (100 MHz, CDCl3) of 
cavitand 6, the presence of two triplets for the ethylene protons (-CH2OCH2CH2N3, Hi, δ 3.37 
ppm, J = 4.7 Hz & -CH2OCH2CH2N3, Hh and δ 3.61, J = 4.7 Hz, Hi) and the corresponding 13C 
resonances (δ 63.1, Ch and δ 50.5, Ci) confirmed its structure (Figure 1.22). 
 
Figure 1.22. Partial 1H- and 13C-NMR spectra of tetra-azido cavitand 6. 
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In the 1H-NMR spectra (400 MHz, CDCl3) of the bulky azido-ligand cavitnads (7 & 8), the 
benzyloxy protons (-CH2O-, Ha) were observed as a singlet at 4.88 ppm and 4.91 ppm in cavitand 
7 and 8, respectively. The aromatic benzene protons (Hj & Hk) in 7 were observed in the region 
of 6.87-6.94 ppm, while the benzene protons (Hj, Hk, Hl & Hm) in 8 were between 6.94-7.10 ppm. 
In their 13C-NMR spectra (100 MHz, CDCl3), the benzyloxy carbons (-CH2O-, Ca) were found at 
61.1 ppm in cavitand 7 and at 62.5 ppm in cavitand 8 (Figure 1.23). 
 
Figure 1.23. Partial 1H- and 13C-NMR spectra of (a) cavitand 7 and (b) cavitand 8. 
 
1.5.3. Synthesis of propargyl and azido β-D-glucopyranose moieties 
The Propynyl and azido-β-D-glucopyranoside monomers were prepared following the 
literature procedure.40,41 D-glucose was treated with acetic anhydride in the presence of sodium 
acetate at 80 0C to obtain as a mixture of α- and β- D-glucopyranoside-1,2,3,4,6-pentaacetate 940 
in 82 % yield with an approximate 1:9 anomeric ratio, as determined form the 1H-NMR spectrum. 
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Nucleophilic substitution on the anomeric position of compound 7 with propargyl alcohol and 2-
chloro ethanol in the presence of BF3 etherate in DCM afforded the (2-propargyl)- and the (2-
chloro)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside moieties 1040 (87 %) and 1141 (83 %), 
respectively. The chloro group in compound 11 was then replaced with an azido group via 
nucleophilic displacement with sodium azide in DMF at 80 0C resulted in the azido-glucose moiety 
1241 in high yield (96 %) (Scheme 1.6). 
 
Scheme 1.6. Synthesis of propargyl and azdio 𝛽-D-glucose moieties 10 and 12. 
 
Compounds 9-12 were characterized from their respective NMR spectra acquired in 
CDCl3. In the 
1H-NMR spectrum (250 MHz, CDCl3) of sugar 9 (Figure 1.24), the anomeric 
protons (-CHOCOCH3, β-H1 & α-H1’) were found as two doublets at 5.68 ppm (J = 8.1 Hz) and 
6.30 ppm (d, J = 3.6 Hz), respectively. In its 13C-NMR spectrum (62.5 MHz, CDCl3), the α- and 
the β-anomeric carbons (-CHOCOCH3, α-C1 & β-C1) were at 91.6 ppm and 99.9 ppm, 
respectively. 
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Figure 1.24. Full 1H- and 13C-NMR spectra of compound 9. 
 
In the 1H-NMR spectrum (250 MHz, CDCl3) of the propargyl monomer 10, the terminal 
alkyne proton (-C≡CH, H9) was a triplet at 2.47 ppm (J = 2.4 Hz), while the methyleneoxy protons 
(-OCH2C≡CH, H7) were found as a doublet at 4.34 ppm (J = 2.4 Hz). The resonance for the 
anomeric proton (-CHOCH2C≡CH, H1) was a doublet at 4.74 ppm (J = 7.9 Hz). In its 13C-NMR 
spectrum (62.5 MHz, CDCl3), the propargyl carbons C9 & C8 were at 75.5 and 78.0 ppm, 
respectively, while the propargyl methylene carbon (-CH2OCH2C≡CH, C7) was at 55.9 ppm 
(Figure 1.25a). Likewise, in the 1H-NMR spectrum (250 MHz, CDCl3) of the azido glucose 12, 
the methylene protons (-OCH2CH2N3, H8) were appeared as two set of multiplets at ~3.22-3.31 
and ~3.42-3.52 ppm and the methylenoxy protons (-OCH2CH2N3, H7) were a multiplet around 
~3.64-3.73 ppm, while the anomeric proton (-CHOCH2CH2N3, H1) was a doublet (J = 7.9 Hz) at 
4.56 ppm. From its 13C-NMR spectrum (62.5 MHz, CDCl3), the ethylenoxy carbons (C8 & C7) 
were at 50.4 and 68.5 ppm, respectively (Figure 1.25b). 
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Figure 1.25. Partial 1H- and 13C-NMR spectra of (a) 10 and (b) 12. 
 
1.5.4. Synthesis of resorcin[4]arene cavitands glycoconjugates (RCGs) 
Resorcin[4]arene cavitand intermediates (4-8) and the acetylated β-D-glucose moieties (10 
& 12) were then subjected to CuAAC for the synthesis of RCG1-5. Initially, the alkyne glucose 
10 was introduced on the upper rim of azido-cavitand intermediates (4, 6-8), while azido-glucose 
12 was coupled on the tetra-alkyne cavitand 5 core. All CuAAC reactions were performed in 
refluxed chloroform in the presence of CuI (10 mol%) and DIPEA (6.0 equiv.) to afford the 
acetylated RCGs (13-17) in quantitative yields (>90 %). The products were purified by column 
chromatography using (1:19) MeOH/DCM solvent mixture in order to separate the excess sugar 
reactants (10 or 12) from the products. Deacetylation on 13-17 was then accomplished using 
NaOMe solution (0.1 M) to obtain RCG1-5 in high yields (>90 %) (Scheme 1.7). 
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Scheme 1.7. Synthesis of resorcin[4]arene cavitand glycocnjugate RCGs. 
 
The structures of all compounds, i.e. 13-17 and RCGs were established from their 
respective 1H- and 13C-NMR data, for example, the absence of the alkyne resonances and the 
emergence of the triazole resonances, the shift of the benzylic protons (Ha) and the propargyl 
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methylenes (He), when compared to the compounds 4 and 5, respectively, were used to confirm 
the structures. In the 1H-NMR (500 MHz, CDCl3) of 13, the benzylic methylene protons (-CH2-N, 
Ha) were shifted downfield and appeared as two sets of doublets at 5.24 and 5.26 ppm (J = 13.7 
Hz) and the methyleneoxy protons (-OCH2-, H7) were also shifted downfield as a pair of doublets 
at 4.77 and 4.84 ppm (J = 12.7 Hz). The resonance, a singlet, at 7.52 ppm was attributed to the 
triazole proton (1H). The splitting of the benzylic and methylenexoy protons (Ha & H7) into pair 
of doublets was suggestive of the chemical shift non-equivalence of the geminal protons attributed 
to rigidity (restrictive rotation) of the molecule which places one of the protons inside (shielded) 
and another outside of the resorcin[4]arene cavity. In its 13C-NMR (125 MHz, CDCl3), the benzylic 
carbons (-CH2-N, Ca) were at 44.0 ppm, while the methyleneoxy carbons in the (-OCH2-, C7) 
showed at 62.7 ppm and the triazole carbons (C1H & C8) were at 123.3 and 143.8 ppm, respectively 
(Figure 1.26a). Correspondingly, in the 1H-NMR (500 MHz, CDCl3) of 14, it was observed the 
disappearance of the alkyne protons from 2.50 ppm in compound 5 (see Figure 1.21) and the 
presence of a new singlet for the triazole protons at 7.66 ppm. The benzylic protons (-CH2OCH2N, 
Ha) were shifted downfield from 4.45 to 4.54 ppm and the methyleneoxy protons (-CH2OCHC, 
He) were at 4.28 ppm. From its 13C-NMR (125 MHz, CDCl3), the benzylic carbons (-CH2OCH2N, 
Ca) were found at 63.5 ppm and the methyleneoxy protons (-CH2OCHC, Ce) were observed at 
67.5 ppm. The triazole carbons (C1H & Cg) were at 124.2 and 144.3 ppm, respectively (Figure 
1.26b). 
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Figure 1.26. Partial 1H- and 13C-NMR spectra of (a) 13 and (b) 14. 
 
In the 1H-NMR (500 MHz, DMSO-d6) of RCG1, the benzylic protons (-CH2-N, Ha) were 
appeared as a broad singlet at 5.31 ppm and the methyleneoxy protons (-OCH2-, H7) were a pair 
of doublets at 4.61 and 4.84 ppm (J = 12.1 Hz). The singlet at 8.08 ppm was attributed to the 
triazole protons (1H). From its 13C-NMR (125 MHz, DMSO-d6), the benzylic carbons (-CH2-N, 
Ca) were at 43.3 ppm and the triazole carbons (C1H & Cg) were at 124.9 and 143.5 ppm, 
respectively (Figure 1.27a). In the 1H-NMR (500 MHz, DMSO-d6) of RCG2, the benzylic protons 
(-CH2-N, Ha) were a singlet at 4.51 ppm. The methyleneoxy protons (-OCH2-, He) were a singlet 
at 4.23 ppm, while the triazole protons (1H) were at 8.20 ppm. In its 13C-NMR (125 MHz, DMSO-
d6), the methylene triazole carbons (-CH2CH2-N, C8) were found at 49.7 ppm, while the resonance, 
at 125.0 and 143.6 ppm were attributed to the triazole carbons C1H and Cg (Figure 1.27b). 
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Figure 1.27. Partial 1H- and 13C-NMR spectra of (a) RCG1 and (b) RCG2. 
 
1.5.5. Synthesis of compound X 
The model compound X was prepared when pentaerythritol was treated with propargyl 
bromide in the presence of potassium hydroxide as a strong base in DMF at 40 0C following the 
typical procedure found in literature.42 The resulted tetra-alkyne pentaerythritol 1842 was reacted 
with (2-azidoethyl)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 12 via the CuAAC to obtain 
compound 19 in gram quantity (90 %). Deacetylation of compound 19 using NaOMe (0.1 M) 
afforded compound X in 90 % yield (Scheme 1.8). 
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Scheme 1.8. Synthesis of compound X. 
 
Compounds 19 and X were characterized from their respective NMR spectra acquired in 
CDCl3 or DMSO-d6. From the 
1H-NMR (500 MHz, CDCl3) of compounds 19, the methyleneoxy 
protons (-CH2OCH2CCH, Hc) were at 4.51 ppm and the triazole protons (1H) were observed at 
7.56 ppm, while the triazole carbons (C1H & Ce) were found at 123.7 and 144.9 ppm, respectively 
in its 13C-NMR (125 MHz, CDCl3) spectrum (Figure 1.28). 
 
Figure 1.28. Partial 1H- and 13C-NMR spectra of compound 19. 
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In the 1H-NMR (500 MHz, DMSO-d6) of compound X, the methylene triazole protons (-
CH2CH2-N, H8) were found at 4.45 ppm. The methyleneoxy protons (-OCH2-, Hc) were appeared 
at 4.56 ppm and the triazole protons (1H) were found as a singlet at 8.09 ppm. In its 13C-NMR 
(125 MHz, DMSO-d6), the triazole carbons C1H and Cg were observed at 124.6 and 144.1 ppm, 
respectively (Figure 1.29). 
 
Figure 1.29. Partial 1H- and 13C-NMR spectra of compound X. 
 
1.6. Conclusions 
In conclusion, a series of azido/alkyne cavitand intermediates were synthesized in high 
yields. Moreover, these cavitands can be used as suitable scaffolds for attaching and orienting 
different ligand on their upper rims in the synthesis of valuable resorcin[4]arene cavitand 
assemblies via the CuAAC methodology. Also, a family of resorcin[4]arene glycoconjugates 
(RCGs) were obtained in gram quantities using the CuAAC as a powerful tool to couple the sugar 
on the cavitands upper rims. The resulted host-guest system, i.e. “pseudo-β-D-glucopyranose 
cavity” can be applied as molecular vessels and micro-reactors to evaluate different organic 
transformations in aqueous media as an eco- and environmental friendly approach. 
30 
 
1.7. Experimental section 
General information 
1H- and 13C-NMR spectra were recorded on a Bruker DRX 250 MHz, a Inova 400 MHz, a 
Inova, a Varian 600 MHz and a Varian VNMRS 500 MHz spectrometers. Sample concentrations 
were about 10 % (w/v) in CDCl3 and DMSO-d6 and the J values are given in Hz. The mass spectral 
analyses were performed on an Aligent Technologies 6540 UHD Accurate-Mass Q-TOF LC/MS. 
Materials 
All reagents were used with no further purification unless otherwise specified. 2-Methyl 
resorcinol (98 %) was purchased from Acros Organics Chemical Company. Azobisisobutylonitrile 
(AIBN) was re-crystallized from hot ethanol. N-Bromosuccinimide (NBS) was re-crystallized 
from hot water. THF was distilled by drying it over sodium metal in the presence of benzophenone 
as an indicator and stored under nitrogen. Compounds 6, 8, 15, 17, RCG3 and RCG5 are reported 
for the first time. 
 
Synthesis of resorcin[4]arene and cavitand intermediates (1-8) 
Octa-hydroxy resorcin[4]arene (1):38 2-methyl resorcinol (10 g, 81 mmol) was dissolved 
in (62.7 mL, 772 mL/mol) ethanol and (14.9 mL, 185 mL/mol) 37 % aqueous HCl. The solution 
was cooled in ice bath and heptaldehyde (11.3 mL, 81 mmol) was then added slowly in 10 min 
period of time. The reaction mixture was stirred at 0 0C for 5 min which was then refluxed for 12 
hrs. A yellow colored compound was precipitated and filtered out using a Buchner funnel and 
washed several times with cooled ethanol and distilled water affording the octa-hydroxy 
resorcin[4]arene 1 as pale yellow solid in 14.2 g (80 %). 1H NMR (250 MHz, DMSO-d6) δ 0.89 
(t, J = 6.5 Hz, 12H), 1.25-1.38 (m, 32H), 1.99 (s, 12H), 2.15-2.29 (m, 8H), 4.25 (t, J = 7.6  Hz, 
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4H), 7.23 (s, 4H), 8.69 (s, 8H); 13C NMR (62.5 MHz, DMSO-d6) δ 10.1, 13.9, 22.2, 28.0, 29.0, 
31.6, 34.3, 111.7, 120.7, 124.7, 149.1. 
Bridge resorcin[4]arene cavitand (2):38 Octa-hydroxy resorcin[4]arene 1 (5 g, 5.7 mmol) 
was dissolved in 110 mL DMF. Potassium carbonate (6.3 g, 45 mmol) was added into the solution 
and allowed to stir for 10 min at room temperature. Dibromomethane (6.4 mL, 90 mmol) was then 
added and the reaction mixture was heated to 70 0C overnight. After completion, the reaction 
mixture was cooled at room temperature and the salt was filtered out. The reaction mixture was 
diluted in 200 mL of water and then extracted using 100 mL of ethyl acetate. The organic phase 
was then washed with water (3 x 100 mL). The organic phase was collected and dried over Na2SO4. 
Ethyl acetate was removed over rotovapor. The product was purified by column chromatography 
using (1:9) ethyl acetate/hexane as a pale yellow solid in 4.7 g (89 %) yield. 1H NMR (250 MHz, 
CDCl3) δ 0.90 (t, J = 6.5 Hz, 12H), 1.27-1.49 (m, 32H), 1.98 (s, 12H), 2.15-2.27 (m, 8H), 4.25 (d, 
J = 7.0 Hz, 4H), 4.76 (t, J = 7.9 Hz, 4H), 5.88 (d, J = 7.0 Hz, 4H), 6.98 (s, 4H); 13C NMR (62.5 
MHz, CDCl3) δ 10.3, 14.0, 22.6, 27.9, 29.5, 30.1, 31.9, 36.9, 98.4, 117.5, 123.6, 137.9, 153.2. 
Tetra-bromo resorcin[4]arene cavitand (3):38 Bridge resorcin[4]arene cavitand 2 (10 g, 
10.7 mmol) and AIBN (0.176 g, 1 mmol) were dissolved in 200 mL benzene. NBS (8.7 g, 48 
mmol) was then added and the reaction mixture was heated to 80 0C for 4-6 hrs. After completion, 
the reaction mixture was allowed to cool in ice for 5 min. The crystalline salt was filtered using 
Buchner funnel and washed with DCM (3 x 30 mL). The solvent mixture was then concentrated 
over rotovapor and the product was re-crystallized from cold acetone as a white solid in 12.5 g (93 
%) yield. 1H NMR (250 MHz, CDCl3) δ 0.90 (t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 2.15-2.27 
(m, 8H), 4.43 (s, 8H), 4.55 (d, J = 7.0 Hz, 4H), 4.79 (t, J = 7.9 Hz, 4H), 6.02 (d, J = 7.0 Hz, 4H), 
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7.14 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 13.9, 22.5, 27.7, 29.4, 30.0, 31.7, 98.9, 120.8, 124.3, 
137.8, 153.6. 
Tetra-azido resorcin[4]arene cavitand (4):38 To a solution of tetra-bromo 
resorcin[4]arene cavitand 3 (5 g, 4 mmol) in 50 mL of DMF, NaN3 (2.1 g, 32 mmol) was added 
and the reaction mixture was allowed to stir at room temperature for 4-6 hrs. After completion, the 
salt was filtered out using Buchner funnel and the reaction mixture was diluted in 50 mL of water 
and then extracted using 50 mL ethyl acetate which was then washed with water (3 x 50 mL). The 
organic phase was collected and dried over Na2SO4. Ethyl acetate was removed by rotovapor and 
the product was re-crystallized from (2:3) acetone/MeOH solvent mixture as a white solid crystal 
in 4.3 g (98 %) yield. 1H NMR (250 MHz, CDCl3) δ 0.91 (t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 
2.19-2.28 (m, 8H), 4.34 (s, 8H), 4.39 (d, J = 7.1 Hz, 4H), 4.80 (t, J = 7.9 Hz, 4H), 5.95 (d, J = 7.1 
Hz , 4H), 7.17 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 13.9, 22.5, 27.7, 29.3, 29.9, 31.7, 36.7, 
44.9, 99.6, 120.6, 122.1, 137.9, 153.5; HRMS [M + Na]+ calcd for C60H76N12O8Na 1115.5807, 
found 1115.5836. 
Tetra-alkyne resorcin[4]arene cavitand (5):38 NaH (60 %) (1.3 g, 32 mmol) was added 
slowly to 50 mL ice cold THF and allowed to stir for 5 min at 0 0C. Propargyl alcohol (1.9 mL, 32 
mmol) was then added dropwise and the solution was allowed to stir for more 5-10 min at 0 0C. 
This was followed by the addition of a solution of tetra-bromo resorcin[4]arene cavitand 3 (5 g, 4 
mmol) in 10 mL THF dropwise and the reaction mixture was allowed to stir at room temperature 
overnight. After completion, the reaction mixture was quenched using MeOH followed by 
concentrating the solvent mixture. The crude mixture was washed with a 100 mL of water followed 
by extracting the product using 50 mL of ethyl acetate. The organic layer was then collected and 
dried over Na2SO4 followed by the concentration of ethyl acetate. The product was re-crystallized 
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from (2:3) DCM/MeOH as a white solid crystal in 4.23 g (92 %) yield. 1H NMR (250 MHz, CDCl3) 
δ 0.90 (t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 2.15-2.26 (m, 8H), 2.45 (t, J = 2.2 Hz, 4H), 4.13 
(d, J = 2.4 Hz, 8H), 4.42 (d, J = 7.3 Hz, 4H), 4.45 (s, 8H) 4.81 (t, J = 7.9 Hz, 4H), 5.87 (d, J = 
7.3 Hz, 4H), 7.14 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 14.0, 22.6, 27.8, 29.4, 30.1, 31.8, 36.8, 
57.7, 61.7, 74.4, 80.0, 99.9, 120.6, 123.4, 137.8, 154.1; HRMS [M + Na]+ calcd for C72H88O12Na 
1167.6173, found 1167.6437. 
Tetra-azido resorcin[4]arene cavitand (6): NaH (60 %) (1.3 g, 32.2 mmol) was added 
slowly to 50 mL ice cold THF and allowed to stir for 5 min. 2-azidoethanol (2.8 g, 32.2 mmol) 
was then added dropwise and the solution was stirred for 10 min. A solution of tetra-bromo 
cavitand 3 (5 g, 4.0 mmol) in 10 mL THF dropwise and the reaction mixture was allowed to stir 
at room temperature overnight. After completion, the reaction mixture was quenched using MeOH 
followed by concentrating the solvent mixture. The crude mixture was washed with a 100 mL of 
water followed by extracting the product using 50 mL of ethyl acetate. The organic layer was then 
collected and dried over Na2SO4 followed by the concentration of ethyl acetate. The product was 
re-crystallized out from (2:3) DCM/MeOH to obtain the tetra-azido cavitand 6 as white solid 
crystals in 4.7 g (92 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 6.5 Hz, 12H), 1.26-1.44 
(m, 32H), 2.19-2.25 (m, 8H), 3.39 (t, J = 5.2 Hz, 8H), 3.62 (t, J = 4.8 Hz, 8H), 4.39 (s, 8H), 4.42 
(d, J = 7.3 Hz, 4H), 4.80 (t, J = 7.9 Hz, 4H), 5.88 (d, J = 7.3 Hz, 4H), 7.14 (s, 4H); 13C NMR (100 
MHz, CDCl3) δ 13.9, 22.6, 22.8, 29.4, 30.1, 31.8, 36.8, 50.5, 63.1, 68.8, 99.8, 120.6, 123.4, 137.8, 
154.0. 
Tetra-azido resorcin[4]arene cavitand (7):38 Potassium carbonate (4.4 g, 32 mmol) was 
added to a solution of 4-azidophenol (4.3 g, 32 mmol) in 50 mL of anhydrous acetone and the 
reaction mixture was stirred at room temperature for 5 min. A solution of bromo-cavitand 3 (5 g, 
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4.0 mmol) in 20 mL of acetone was transferred to the reaction mixture which was then refluxed 
for 6 hrs. After completion, the salt was filtered out and acetone was concentrated followed by 
subjecting the crude mixture to column chromatography using (2:8) ethyl acetate/hexane mixture 
to obtain cavitand 6 as a light brown solid in 4.6 g (91 %) yield. 1H NMR (400 MHz, CDCl3) δ 
0.92 (t, J = 6.5 Hz, 12H), 1.27-1.57 (m, 32H), 2.27-2.31 (m, 8H), 4.61 (d, J = 7.3 Hz, 4H), 4.86 (t, 
J = 7.9 Hz, 4H), 4.88 (s, 8H), 5.74 (d, J = 7.3 Hz , 4H), 6.87-6.94 (m, 8H), 7.26 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 14.0, 22.7, 27.9, 29.5, 30.2, 31.9, 36.8, 61.1, 99.9, 115.8, 120.0, 121.1, 122.6, 
132.9, 130.0, 154.3, 156.0; HRMS [M*]- calcd for C84H92ClN12O12 1495.6646, found 1495.6434. 
Tetra-azido resorcin[4]arene cavitand (8): Potassium carbonate (4.4 g, 32.2 mmol) was 
added to a solution of 2-azidophenol (4.3 g, 32.2 mmol) in 50 mL of anhydrous acetone and the 
reaction mixture was stirred at room temperature for 5 min. A solution of bromo-cavitand 5 (5 g, 
4.0 mmol) in 20 mL of acetone was transferred to the reaction mixture which was then refluxed 
for 6 hrs. After completion, the salt was filtered out and acetone was concentrated followed by 
subjecting the crude mixture for column chromatography using (2:8) ethyl acetate/hexane mixture 
to obtain cavitand 8 as a light brown oil in 5.11 g (87 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.92 
(t, J = 6.5 Hz, 12H), 1.28-1.48 (m, 24H), 2.24-2.30 (m, 8H), 4.62 (d, J = 7.3 Hz, 4H), 4.87 (t, J = 
7.9 Hz, 4H), 4.91 (s, 8H), 5.84 (d, J = 7.3 Hz , 4H), 6.93-7.01 (m, 8H), 7.03-7.10 (m, 8H), 7.18 (s, 
4H); 13C NMR (100 MHz, CDCl3) δ 14.0, 22.6, 27.8, 29.5, 30.2, 31.8, 36.8, 62.5, 100.1, 115.1, 
119.8, 121.2, 122.0, 122.1, 125.5, 129.2, 138.0, 150.6, 154.4. 
 
Synthesis of propargyl and azido β-D-glucopyranose monomers (10 & 12) 
β-D-glucopyranoside-1,2,3,4,6-pentaacetate (9):40 D-Glucose (5 g, 27.8mmol) and 
sodium acetate (11 g, 140 mmol) were added to 50 mL of acetic anhydride. The reaction mixture 
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was heated to 80 0C for 4 hrs. After completion, the reaction mixture was transferred into ice cold 
water and allowed to stir for 30 min. The precipitated solid material was then filtered out using a 
Buchner funnel and washed with water (3 x 30 mL). The product was re-crystallized from (1:3) 
ethyl acetate/hexane as a white solid in 8.83 g (82 %). 1H NMR (250 MHz, CDCl3) δ 1.99 (s, 3H), 
2.01 (s, 3H), 2.06 (s, 3H), 2.09 (s, 3H), 3.8 (ddd, J = 2.2, 4.4, 10.0 Hz, 1H), 4.08 (dd, J = 2.2, 12.5 
Hz, 1H), 4.27 (dd, J = 4.6, 12.5 Hz, 1H), 5.09 (dd, J = 2.4, 9.3 Hz, 1H), 5.14 (t, J = 9.3 Hz , 1H), 
5.24 (t, J = 9.3 Hz, 1H), 5.7 (d, J = 8.0 Hz, 1H); 13C NMR (62.5 MHz, CDCl3) δ 20.5, 20.6, 20.7, 
61.4, 67.7, 70.1, 72.6, 72.7, 91.6, 168.9, 169.1, 169.3, 170.0, 170.5. 
1-(2-propynyl)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (10):40 β-D-Glucose 
pentaacetate 9 (5 g, 12.8 mmol) and propargyl alcohol (1.5 mL, 25.6 mmol) were dissolved in 100 
mL DCM. The solution was cooled in ice bath to 0 0C and BF3 etherate (48 %) (4 mL, 15.4 mmol) 
was then added dropwise to the solution and the reaction mixture was stirred at room temperature 
for 2 h. After completion, K2CO3 (3.5 g, 25.6 mmol) was added and the reaction mixture was 
allowed to stir for 20 min. The salt was filtered out using Buchner funnel and the reaction mixture 
was washed with water (2 x 100 mL). The organic layer was collected and dried over Na2SO4 and 
DCM was removed. The product was re-crystallized from (1:3) ethyl acetate/hexane as pale yellow 
solid in 4.3 g (87 %). 1H NMR (250 MHz, CDCl3) δ 1.98 (s, 3H), 2.00 (s, 3H), 2.03 (s, 3H), 2.06 
(s,3H), 2.47 (t, J = 2.4 Hz, 1H), 3.71 (ddd, J = 2.4, 4.6, 9.8 Hz, 1H), 4.12 (dd, J = 2.5, 12.5 Hz, 
1H), 4.26 (dd, J = 4.6, 12.3 Hz, 1H), 4.43 (d, J = 2.5 Hz, 2H), 4.75 (d, J = 8.0 Hz, 1H), 4.99 (dd, 
J = 8.0, 9.5 Hz, 1H), 5.07 (t, J = 9.8 Hz, 1H), 5.22 (t, J = 9.3 Hz, 1H); 13C NMR (62.5 MHz, 
CDCl3) δ 20.5, 20.6, 20.6, 55.9, 61.7, 68.2, 70.9, 71.8, 72.7, 75.4, 78.0, 98.0, 169.3, 170.1, 170.5. 
1-(2-chloroethyl)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (11):41 β-D-Glucose 
pentaacetate 9 (5 g, 12.8 mmol) and 2-chloroethanol (1.7 mL, 25.6 mmol) were dissolved in 100 
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mL DCM. The solution was cooled in ice bath to 0 0C and BF3 etherate (48 %) (4 mL, 0.015 mol) 
was then added dropwise to the solution and the reaction mixture was stirred at room temperature 
for 2 h. After completion, K2CO3 (3.5 g, 25.6 mmol) was added and the reaction mixture was 
allowed to stir for 20 min. The salt was filtered out using a Buchner funnel and the reaction mixture 
was washed with water (2 x 100 mL). The organic layer was collected and dried over Na2SO4. and 
DCM was removed. The product was re-crystallized from (1:3) ethyl acetate/hexane as a white 
solid in 4.39 g (83 %). 1H NMR (250 MHz, CDCl3) δ 2.02 (s, 3H), 2.04 (s, 3H), 2.07 (s, 3H), 2.10 
(s, 3H), 3.62 (ddd, J = 5.5, 6.8, 10.8 Hz, 1H), 3.63 (ddd, J = 5.3, 7.0, 10.7 Hz, 1H), 3.75 (m, 2H), 
4.11 (dt, J = 5.3, 11.2 Hz, 1H), 4.14 (dd, J = 2.4, 12.2 Hz, 1H), 4.24 (dd, J = 4.7, 12.3 Hz, 1H), 
4.57 (d, J = 7.9 Hz, 1H), 5.02 (dd, J = 6.9, 8.5 Hz, 1H), 5.09 (t, J = 9.8 Hz, 1H), 5.23 (t, J = 9.3 
Hz, 1H); 13C NMR (62.5 MHz, CDCl3) δ 20.5, 20.5, 20.6, 42.3, 61.7, 68.2, 69.8, 70.9, 71.8, 72.5, 
101.0, 169.3, 170.1, 170.5. 
1-(2-azidoethyl)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (12):38 NaN3 (1.6 g, 24.4 
mmol) was added to a solution of chloro-β-D-glucose monomer 11 (5 g, 12.2 mmol) in 50 mL 
DMF. The reaction mixture was heated to 80 0C overnight. After completion, the reaction mixture 
was extracted with ethyl acetate (50 mL) and washed with water (3 x 50 mL). The organic layer 
was collected and dried over Na2SO4. The product was re-crystallized from (1:3) ethyl 
acetate/hexane as a white solid in 4.86 g (96 %). 1H NMR (250 MHz, CDCl3) δ 1.98 (s, 3H), 2.00 
(s, 3H), 2.02 (s, 3H), 2.06 (s, 3H), 3.28 (ddd,  J = 3.3, 4.7, 13.4 Hz, 1H), 3.50 (ddd, J = 3.5, 8.4, 
13.4 Hz, 1H), 3.69 (ddd, J = 3.3, 8.2, 10.7 Hz, 1H), 3.71 (ddd, J = 2.8, 4.5, 10.0 Hz, 1H), 4.04 
(ddd, J = 3.5, 4.9, 10.6 Hz, 1H), 4.13 (dd, J = 2.4, 12.3 Hz, 1H), 4.26 (dd, J = 4.6, 12.3 Hz, 1H), 
4.6 (d, J = 7.9 Hz, 1H), 5.03 (dd, J = 8.0, 9.7 Hz, 1H), 5.07 (t, J = 9.8 Hz, 1H), 5.19 (t, J = 9.3 
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Hz, 1H); 13C NMR (62.5 MHz, CDCl3) δ 20.5, 20.6, 20.6, 50.4, 61.7, 68.2, 68.5, 71.0, 71.8, 72.7, 
100.6, 169.3, 170.1, 170.5. 
 
General procedure for the synthesis of glycoconjugates (13-17) 
Cavitand intermediate (4-8) (1.0 mmol) was dissolved in 30 mL chloroform. CuI (10 
mol%) and DIPEA (6.0 mmol) were then added. This was followed by the addition of glucose 
monomer (10 & 13) (8.0 mmol) to the solution and the reaction mixture was refluxed overnight. 
After completion, the reaction was cooled at room temperature and washed with ammonium 
hydroxide solution followed by collecting and drying the organic phase over Na2SO4. Chloroform 
was evaporated and the product was purified by column chromatography using (1:19) 
MeOH/DCM. 
Tetra-glucose acetate cavitand (13):38 Pale yellow solid (95 %) yield. 1H NMR (500 
MHz, CDCl3) δ 0.86 (t, J = 6.6 Hz, 12H), 1.23-1.32 (m, 24H), 1.37-1.43 (m, 8H), 1.93 (s, 12H), 
1.95 (s, 12H), 1.99 (s, 12H), 2.04 (s, 12H), 2.15-2.21 (m, 8H), 3.69 (ddd, J = 2.5, 4.4, 10.3 Hz, 
4H), 4.11 (dd, J = 2.5, 12.2 Hz, 4H), 4.20 (d, J = 7.3 Hz, 4H), 4.23 (dd, J = 4.4, 12.2 Hz, 4H), 
4.64 (d, J = 7.8 Hz, 4H), 4.70 (t, J = 7.8 Hz, 4H), 4.75 (d, J = 12.7 Hz, 4H), 4.85 (d, J = 12.7 Hz, 
4H), 4.94 (dd, J = 8.3, 9.8 Hz, 4H), 5.05 (t, J = 9.8 Hz, 4H), 5.13 (t, J = 9.3 Hz, 4H), 5.24 (d, J = 
13.7 Hz, 4H), 5.26 (d, J = 13.7 Hz, 4H), 7.17 (s, 4H), 7.52 (s, 4H); 13C NMR (125 MHz, CDCl3) 
δ 13.9, 20.4, 20.5, 20.6, 22.5, 27.7, 29.3, 30.0, 31.6, 36.8, 44.0, 61.6, 62.7, 68.1, 71.0, 71.7, 72.5, 
99.3, 99.7, 120.4, 121.2, 123.3, 138.0, 143.8, 153.6, 169.2, 169.3, 170.0, 170.5; HRMS [M + 
2Na]2+ calcd for C128H264N12O48Na2 1341.5278, found 1341.5345. 
Tetra-glucose acetate cavitand (14):38 Pale yellow solid (96 %) yield. 1H NMR (500 
MHz, CDCl3) δ 0.82 (t, J = 6.6 Hz, 12H), 1.23 (m, 24H), 1.34 (m, 8H), 1.89 (s, 12H), 1.93 (s, 
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12H), 1.95 (s, 12H), 2.02 (s, 12H), 2.10 (m, 8H), 3.66 (m, 4H), 3.90 (m, 4H), 4.06 (dd, J = 2.2, 
12.5 Hz, 4H), 4.20 (m, 12H), 4.28 (s, 8H), 4.49 (d, J = 8.1 Hz, 4H), 4.54 (d, J = 3.3 Hz, 8H), 4.57-
4.62 (m, 4H), 4.66 (t, J = 8.1 Hz, 4H), 4.94 (dd, J = 8.1, 9.5 Hz, 4H), 5.01 (t, J = 9.9 Hz, 4H), 
5.12 (t, J = 9.5 Hz, 4H), 5.60 (d, J = 7.3 Hz, 4H), 7.00 (s, 4H), 7.66 (s, 4H); 13C NMR (125 MHz, 
CDCl3) δ 13.8, 20.3, 20.5, 22.4, 27.7, 29.3, 29.9, 31.6, 36.6, 49.6, 60.1, 61.5, 61.9, 63.5, 67.5, 68.0, 
70.7, 71.7, 72.3, 99.4, 100.2, 120.2, 123.4, 124.2, 137.5, 144.3, 153.8, 169.1, 169.8, 170.3; HRMS 
[M + 2Na]2+ calcd for C136H180N12O52Na2 1429.5802, found 1429.5816. 
Tetra-glucose-acetate cavitand (15): Pale yellow solid (92 %) yield. 1H NMR (400 MHz, 
CDCl3) δ 0.89 (t, J = 6.4 Hz, 12H), 1.25-1.44 (m, 24H), 1.98 (s, 12H), 2.02 (s, 12H), 2.06 (s, 12H), 
2.16-2.22 (m, 8H), 3.79 (m, 4H), 3.94 (bs, 4H), 4.16-4.28 (m, 12H), 4.35 (bs, 12H), 4.55 (bs, 4H),  
4.71-4.82 (m, 12H), 4.92 (m, 4H), 5.01 (t, J = 8.4 Hz, 4H), 5.09 (t, J = 9.6 Hz, 4H), 5.21 (t, J = 
9.4 Hz, 4H), 5.57 (d, J = 3.9 Hz, 4H),   7.10 (s, 4H), 7.79 (bs, 4H); 13C NMR (100 MHz, CDCl3) 
δ 13.9, 20.4, 20.5, 20.6, 22.5, 27.7, 29.5, 30.0, 31.7, 36.7, 50.1, 61.7, 62.7, 63.0, 68.2, 68.7, 71.1, 
71.8, 72.7, 99.4, 99.9, 120.7, 123.0, 124.0, 137.8, 143.9, 153.9, 169.3, 170.0, 170.5. 
Tetra-maltose acetate cavitand (16):38 Pale yellow solid (88 %) yield. 1H NMR (500 
MHz, CDCl3) δ 0.88 (t, J = 6.4 Hz, 12H), 1.25-1.34 (m, 24H), 1.37-1.45 (m, 8H), 1.95 (s, 12H), 
1.97 (s, 12H), 1.99 (s, 12H), 2.02 (s, 12H), 2.03 (s, 12H), 2.09 (s, 12H), 2.14 (s, 12H), 2.15-2.21 
(m, 8H), 3.65-3.71 (m, 4H), 3.94 (m, 4H), 4.00-4.05 (m, 8H), 4.20-4.26 (m, 8H), 4.53-4.55 (m, 
4H),  4.67 (t, J = 8.6 Hz, 4H), 4.79 (t, J = 9.6 Hz, 4H), 4.82-4.86 (m, 8H), 5.05 (t, J = 9.9 Hz, 4H), 
5.20 (t, J = 9.4 Hz, 4H), 5.22-5.31 (m, 8H), 5.34 (t, J = 10.0 Hz, 4H), 5.38 (d, J = 3.9 Hz, 4H), 
5.76 (d, J = 7.1 Hz, 4H),   7.18 (s, 4H), 7.54 (s, 4H); 13C NMR (125 MHz, CDCl3) δ 14.0, 20.6, 
20.7, 20.8, 20.9, 22.6, 27.8, 28.8, 28.9, 29.5, 30.2, 31.8, 36.9, 44.1, 68.0, 68.4, 70.0, 71.9, 72.3, 
72.6, 75.2, 95.5, 99.5, 120.6, 121.3, 123.5, 138.1, 143.9, 153.7, 169.4, 169.6, 169.9, 170.2, 170.5. 
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Tetra-glucose-acetate cavitand (17): Pale yellow solid (94 %) yield. 1H NMR (400 MHz, 
CDCl3) δ 0.86 (t, J = 6.4 Hz, 12H), 1.21-1.42 (m, 24H), 1.86 (s, 12H), 1.92 (s, 12H), 1.94 (s, 12H), 
1.97 (s, 12H), 2.12-2.21 (m, 8H), 3.71 (m, 4H), 4.04 (m, 4H), 4.18-4.23 (m, 8H), 4.68-4.73 (m, 
8H), 4.78 (t, J = 12.1 Hz, 4H), 4.93-4.97 (m, 8H), 5.03 (t, J = 9.7 Hz, 4H), 5.14 (t, J = 9.3 Hz, 
4H), 5.66 (d, J = 3.9 Hz, 4H), 7.07-7.14 (m, 8H), 7.34-7.48 (m, 8H), 7.61 (d, J = 7.6 Hz, 4H), 8.13 
(s, 4H); 13C NMR (100 MHz, CDCl3) δ 13.9, 20.4, 22.5, 27.7, 29.4, 31.7, 36.8, 61.7, 62.4, 62.9, 
71.1, 71.7, 72.7, 99.4, 99.8, 116.3, 121.3, 121.8, 122.2, 125.5, 127.2, 130.5, 138.1, 143.4, 150.6, 
153.8, 154.0, 169.3, 169.9, 170.4. 
 
General procedure for the synthesis RCG1-5 
Acetylated glycoconjugate (13-17) (1 g) was dissolved in (0.1 M) sodium methoxide 
solution. The reaction mixture was allowed to stir at room temperature for 2-4 hrs. After 
completion, the reaction mixture was neutralized with Dowex 50W-X8. This was followed by 
filtrating and concentrating of methanol with no furthermore purification. All products were dried 
and NMR was taken in DMSO-d6. 
Resorcin[4]arene Cavitand Glycoconjugate 1 (RCG1):38 Pale yellow solid (95 %); 1H 
NMR (500 MHz, DMSO-d6) δ 0.84 (t, J = 6.6 Hz, 12H), 1.25 (m, 24H), 1.39 (m, 8H), 2.36 (m, 
8H), 2.99 (t, J = 8.4 Hz, 4H), 3.06 (t, J = 8.8 Hz, 4H), 3.11-3.18 (m, 12H), 3.47 (dd, J = 6.2, 11.7 
Hz, 4H), 3.71 (d, J = 10.3 Hz, 4H), 4.26 (d, J = 7.7 Hz, 8H), 4.61 (t, J = 8.1 Hz, 4H), 4.61 (d, J = 
12.11 Hz, 4H), 4.81 (d, J = 12.11 Hz, 4H), 5.31 (s, 8H), 5.99 (d, J = 7.0 Hz, 4H), 7.67 (s, 4H), 
8.08 (s, 4H); 13C NMR (125 MHz, DMSO-d6) δ 13.9, 22.1, 27.7, 28.9, 29.3, 31.4, 37.0, 48.6, 61.2, 
61.4, 70.2, 73.4, 76.9, 77.0, 99.4, 102.1, 121.6, 122.9, 124.9, 138.1, 143.5, 153.1; HRMS [M + H]+ 
calcd for C96H133N12O32 1965.9143, found 1965.9075. 
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Resorcin[4]arene Cavitand Glycoconjugate 2 (RCG2):38 Pale yellow solid (94 %); 1H 
NMR (500 MHz, DMSO-d6) δ 0.85 (t, J = 6.6 Hz, 12H), 1.26 (m, 24H), 1.39 (m, 8H), 2.33 (m, 
8H), 3.00 (t, J = 8.7 Hz, 4H), 3.07 (t, J = 9.2 Hz, 4H), 3.12-3.19 (m, 8H), 3.45 (dd, J = 5.9, 11.7 
Hz, 4H), 3.68 (d, J = 9.9 Hz, 4H), 3.93 (m, 4H), 4.10 (m, 4H), 4.23 (m, 8H), 4.25 (d, J = 7.7 Hz, 
4H), 4.51 (s, 8H), 4.56-4.68 (m, 16H), 5.68 (d, J = 6.2 Hz, 4H), 7.55 (s, 4H), 8.20 (s, 4H); 13C 
NMR (125 MHz, DMSO-d6) δ 13.9, 22.2, 27.8, 29.0, 29.4, 31.5, 36.8, 49.7, 61.2, 61.1, 61.4, 63.3, 
67.4, 70.0, 73,3, 76.6, 77.0, 99.2, 102.9, 122.0, 124.1, 125.0, 137.7, 143.6, 153.3; HRMS [M + H]+ 
calcd for C104H149N12O36 2142.0192, found 2142.0028. 
Resorcin[4]arene cavitand glycoconjugate 3 (RCG3). Pale yellow solid (87 %); 1H 
NMR (600 MHz, DMSO-d6) δ 0.85 (t, J = 6.6 Hz, 12H), 1.18-1.31 (m, 24H), 1.40 (m, 8H), 2.33 
(m, 4H), 3.02 (t, J = 8.1 Hz, 4H), 3.09 (t, J = 9.0 Hz, 4H), 3.18 (m, 8H), 3.48-3.51 (m, 4H), 3.73 
(d, J = 11.2 Hz, 4H), 3.90 (bs, 8H), 4.09 (m, 4H), 4.31 (d, J = 7.7 Hz, 4H), 4.54 (bs, 8H), 4.58 (m, 
4H), 4.64 (d, J = 11.9 Hz, 4H), 4.88 (d, J = 11.9 Hz, 4H), 5.65 (d, J = 7.3 Hz, 4H), 7.54 (s, 4H), 
8.16 (s, 4H); 13C NMR (150 MHz, DMSO-d6) δ 13.9, 22.2, 27.8, 29.0, 29.4, 31.5, 36.8, 49.1, 61.2, 
62.0, 62.1, 70.2, 73.5, 76.7, 77.0, 99.7, 102.3, 121.8, 124.7, 125.1, 137.1, 143.9, 153.3. 
Resorcin[4]arene Cavitand Glycoconjugate 4 (RCG4):38 Pale yellow solid (90 %); 1H 
NMR (600 MHz, DMSO-d6) δ 0.88 (t, J = 6.6 Hz, 12H), 1.22-1.33 (m, 24H), 1.45 (m, 8H), 3.00 
(t, J = 8.3 Hz, 4H), 3.06 (t, J = 9.2 Hz, 4H), 3.16 (m, 8H), 3.45-3.48 (m, 4H), 3.71 (d, J = 11.3 
Hz, 4H), 4.31 (d, J = 7.7 Hz, 4H), 4.50 (d, J = 7.3 Hz, 4H), 4.71 (d, J = 12.7 Hz, 4H), 4.90 (d, J 
= 12.7 Hz, 4H), 5.86 (d, J = 7.3 Hz, 4H), 7.13 (d, J = 8.5 Hz, 4H), 7.75 (d, J = 8.5 Hz, 4H), 7.78 
(s, 4H), 8.68 (s, 4H); 13C NMR (150 MHz, DMSO-d6) δ 13.9, 22.2, 27.7, 28.9, 29.3, 31.5, 36.9, 
60.9, 61.1, 61.2, 61.6, 70.2, 73.4, 76.7, 77.0, 99.5, 102.3, 115.6, 121.8, 122.6, 123.0, 130.4, 137.9, 
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138.1, 144.9, 153.6, 158.4; HRMS [M + 2H]+2 calcd for C120H150N12O36 1167.5132, found 
1167.5106. 
Resorcin[4]arene cavitand glycoconjugate 5 (RCG5): Pale yellow solid (91 %); 1H 
NMR (400 MHz, DMSO-d6) δ 0.86 (t, J = 6.6 Hz, 12H), 1.16-1.32 (m, 24H), 1.42 (m, 8H), 3.04 
(m, 4H), 3.12-3.21 (m, 8H), 3.40 (s, 12H), 3.50 (m, 4H), 3.70 (m, 4H), 4.21 (m, 4H), 4.30 (d, J = 
7.6 Hz, 4H), 4.55 (m, 4H), 4.60-4.67 (m, 8H), 4.87 (d, J = 12.1 Hz, 4H), 4.95 (s, 8H), 5.02 (m, 
4H), 5.97 (d, J = 7.3 Hz, 4H), 7.19 (s, 4H), 7.52-7.69 (m, 12H), 8.40 (s, 4H); 13C NMR (100 MHz, 
DMSO-d6) δ 13.9, 21.1, 22.2, 27.3, 28.9, 31.2, 31.5, 61.1, 61.4, 62.6, 70.1, 70.4, 76.7, 77.0, 99.7, 
102.5, 122.0, 123.0, 125.9, 126.6, 131.0, 138.1, 143.6, 151.0, 153.5. 
 
Synthesis of compound X 
Tetra-alkyne pentaerythritol (18):41 Pentaerythritol (5 g, 36.7 mmol) was dissolved in 
anhydrous DMF (75 mL). KOH (16.5 g, 0.29 mol) was then added and the reaction mixture was 
allowed to stir for 30 min at room temperature. Propargyl bromide (32 g, 0.22 mol) was slowly 
added over a 30 min period. The reaction mixture was then heated to 40 0C overnight. After 
completion, the reaction mixture was cooled and diluted with 100 mL of water and was extracted 
with ether (3 x 75 mL). The organic layers were combined, washed with water (3 x 50 mL) and 
then dried over Na2SO4. The solvent was then removed by evaporation under reduced pressure 
followed purifying the product by flash chromatography on silica gel eluting with ethyl 
acetate/hexanes (2:8) to give tetrakis (2-propynyloxymethyl) methane 18 (8.6 g, 81 %) as an 
orange viscous oil. 1H NMR (400 MHz, CDCl3) δ 2.24 (t, J = 2.3 Hz, 4H), 3.51 (s, 8H), 4.09 (d, J 
= 2.3 Hz); 13C NMR (500 MHz, CDCl3) δ 44.5, 58.6, 69.6, 74.5, 79.6. 
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Tetra-sugar acetate pentaerythritol (19):38 Tetra-proparyl 18 (250 mg, 0.8 mmol) and 
compound 12 (1.81 g, 4.3 mmol) were dissolved in chloroform (30 mL). CuI (16 mg, 0.08 mmol) 
and DIPEA (0.67 g, 5.2 mmol) were then added to the solution and the reaction mixture was 
refluxed overnight. After completion, the reaction was washed with ammonium hydroxide solution 
and the organic phase was collected and dried using Na2SO4. Chloroform was evaporated and the 
product was purified by column chromatography using (1:19) MeOH/DCM. The product was 
obtained as yellow oil that solidified slowly to pale yellow solid in 1.5 g (90 %) yield.  1H NMR 
(500 MHz, CDCl3) δ 1.92 (s, 12H), 1.97 (s, 12H), 1.99 (s, 12H), 2.06 (s, 12H), 3.51 (s, 8H), 3.67 
(m, 4H), 3.92 (m, 4H), 4.09 (dd, J = 2.2, 12.4 Hz, 4H), 4.19-4.24 (m, 8H), 4.48 (d, J = 8.0 Hz, 
4H), 4.56 (s, 8H), 4.96 (dd, J = 7.8, 9.9 Hz, 4H), 5.04 (t, J = 9.6 Hz, 4H), 5.15 (t, J = 9.6 Hz, 4H), 
7.60 (s, 4H); 13C NMR (125 MHz, CDCl3) δ 20.4, 20.5, 20.6, 45.2, 49.8, 61.6, 64.7, 67.7, 67.7, 
68.2, 70.1, 70.8, 71.8, 72.4, 100.4, 123.7, 144.9, 169.2, 169.3, 170.0, 170.5. 
Pentaerythritol glycoconjugate (compound X):38 Acetylated glycoconjugate 19 (1 g) 
was dissolved in (0.1 M) sodium methoxide solution. The reaction was allowed to stir at room 
temperature for 2-4 hrs. After completion, the reaction mixture was neutralized with Dowex 50W-
X8. This was followed by filtrating and concentrating methanol with no further purification to 
obtain compound X as a pale orange viscous solid in 0.59 g (90 %). 1H NMR (500 MHz, DMSO-
d6) δ 2.96 (t, J = 8.5 Hz, 4H), 3.03 (t, J = 9.0 Hz, 4H), 3.11-3.17 (m, 8H), 3.35-3.37 (m, 12H), 
3.41 (m, 4H), 3.66 (d, J = 10.7 Hz, 4H), 3.88 (m, 4H), 4.07 (s, 4H), 4.22 (d, J = 7.7 Hz, 4H), 4.46 
(m, 8H), 4.56 (s, 8H), 8.09 (s, 4H); 13C NMR (125 MHz, DMSO-d6) δ 45.1, 49.7, 58.2, 64.3, 70.1, 
73.4, 76.7, 77.0, 102.9, 124.6, 144.1. 
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Chapter 2 
Thiocyanation and Thiazole Formation in Aqueous Media Using RCGs 
 
2.1. Introduction 
Molecules containing thiocyanate moieties have received a great interest in the field of 
organosulfur chemistry.1 Thiocyanates are known to have insecticidal2 and biocidal3 activities and 
are found in some anti-cancer natural products derived from cruciferous vegetables.4 Thiocyanate 
compounds are generally obtained from nucleophilic displacement of good leaving groups in the 
presence of thiocyanate ions5 or attained from different functionalities, i.e. alcohols,6 silyl7 ethers 
or amines,8 using in situ prepared electrophilic phosphorane Ph3P(SCN)2. However, due to the low 
thermal stability of the required intermediate (SCN)2, the results can be unreliable and not 
reproducible. 
Thiocyanate ions (NCS-) are poor nucleophiles and their low stability under thermal or 
acidic conditions is a drawback and low yields have been observed for these thiocyanation 
procedures.9 Additionally, an intramolecular rearrangement to the thermodynamically favored 
isothiocyanate can occur when a simple chromatography on silica gel or prolonged heating over 
50 0C is applied.10 Thus, a number of methods reported in literature have sought to develop new 
strategies in order to achieve the thiocyanate substrates in quantitative yields using phase transfer 
catalysts (PTCs),11 microwave assistance,12 and ionic liquids (ILs).13 
Furthermore, thiocyanates are used as a key intermediate in various organic 
transformations,14 especially, α-thiocyanato carbonyl compounds which are applied as starting 
50 
 
materials in the synthesis of thiazoles. This type of five membered heterocyclic ring is recognized 
as an important class of molecular backbone that exists in a number of natural products and 
herbicides.14,15 Many thiazole compounds have been known to possess biological activities and 
have been investigated as valuable ingredients with a wide range of applications in drug discovery 
due to their unique properties such as anti-inflammatory,16 anti-bacterial,17 anti-hypertensive,18 
anti-hyperlipidemic,19 anti-tumor20 and others.21 
Different approaches have been established for the formation of 2-aminothiazoles. The 
Hantzsch reaction is one of the most widely used method in the synthesis of thiazoles involving 
the condensation of α-halocarbonyl compounds with thiourea/thioamides; the 2-aminothiazoles 
can be obtained from the reaction of α-thiocyanatoketones with amines.22,23 Likewise, they can be 
afforded from the reaction of phenylacetylene or styrene with N-bromosuccinimide in the presence 
of thiourea.24 The synthesis of thiazoles in aqueous media have also been reported in literature 
using β-cyclodextrin (β-CD)24,25 and lipase bio-catalysts.26 Also, the use of Cu(I) as a catalyst in 
the synthesis of 2-aminobenzothiazoles in water has been described.27 
In this chapter, the main focus was on evaluating the thiocyanation and thiazole formation 
in aqueous media using RCGs. For comparative study, the thiocyanation and thiazole formation 
were also investigated using β-CD and compound X. β-CD, a well-known phase transfer catalyst, 
was investigated to validate the ability of RCGs to catalyze the reactions in water. The compound 
X, derived from the flexible pentaerythritol core that does not offer any pseudo-saccharide host 
system, served as a control to understand the importance of spatial directionality provided by the 
resorcin[4]arene cavitand core. 
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2.2. Thiocyanation in water using RCGs 
2.2.1. Optimizing the thiocyanation in water using RCGs 
RCGs, β-CD and compound X were investigated as catalysts to examine their abilities in 
catalyzing the thiocyanation reactions in water. Initially, the thiocyanation reaction condition was 
optimized upon the reaction of benzyl bromide (1.0 mmol) with potassium thiocyanate (1.1 equiv.) 
in 10 mL of water. All reactions were conducted in the presence and in the absence of the additive 
catalysts (1 mol%) at 80 0C for 5 min (Figure 2.1). 
 
 
Figure 2.1. Conversion (%) of benzyl thiocyanate 1a at 80 0C with/without the catalysts. 
 
It was observed that the benzyl thiocyanate 1a was poorly obtained in the presence or in 
the absence of compound X (<25 %), while it was isolated in approximate ~45 % when β-CD or 
RCG5 waw introduced. Further, the reaction was enhanced to 67 % with RCG4. Interestingly, it 
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was determined that the thiocyanation reactions catalyzed by RCG1-3 were nearly complete in 
only 5 min at 80 0C to afford benzyl thiocyanate 1a in >90 % conversion. 
From the data collected, it was indicated that RCG1-3 were more efficient than β-CD in 
catalyzing the thiocyanation reaction in water, for example, in the reaction carried out at 80 0C, 
only 46 % conversion was observed using β-CD versus >90 % conversion with the RCG1-3 
catalysts. Also, it was observed that the non-directional compound X did not enhance the 
thiocyanation reaction. It was inferred that, in water, compound X due to its flexible backbone 
structure did not possess a pseudo-saccharide cavity, however, the rigid cavitand cores, in RCGs, 
had a major directing influence on the β-D-glucopyranose units on their upper rims providing 
saccharide host systems that was capable of catalyzing the thiocyanation reaction in water. Also, 
it was suggested that the lower conversion, i.e. 67 %, obtained with RCG4 was due to the possible 
unfavorable sterics and linear nature of the 1,4-phenyl linker which could disrupt the flexibility 
and possibly the hydrogen bonding  required for a well-defined pseudo-β-D-glucose cavity 
(Figure 2.2). 
 
Figure 2.2. Altering the pseudo-cavity by the bulky phenyl ligands in RCG4. 
 
Likewise, the low effectivity of RCG5 catalyzing the thiocyanation reaction in water (45 
% conversion) was due to the unfavorable orientation of the β-D-glucose moieties on the ortho-
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position of the bulky 1,2-phenyl linkers in which the β-D-glucopyranose moieties would be forced 
to point away from the cavitand core leading RCG5 to lose its efficiency in enhancing the 
thiocyanation. These results confirmed that the less-hindered linker, the directionality and the 
spatial orientation of the β-D-glucopyranose units (up) are significant in order for the pseudo-
saccharide cavity to be assembled and be catalytic (Figure 2.3). 
 
Figure 2.3. Possible conformational structure of RCG5. 
 
2.2.2. Scoping the thiocyanation in water using RCG1 
Next, after establishing the thiocyanation reaction condition, RCG1 was chosen, among 
the RCG family, to scope the thiocyanation for different alkyl/aryl bromides in water. The results 
are listed in Table 2.1. 
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Table 2.1. Synthesis of alkyl/aryl thiocyanate using RCG1.a 
 
Entry Product Structure Time (min) Conv. (%)b 
1 2a 
 
30 91 
2 3a 
 
30 92 
3 4a 
 
30 98 
4 5a 
 
60 97 
5 6a 
 
30 96 
6 7a 
 
35 99 
7 8a 
 
35 95 
8 9a 
 
20 96 
9 10a 
 
30 98 
10 11a 
 
35 99 
11 12a 
 
25 93 
12 13a 
 
50 96 
13 14a 
 
40 92 
14 15a 
 
45 95 
15 16a  40 83 
a Reaction condition: aryl/alkyl bromide (1.0 mmol), KSCN (1.1 mmol) and RCG1 (1 mol%), H2O (10 mL), 80 0C, b 
Determined by 1H-NMR for the crude reaction mixture after extraction with DCM. 
 
It was determined that a variety of alkyl/aryl bromides were well tolerated and, within 20-
35 min, more than 90 % conversions were observed. Functionalities included unsaturation, 
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carbonyl groups, substituted phenyl rings and esters (entries 1-9). The substitution of a secondary 
(20) bromide, cyclic/acyclic proceeded with equal ease (entries 10 & 11). Also, di-thiocyanation 
of alkyl/aryl di-bromides was tested and the reactions were obtained in high yield within 40-50 
min (entries 12-15). 
 
2.2.3. Recoverability and reusability of RCG1 
The recoverability of the RCG1 was examined for the thiocyanation reaction of benzyl 
bromide in water. RCG1 is soluble in highly polar solvents such as DMF, DMA and DMSO, 
however, it is insoluble in water-immiscible organic solvents, i.e. DCM, chloroform, diethyl ether 
or ethyl acetate. Thus, the recoverability of the RCG1 was accomplished by reusing the aqueous 
phase containing the RGC1, recovered after extracting the reaction product with DCM, for the 
next thiocyanation reaction cycle in order to study the reusability of RCG1. The reusability of the 
RCG1 was investigated for five successive thiocyanation reactions and no significant loss of 
catalytic activity was observed; the results are shown in Figure 2.4. 
 
Figure 2.4. Reusability of RCG1 for thiocyanation of benzyl bromide in water. 
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2.3. Thiazole formation in water using RCGs 
2.3.1. Optimizing the thiazole formation in water using RCGs 
RCGs were then evaluated in the synthesis of 2-aminothiazoles in water and the reaction 
conditions were optimized by studying the reaction between 𝛼-thiocyanato propiophenone (1.0 
mmol) and aniline (1.1 mmol) in 10 mL of water. All reactions were carried out with/without the 
catalysts (1 mol%) at 80 0C for 1 hr (Figure 2.5). 
 
 
Figure 2.5. Conversion (%) of thiazole 1b at 80 0C with/without the catalysts. 
 
From the results, it was obvious that the thiazole formation was low (<10 %) with/without 
the compound X. Even with the added RCG5 β-CD or RCG4, the thiazole 1b was isolated only 
in 14 %, 17 % and 23 % yields, respectively. Interestingly, in the presence of RCG1 and RCG3 
the reaction was accelerated and yield of the thiazole 1b was 65 % and 79 %, respectively. Notably, 
the highest yield of 82 % was obtained when the thiazole formation was catalyzed by RCG2. 
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The formation of thiazole 1b was not efficiently catalyzed by β-CD, i.e. <20 %, while 
RCG1-3 resulted in higher conversions suggesting that the flexibility of the pseudo-saccharide 
cavity plays a significant role in this catalysis. Also, it was observed that the flexibility of the 
linkers between the β-D-glucose units on the resorcin[4]arene cavitand core has a major influence 
in catalyzing the thiazole formation, for example, the reaction catalyzed by the flexible saccharide 
linkers RCG2 and RCG3 resulted in ~80 % conversion, while 65 % conversion was observed with 
RCG1 which had a shorter linker, i.e. RCG1 was less efficient than RCG2 and RCG3 due to the 
rigidity of the β-D-glucose linkers are present on the upper rim of RCG1 (Figure 2.6). 
 
Figure 2.6. Partial 1H-NMR spectrum of RCG1. 
 
From Figure 2.6, it was expected that the methyleneoxy protons (-OCH2-, H7) in RCG1 
would appear as a singlet, however, they were observed as a pair of doublets at 4.61 and 4.84 ppm 
(J = 12.1 Hz). This splitting of the methylenexy protons (H7) is due to the non-equivalence of the 
geminal protons attributed to rigidity (restrictive rotation) of the molecule. As a result, one of the 
protons (H7) points toward the cavity (shielded) and the other proton (H7’) is pointing a way from 
the cavity system. 
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2.3.2. Scoping the thiazole formation in water using RCG2 
The thiazole formation was then scoped for the reaction of 𝛼-thiocyanato propiophenone 
(1.0 mmol) with different substituted anilines (1.1 equiv.) catalyzed by RCG2 (1 mol%). The 
reactions were carried out in 10 mL of water for 1 hr and the results are listed in Table 2.2. 
 
Table 2.2. Scoping the thiazole formation using RCG2.a 
 
Entry Product Structure Conversion (%)b 
 
1 
 
2b 
 
 
98 
 
2 
 
3b 
 
 
97 
 
3 
 
4b 
 
 
98 
 
4 
 
5b 
 
 
97 
 
5 
 
6b 
 
 
96 
 
6 
 
7b 
 
 
98 
 
7 
 
8b 
 
 
98 
 
8 
 
9b 
 
 
99 
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Table 2.2 (Continued) 
Entry Product Structure Conversion (%)b 
 
9 
 
10b 
 
 
23 
 
10 
 
11b 
 
 
35 
 
11 
 
12b 
 
 
28 
 
12 
 
13b 
 
 
31 
 
13 
 
14b 
 
 
88 
 
14 
 
15b 
 
 
N/A 
 
15 
 
16b 
 
 
N/A 
 
16 
 
17b 
 
 
N/A 
a Reaction condition: α-thiocyanato propiophenone (1.0 mmol), aniline derivatives (1.1 mmol) and RCG2 (1 mol%), 
H2O (10 mL), 1 hr, 80 0C, b Conv. (%) for the crude reaction mixture after extraction with ethyl acetate. 
 
The 2-amino thiazole synthesis catalyzed by RCG2 was determined to be highly efficient 
and the product isolation was with excellent yields (>95 %) with electron donating groups on the 
anilines, i.e. -OH, -OMe and -Me (entries 1-8). However, the presence of chloro (-Cl) or bromo (-
Br) groups on the aniline ring, resulted in slower reactions and the thiazoles 10b-13b could only 
be isolated in low yields (entries 9-12). With even stronger electron withdrawing groups, such as 
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nitro (-NO2) or carbontrifloride (-CF3), only a trace amount of thiazoles 15b-17b was isolated (<5 
%) (entries 14-16). 
 
2.3.3. One-pot thiazole formation in water using RCG2 
The capability of RCG2 to catalyze the one-pot thiazole formation in water was also 
investigated. The one-pot thiazole formation is a combination of two successive synthetic 
reactions. The first is the formation of the 𝛼-thiocyanato carbonyls upon the reaction of 𝛼-bromo 
ketones with potassium thiocyanate. The second step is the addition of aniline to the 𝛼-thiocyanato 
carbonyls resulting in the formation of the thiazole. The reactions performed for 1 hr at 80 0C 
(Figure 2.7). 
 
Figure 2.7. One-pot thiazole formation in water catalyzed by RCG2. 
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The one-pot thiazole formation was accomplished by treating α-bromo ketones (1.0 mmol) 
with potassium thiocyanate (1.1 mmol) in the presence of RCG2 (1 mol%). The nucleophilic 
substitution was carried out in 10 mL of water for 30 min at 80 0C, the fromation of the α-
thiocyanato ketones was monitored by TLC, and upon 100 % conversion, aniline derivatives (1.1 
mmol) were added and the reaction mixture was stirred for 1 hr at 80 0C (Scheme 2.1). 
 
Scheme 2.1. One-pot thiazole formation using RCG2.a 
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Within 1 hr, all reactions were well progressed and the respective thiazole products were 
isolated in good to high yield (66-87 %), thus establishing RCG2 as an active catalyst for the one-
pot thiazole formation in water. 
 
2.3.4. Recoverability and reusability of RCG2 
The recoverability and the reusability of the RCG2 was examined following the same 
procedure mentioned previously for recovering and reusing RCG1 (see Chapter 2, section 2.2.3). 
After extraction of the reaction product 1b with ethyl acetate, the aqueous phase, which contains 
the RCG2, was collected and used in five successive thiazole formation reactions. All reactions 
were performed for 1 hr at 80 0C (Figure 2.8). From the results, it was clear that RCG2 was still 
effective in the formation of thiazole 1b in good yield (>65 % conversion), but the yield of the 
product was lower, only 69 % after four cycles. 
 
Figure 2.8. Reusability of RCG2 for thiazole formation of 1b in water. 
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2.4. Conclusions 
In conclusion, RCGs demonstrated several advantages such as recoverability, reusability, 
low catalytic loading (1 mol%), significantly shorter reaction time, eco-friendly aqueous reaction 
environment and high reaction yield in thiocyanation and thiazole formation reactions.  RCG1-3 
were efficient catalysts enhancing the thiocyanation reaction in water, while RCG2 was the most 
effective in catalyzing the thiazole formation reaction. In addition, it was determined that the 
flexibility of the β-D-glucopyranose moieties on the cavitand core play a major role improving the 
formation of thiocyanate and thiazole species in water. The flexibility of the linkers, their spatial 
directionality and the orientation of the β-D-glucopyranose units (up) were a significant influence 
on the assembly of the pseudo-saccharide cavity in the RCGs. 
 
2.5. Experimental section 
General information 
1H- and 13C-NMR spectra were recorded on a Bruker DRX 250 MHz, a Varian Inova 400 
MHz spectrometers. Sample concentrations were about 10 % (w/v) in CDCl3 and DMSO-d6 and 
the J values are given in Hz. 
Materials 
All reagents were used with no further purification unless otherwise specified. 2-, 3-, 4-
amino phenols and 4-anisidine were re-crystallized from (3:7) ethyl acetate/hexane. Thiazoles 2b-
9b and 25b are reported for the first time. 
 
 
 
64 
 
General procedure for thiocyanation reaction in water using RCG1 
Alkyl/aryl bromide (1.0 mmol) and KSCN (1.1 equiv./Br) were added into 10 mL of water. 
RCG1 (1 mol%) was then added and the reaction mixture was heated to 80 0C. After completion, 
the reaction mixture was allowed to cool at room temperature followed by extracting the product 
with DCM. The organic layer was dried over Na2SO4 and DCM was then concentrated and NMR 
was taken. 
 
General procedure for thiazole formation in water using RCG2 
α-Thiocyanato propiophenone (1.0 mmol) and aniline derivative (1.1 mmol) were added 
into 10 mL of water. RCG2 (1 mol%) was then added and the reaction mixture was heated to 80 
0C for 1 hr. The reaction mixture was allowed to cool at room temperature followed by extracting 
the product with ethyl acetate. The organic layer was dried over Na2SO4 and ethyl acetate was then 
concentrated and NMR was taken. 
 
General procedure for one-pot thiazole formation in water using RCG2 
α-Bromoketones (1.0 mmol) and potassium thiocyanate (1.1 mmol) were added into 10 mL 
of water. RCG2 (1 mol%) was then added and the reaction mixture was heated to 80 0C for 30 
min. This was followed by the addition of the aniline derivative (1.1 mmol) and the reaction was 
allowed to run for 1 hr at 80 0C. After completion, the reaction mixture was allowed to cool at 
room temperature followed by extracting the product with ethyl acetate. The organic layer was 
then dried over Na2SO4 and the thiazole products were purified by re-crystallizing them from 3:7 
(v/v) of ethyl acetate/hexane. 
65 
 
Thiazole (1b): Yellow solid (82 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.44 (s, 3H), 7.01 
(t, J = 7.1 Hz, 1H), 7.21-7.32 (m, 5H), 7.39 (t, J = 7.5 Hz, 2H), 7.61 (d, J = 7.6 Hz, 2H); 13C NMR 
(100 MHz, CDCl3) δ 12.3, 116.5, 118.0, 122.7, 127.4, 128.3, 128.5, 129.3, 134.9, 140.5, 145.9, 
161.2. 
Thiazole (2b): Brown solid (98 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.40 (s, 3H), 
6.80 (m, 1H), 6.85 (t, J = 7.3 Hz, 1H), 7.32 (t, J = 7.3 Hz, 2H), 7.44 (t, J = 7.5 Hz, 2H), 7.64 (t, J 
= 7.4 Hz, 2H) 8.14 (d, J = 8.9 Hz, 1H), 9.27 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 11.9, 
116.5, 118.7, 119.2, 122.0, 127.0, 127.9, 128.3, 129.4, 135.2, 144.6, 146.2, 160.3. 
Thiazole (3b): Brown solid (97 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.39 (s, 3H), 
6.73 (d, J = 8.7 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.42-7.45 (m, 4H), 7.64 (d, J = 7.7 Hz, 2H), 9.07 
(s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 12.4, 115.9, 119.5, 127.4, 128.4, 128.7, 133.9, 135.8, 
145.7, 152.5, 160.8. 
Thiazole (4b): Brown solid (98 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.39 (s, 3H), 
6.73 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 7.1 Hz, 1H), 7.41 (m, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.64 (d, 
J = 7.7 Hz, 2H) 9.07 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 12.0, 115.1, 115.4, 119.0, 126.9, 
128.0, 128.2, 133.5, 135.3, 145.2, 152.1, 160.4. 
Thiazole (5b): Yellow solid (97 %) yield; 1H NMR (400 MHz, CDCl6) δ 2.49 (s, 3H), 3.88 
(s, 3H), 6.88 (d, J = 7.7 Hz, 1H), 6.97 (m, 2H), 7.35 (m, 1H), 7.45 (t, J = 7.5 Hz, 2H), 7.70 (d, J = 
7.4 Hz, 2H), 8.03 (d, J = 6.6 Hz, 1H); 13C NMR (100 MHz, CDCl6) δ 12.2, 55.6, 101.0, 115.7, 
121.0, 121.4, 127.4, 127.1, 128.2, 128.3, 130.1, 135.2, 146.7, 147.2, 159.5. 
Thiazole (6b): Yellow solid (96 %) yield; 1H NMR (400 MHz, CDCl6) δ 2.45 (s, 3H), 3.71 
(s, 3H), 6.53-6.55 (dd, J = 2.1, 8.2 Hz, 1H), 6.69-6.71 (dd, J = 1.7, 8.0 Hz, 1H), 6.84 (t, J = 2.2 
Hz, 1H), 7.12 (t, J = 8.2 Hz, 2H), 7.29 (m, 1H), 7.38 (t, J = 7.3 Hz, 2H), 7.63 (d, J = 7.2 Hz, 2H); 
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13C NMR (100 MHz, CDCl6) δ 12.3, 55.1, 103.7, 108.2, 110.4, 116.5, 127.3, 128.2, 128.4, 129.9, 
134.9, 141.8, 145.7, 160.4, 161.3. 
Thiazole (7b): Brown solid (98 %) yield; 1H NMR (400 MHz, CDCl6) δ 2.38 (s, 3H), 3.77 
(s, 3H), 6.75 (d, J = 8.7 Hz, 2H), 7.05 (d, J = 8.7 Hz, 2H), 7.26 (m, 1H), 7.33 (t, J = 7.2 Hz, 2H), 
7.56 (d, J = 7.3 Hz, 2H); 13C NMR (100 MHz, CDCl6) δ 12.2, 55.4, 114.4, 115.3, 122.0, 127.2, 
128.1, 128.5, 134.1, 146.0, 156.0, 164.2. 
Thiazole (8b): Yellow solid (98 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.28 (s, 3H), 
2.39 (s, 3H), 6.97 (d, J = 7.6 Hz, 1H), 7.18 (m, 2H), 7.31 (m, 1H), 7.42 (t, J = 7.6 Hz, 2H), 7.61 
(d, J = 7.5 Hz, 2H), 7.92 (d, J = 7.9 Hz, 1H), 9.10 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 12.0, 
18.1, 116.3, 120.7, 123.0, 126.4, 127.0, 128.0,  128.2, 128.6, 130.5, 139.6, 145.1, 161.3. 
Thiazole (9b): Orange solid (99 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.31 (s, 3H), 2.39 
(s, 3H), 7.08 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 8.1 Hz, 2H), 7.25 (m, 1H), 7.35 (t, J = 7.8 Hz, 2H), 
7.53 (t, J = 7.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 12.2, 20.7, 115.8, 118.7, 127.3, 128.2, 
128.4, 129.8, 132.5, 134.8, 138.1, 145.5, 162.1. 
Thiazole (14b): Yellow solid (88 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.41 (s, 3H), 
7.14 (t, J = 8.8 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.66 (t, J = 8.6 Hz, 2H), 
7.67-7.72 (m, 2H), 10.08 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 11.9, 115.3, 115.5, 118.1, 
127.0, 128.3, 135.1, 137.9, 145.2, 159.3. 
Thiazole (18b): Brown solid (81 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 6.97 (m, 1H), 
7.30 (s, 3H), 7.36 (m, 2H), 7.43 (m, 2H), 7.76 (d, J = 7.3 Hz, 2H), 7.93 (d, J = 6.9 Hz, 2H), 10.30 
(s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 102.8, 116.8, 121.2, 125.7, 127.5, 128.6, 128.6, 130.0, 
134.5, 141.2, 150.1, 163.1. 
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Thiazole (19b): Yellow solid (86 %) yield;1H NMR (400 MHz, DMSO-d6) δ 6.88 (m, 3H), 
7.25-7.29 (m, 2H), 7.89 (d, J = 5.0 Hz, 2H), 8.30 (s, 1H), 9.49 (s, 1H), 9.95 (s, 1H); 13C NMR (100 
MHz, DMSO-d6) δ 103.2, 115.1, 119.0, 122.3, 125.6, 127.4, 128.6, 129.3, 134.6, 146.3, 149.5, 
164.2. 
Thiazole (20b): Brown solid (85 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 6.4 (d, J = 
7.2 Hz, 1H), 7.08 (m, 1H), 7.13 (t, J = 7.8 Hz, 1H), 7.28 (s, 1H), 7.31 (t, J = 7.1 Hz, 1H), 7.39 (s, 
1H), 7.43 (d, J = 7.5 Hz, 2H), 7.94 (d, J = 7.3 Hz, 2H), 9.45 (s, 1H), 10.17 (s, 1H); 13C NMR (100 
MHz, DMSO-d6) δ 102.8, 104.1, 107.9, 108.6, 125.8, 127.6, 128.6, 129.7, 134.6, 142.3, 150.1, 
158.0, 163.1. 
Thiazole (21b): Brown solid (89 %) yield; 1H NMR (100 MHz, DMSO-d6) δ 6.78 (d, J = 
8.7 Hz, 2H), 7.18 (s, 1H), 7.29 (t, J = 7.3 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 7.50 (d, J = 8.7 Hz, 
2H), 7.89 (d, J = 7.5 Hz, 2H), 9.14 (s, 1H), 9.92 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 101.8, 
115.5, 119.3, 125.6, 127.6, 128.6, 133.6, 134.7, 150.1, 152.3, 164.3. 
Thiazole (22b): Brown solid (83 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.26 (s, 3H), 
7.14 (d, J = 8.3 Hz, 2H), 7.27 (s, 1H), 7.30 (t, J = 7.3 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.61 (d, J 
= 8.4 Hz, 2H), 7.91 (d, J = 7.3 Hz, 2H), 10.17 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 20.4, 
117.0, 120.5, 125.6, 127.5, 128.6, 129.4, 130.1, 134.6, 138.8, 150.1, 163.3. 
Thiazole (23b): Brown solid (81 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 2.31 (s, 3H), 
7.01 (t, J = 7.2 Hz, 2H), 7.22 (s, 1H), 7.25 (s, 2H), 7.27 (d, J = 7.3 Hz, 1H), 7.40 (t, J = 7.5 Hz, 
2H), 7.87 (d, J = 7.5 Hz, 2H), 8.02 (d, J = 8.0 Hz, 1H), 9.36 (s, 1H); 13C NMR (100 MHz, DMSO-
d6) δ 18.1, 102.8, 120.9, 123/3, 125.6, 126.5, 127.4, 128.5, 128.8, 130.6, 134.7, 139.4, 149.9, 165.4. 
Thiazole (24b): Yellow solid (73 %) yield; 1H NMR (100 MHz, DMSO-d6) δ 6.78 (t, J = 
7.5 Hz, 1H), 7.30-7.39 (m, 4H), 7.44 (t, J = 7.6 Hz, 2H), 7.83 (d, J = 12.2 Hz, 1H), 7.91 (d, J = 7.7 
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Hz, 2H), 10.54 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 103.6, 107.3, 107.5, 112.7, 125.6, 127.7, 
128.7, 130.6, 134.4, 147.8, 150.2, 162.7. 
Thiazole (25b): Green solid (70 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 7.20 (t, J = 
8.9 Hz, 2H), 7.30 (t, J = 8.4 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.77-7.80 (m, 2H), 7.92 (d, J = 7.5 
Hz, 2H), 10.17 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 102.8, 115.4, 115.6, 118.4, 118.4, 125.7, 
127.6, 128.6, 134.5, 137.8, 150.0, 163.2. 
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Chapter 3 
CuAAC in Aqueous Media Using Resorcin[4]arene Glycoconjugate (RG) 
 
3.1. Introduction 
The Huisgen1 1,3-dipolar cycloaddition (Scheme 3.1), which was introduced by Sharpless 
and co-workers in 2001 as a major example of “click chemistry” (CC),2 is an attractive organic 
transformation that takes place between organic azides and terminal alkynes resulting in the 
formation of a very stable 1,2,3-triazole. Although, the azide-alkyne coupling reaction proceeds 
with poor regioselectivity under thermal conditions to give an approximate 1:1 mixture of 1,4- and 
1,5-disubstituted 1,2,3-triazole isomers.2 In 2002, groups of Meldal and Sharpless independently 
developed this azide-alkyne click reaction by introducing Cu(I) as a catalyst for accelerating and 
controlling the regioselectivity of the reaction to afford only the 1,4-disubstituted 1,2,3-triazole 
isomer.3 In recent years, Au-nanoparticles and Zn(II)-complex have been reported as efficient 
catalysts for the azide-alkyne cycloaddition reaction resulting in the synthesis of 1,4-disubstituted 
1,2,3-triazole ring.4 Additionally, the 1,5-disubstituted 1,2,3-triazole have been synthesized 
selectively via the ruthenium-catalyzed azide-alkyne cycloaddition (RuAAC).5 
In particular, the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC)3 has been of a wide 
interest and attracts considerable attention with numerous applications in different fields such as 
polymer and material science,6 supramolecular chemistry,7 bioconjugation8 and combinatorial 
chemistry.9 Likewise, in the field of drug discovery,10 it was found that many compounds 
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containing 1,2,3-triazole functionality tend to have a broad range of biological activities, i.e. 
antibacterial,11 herbicidal and fungicidal,12 antiallergic13 and anti-HIV.14 
 
Scheme 3.1. Azide-alkyne cycloaddition (AAC) reaction under different conditions. 
 
The CuAAC reaction is believed to proceed via a mechanism as shown in Scheme 3.2. 
Initially, copper (I) coordinates to the alkyne triple bond to form a Cu(I)-acetylide complex (A). 
The resulting π-interaction makes the alkyne proton more acidic such that can be easily abstracted 
by a base, resulting in the copper acetylide intermediate (B). Next, in the transition state (C), two 
copper ions are involved in the mechanism in which the first copper ion is bonded to the acetylide 
moiety, while the role of the second copper ion is to activate the azide by coordinating with the 
electrons on the nitrogen atom present in the azido substrate. The azide then displaces one of the 
ligands to generate copper-azide-acetylide metalocyclic complex (D). A cyclization of the azide 
and the alkyne to the triazole-copper complex (E) followed by protonation and dissociation of the 
(anti)-triazole product, i.e. the 1,4- disubstituted 1,2,3-triazole (F), completes the catalytic cycle.15  
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Scheme 3.2. Cu(I)-catalyzed azide-alkyne cycloaddition proposed mechanism.15 
 
Because of the insolubility of organic azides and/or alkynes in water, the CuAAC reactions 
are usually carried out in a mixture of water and water-miscible co-organic solvents such as 
DMSO, THF, CH3CN, dioxane and 
tBuOH in the presence of Cu(I) catalyst, which is prepared in 
situ.16 More recently, a mixture of water and water immiscible co-organic solvent, i.e. DCM, has 
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also been reported for this reaction.17 However there is no denying that replacing volatile, 
expensive, flammable and toxic organic solvents with an ideal solvent like water is an important 
goal for exploiting this important reaction. This also needs to be given due attention in organic 
syntheses with the precipitous increase in environmental regulations. Accordingly, new methods 
to enhance the CuAAC in water without the use of any harmful organic solvent have been 
demonstrated using phase transfer catalaysts (PTCs),18 ionic liquids (ILs),19 Cu-complexes,20 Cu-
nanoparticles (Cu-NPs),21 heterogeneous catalysis22 and others.23  
In the previous chapter (Chapter 2) it was determined that RCGs have the ability to 
catalyze and enhance both thiocyanation and thiazole formation in water and that the spatial 
directionality and the flexibility of the β-D-glucose moieties had a major influence in their catalytic 
activity. 
In this chapter, the design and synthesis of an eight arm resorcin[4]arene glycoconjugate 
(RG) (Figure 3.1) was accomplished and its application as a micro-catalyst in the synthesis of 1,4-
disubstituted 1,2,3-triazoles in water is described. 
 
Figure 3.1. General structure of resorcin[4]arene glycoconjugate (RG). 
 
RG structure consists of eight β-D-glucopyranoside ligated to the phenolic (OH) groups 
on the resorcin[4]arene upper rim via azide-alkyne cycloaddition reaction. The multiple β-D-
glucopyranoside moieties and the flexibility of the overall structure of the RG offer a flexible 
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pseudo-saccharide cavity that is capable of acting like a molecular vessel for water-insoluble azido 
and/or alkyne substrates in aqueous solution (Figure 3.1). 
 
3.2. Synthesis of resorcin[4]arene glycoconjugate (RG) 
3.2.1. Synthesis of octa-propargyl resorcin[4]arene intermediate 
Octa-alkyne resorcin[4]arene intermediate 20 was obtained in high yield (88 %) upon the 
reaction of octa-hydroxy resorcin[4]arene 124 (for the synthesis of compound 1, see Chapter 1, 
Scheme 1.4) with propargyl bromide using potassium carbonate as a base in refluxed acetone 
(Scheme 3.3). 
 
Scheme 3.3. Synthesis of octa-propargyl resorcin[4]arene 20. 
 
Resorcin[4]arene 20 was characterized conclusively from its NMR and spectral data 
(Figure 3.2). In its 1H-NMR spectrum (250 MHz, CDCl3), the benzylic protons (-CH3, Ha) were 
found as a singlet at 2.25 ppm, while the alkyne protons (-OCH2CCH, He) were observed as a 
triplet at 2.50 ppm (J = 2.4 Hz) and the propargyl methylene protons (-OCH2CCH, Hc,c’) showed 
as two set of doublets at 4.11 (J = 15.3 Hz) and 4.25 (J = 15.3 Hz) ppm. Its 13C-NMR spectrum 
had resonances for the alkyne carbons Ce and Cf at 74.8 and 79.5 ppm, respectively, and the 
propargyl methylene carbons (-OCH2CCH, Cc) were at 60.3 ppm. 
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Figure 3.2. Full 1H- and 13C-NMR spectra of octa-propargyl resorcin[4]arene 20. 
 
3.2.2. Synthesis of RG 
Octa-propargyl resorcin[4]arene 20 and azido-glucose 12 (for the synthesis of compound 
12, see Chapter 1, Scheme 1.6) were then coupled together via the CuAAC reaction in refluxed 
chloroform in the presence of CuI (10 mol%) and DIPEA (6.0 equiv.) to afford the octa-
glucopyranoside acetate resorcin[4]arene 21 in excellent yield. Deacetylation of the acetate groups 
on the saccharide monomer units using NaOMe solution (0.1 M) resulted in RG in a gram quantity 
(Scheme 3.4). 
 
Scheme 3.4. Synthesis of resorcin[4]arene glycoconjugate (RG). 
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The structures of the novel compounds 21 and RG were established from the respective 
1H- and 13C-NMR data. Namely, the absence of the alkyne protons (Hf), the emergence of the 
triazole protons (1H) and the shift of the propargyl protons (Hc) in resorcin[4]arene 20, were used 
to confirm the structures. In the 1H-NMR spectrum (500 MHz, CDCl3) of compound 21 (Figure 
3.3), it was observed the disappearance of the terminal alkyne protons (-OCH2CCH, Hf) from 
compound 20 (see Figure 3.2) and the presence of the triazole protons (1H) as a singlet at 7.69 
ppm. The propargyl methylene protons (-OCH2CCH, Hc,c’) were shifted downfield from 4.11 ppm 
to ~4.50 ppm. In its 13C-NMR spectrum (125 MHz, CDCl3), the triazole carbons (C1H & Cf) were 
at 124.1 ppm and 144.2 ppm (Figure 3.3). 
 
Figure 3.3. Partial 1H- and 13C-NMR spectra of compound 21. 
 
Furthermore, in the 1H-and 13C-NMR spectrum of RG (Figure 3.4), the disappearance of 
the acetate protons (-OCOCH3, OAc) from the region of 1.70-2.10 ppm was observed. The 
methyleneoxy protons (-OCH2-, Hc) were observed as a broad singlet around 4.52 ppm and the 
methylene carbons (-OCH2CH2N3, C8) were at 49.6 ppm, while the methyleneoxy carbons (-
OCH2-, Cc) were at 67.3 ppm. 
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Figure 3.4. Partial 1H- and 13C-NMR spectra of RG. 
 
3.3. CuAAC in water using RG 
3.3.1. Optimizing the CuAAC in water 
RCGs (see Chapter 1, Scheme 1.7), compound X (see Chapter 1, Scheme 1.8) and RG 
were examined as catalysts in the CuAAC reactions in water. Initially, benzyl azide 1a (1.0 mmol) 
and phenyl acetylene 1b (1.05 equiv.) were chosen as candidates to optimize the CuAAC reaction 
condition. The CuAAC reactions were performed with/without the added catalysts (1 mol%) in 
the presence of CuSO4.5H2O (1 mol%) and Na-L-ascorbate (3 mol%) in 10 mL of water at 80 
0C 
(Figure 3.5). 
From the results, it was observed that the CuAAC reactions between 1a and 1b were 
sluggish (<40 % conversion) in the presence/absence of compound X, RCG4 and RCG5. 
Somewhat higher yield of the triazole 1c was obtained (52-59 %) in the presence of RCG1-3. 
Remarkably, the reaction was almost completed, i.e. >90 %, only in 10 min when RG was added. 
Obviously, the fast CuAAC in the existence of RG indicates that the presence of the multiple β-
D-glucopyranoside units and the flexibility of the resorcin[4]arene core provide a wider-type of a 
flexible molecular host environment capable of catalyzing the CuAAC coupling reaction.  
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Figure 3.5. Optimizing the CuAAC reaction condition in water. 
 
3.3.2. Scoping the CuAAC in water 
RG was then subjected to scope the CuAAC reactions in aqueous media by treating benzyl 
azide derivatives 1a-4a with aromatic/aliphatic alkynes 1b-4b (Table 3.1). The efficiency of the 
RG in catalyzing the CuAAC reactions in water between a variety of alkyne and azide substrates 
was established and all reactions were fast, resulting in the desired triazole products (1c-16c) in 
high yields (>90 %) within 15-65 min. The reaction between 4-benzyl azides 4a with the flexible 
1-hexyne 3b was the slowest (65 min) due to the hydrophobicity and poor solubility of both 
substrates in water (entry 15). On the other hand, the reactions progressed best when propargyl 
alcohol 4b was used, i.e. >90 % in 15-20 min (entries 4, 8, 12 & 16). 
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Table 3.1. Scoping the CuAAC in water using RG.a 
 
Entry Product R1 R2 R3 R
’ Time (min) Yield (%)b 
1 1c H H H Ph 20 98 
2 2c H H H CH2OBn 20 98 
3 3c H H H C4H9 45 99 
4 4c H H H CH2OH 15 95 
5 5c CH3 H H Ph 25 99 
6 6c CH3 H H CH2OBn 25 98 
7 7c CH3 H H C4H9 45 92 
8 8c CH3 H H CH2OH 15 95 
9 9c H OMe H Ph 20 98 
10 10c H OMe H CH2OBn 25 94 
11 11c H OMe H C4H9 45 91 
12 12c H OMe H CH2OH 15 94 
13 13c H H Br Ph 30 99 
14 14c H H Br CH2OBn 45 92 
15 15c H H Br C4H9 65 94 
16 16c H H Br CH2OH 20 91 
a Reaction condition: benzyl azide derivative 1a-4a (1.0 mmol) and alkyne substrates 1b-4b (1.05 mmol), Cu(II) 
(1mol%), Na-L-ascorbate (3 mol%), RG (1 mol%), water (10 mL), 80 0C; b Isolated yield. 
 
3.3.3. CuAAC reactions of o-azidophenol derivatives in water 
To further understand and probe the role of the pseudo-cavity system of RG in catalyzing 
the 1,3-dipolar cycloaddition reactions in water, reactions of substituted o-azidophenol derivatives 
5a-9a with phenyl acetylene 1b were explored (Table 3.2). 
Varying the substituent size on the ortho-positions from small (-OH) to large groups (-
OMe, -OEt, -OBu, -OBn) may affect the cycloaddition due to the increase of the hydrophobic 
character and the steric bulk. 
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Table 3.2. The CuAAC of o-azidophenols 5a-9a and phenyl acetylene 1b using RG.a 
 
Entry Product Structure Cat. Time (min) Yield (%)b 
 
1 
 
17c 
 
 
none 
RG 
 
20 
20 
 
64 
96 
 
2 
 
18c 
 
 
none 
RG 
 
30 
30 
 
22 
97 
 
3 
 
19c 
 
 
none 
RG 
 
30 
30 
 
16 
98 
 
4 
 
20c 
 
 
none 
RG 
 
30 
30 
 
12 
98 
 
5 
 
21c 
 
 
none 
RG 
 
45 
45 
 
<10 
99 
a Reaction condition: azidophenol derivative (1.0 mmol) and phenyl acetylene 1b (1.05 mmol), Cu(II) (1 mol%), Na-
L-ascorbate (3 mol%), RG (1 mol%), water (10 mL), 80 0C;b Isolated yield. 
 
o-Azidophenols 5a was treated with phenylacetylene 1b resulted in triazole 17c in 96 % 
and 64 % with and without the presence of RG, respectively (entry 1). Replacing the hydroxyl 
functionality with alkoxy groups, i.e. -OMe, -OEt, -OBu, led to slowing of the reaction in the 
absence of RG to afford the products 18c-20c in low yields (<20 %). Though, all reactions were 
nearly completed within 30 min to obtain the corresponding alkoxy triazoles in more than 90 % 
yield (entries 2-4). Further, substituting the phenolic hydroxyl (-OH) with a benzyl group, 
increased the hydrophobicity of azido 9a and the rate of the reaction was even slower and <10 % 
conversion was observed without the added catalyst, while the reaction was completed within 45 
min in the presence of RG (entry 5). It was proven that the pseudo-saccharide molecular cavity of 
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the RG plays a major role mediating the CuAAC for small and bulky azido substrates in water 
affording triazoles 17c-21c in excellent yields (>90 %) within a short period of time (20-45 min). 
 
3.3.4. Di-CuAAC reactions in water 
RG was then used to examine the di-CuAAC reactions in water for di-propargyl benzene 
derivatives 5b-7b with benzyl azide derivatives 1a-4a (Scheme 3.5). 
 
Scheme 3.5. Di-CuAAC in water using RG.a 
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The aim from this sequence of reactions was to validate the ability of RG in catalyzing the 
CuAAC reactions in water for the synthesis of more diverse molecules that can be used as suitable 
scaffolds in the formation of dendrimers. Amazingly, the di-CuAAC reaction were carried out 
successfully within 45-60 min to result the desired 1,2-, 1,3- and 1,4-bis-(1-benzyl-4-methyl 
etherl-1H-1,2,3-triazole) benzene products 22c-33b in gram quantities. 
 
3.3.5. One-pot CuAAC reactions in water 
Next, the efficiency of RG catalyzing the one-pot CuAAC reaction in water was 
investigated in the reaction of phenylacetylene 1b with different bromide substrates in the presence 
of sodium azide and results are shown in Scheme 3.6. 
 
Scheme 3.6. One-pot CuAAC in water using RG.a 
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The one-pot CuAAC reactions of phenylacetylene 1b with benzyl bromide derivatives 
were accomplished within 25-55 min even with a bulkier aryl system, i.e. naphthyl bromide was 
used to achieve the 1,2,3-triazole products 1c, 5c, 9c, 13c and 34c in excellent yield (90-96 %). 
Also, different functionalized bromides were incorporated within 25-30 min resulting in triazoles 
35c-37c in 91-95 %. However, the one-pot CuAAC reactions did not proceed efficiently, i.e. <10 
% in 200 min, when aliphatic bromo substrates were used. 
 
3.3.6. Inclusion complex of RG with 1a and 1b in D2O 
To evaluate the role of RG catalyzing the CuAAC in water, the ability of RG to act as a 
molecular vessel in encapsulating benzyl azide (1a) and phenylacetylene (1b) was investigated. 
The inclusion complex study was accomplished using NMR; chemical shift variations of either 
the guests (1a & 1b) and/or the host (RG) which would provide the results for the encapsulation 
process were carefully measured. Specifically, 1H-NMR chemical shift of the host and guest in 
RG: benzyl azide (1:1) or RG: phenylacetylene (1:1)   mixture were recorded and compared to the 
corresponding chemical shift in pure host or guest molecule, i.e, RG, benzyl azide or 
phenylacetylene. The sample concentration was 2 mM in D2O at 25 
0C (Figure 3.6). 
It was observed that RG led to the dissolution of both guests (1a & 1b) in D2O. The 
encapsulation of benzyl azide 1a or phenylacetylene 1b in RG was evident from the chemical shift 
changes in the aromatic benzene protons. For example, the aromatic benzene protons (H2, H3, H4) 
in 1a were shifted upfield from ~7.35-7.40 ppm (Figure 3.6a) to ~ 6.88-6.98 ppm (Figure 3.6d) 
and the aromatic benzene protons (H6, H7, H8) in 1b were shifted upfield from ~7.34-7.53 ppm 
(Figure 3.6b) to ~ 6.96-7.15 ppm (Figure 3.6e). Also, the benzylic proton (H1) in guest 1a was 
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shielded from 4.36 ppm to 3.89 ppm and the alkyne proton (H5) in guest 1b was at 3.04 ppm 
suggesting the encapsulation of the guests and in the host molecular cavity. 
 
Figure 3.6. Partial 1H-NMR spectra (250 MHz, D2O, 2 mM) at 25 
0C of (a) 1a; (b) 1b; (c) RG; 
(d) (1:1) mole ratio of 1a & RG and (e) (1:1) mole ratio of 1b & RG. 
 
3.3.7. Proposed mechanism for the CuAAC catalyzed by RG 
A plausible mechanism for the CuAAC reaction in aqueous environment catalyzed by RG 
can be visualized as an encapsulation of the azide and alkyne substrates within the pseudo-β-D-
glucopyranoside cavity provided by RG. The close proximity of the two substrates with the 
molecular cavity of the RG in the presence of Cu(I) catalyst could be attributed to the significant 
rate enhancement of the coupling reaction. A schematic cartoon of the plausible encapsulation 
process is depicted in the scheme below (Figure 3.7). 
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Figure 3.7. Proposed mechanism for the CuAAC in water catalyzed by RG. 
 
3.4. Conclusions 
In conclusion, it was determined that RG was an efficient catalyst for the CuAAC reaction 
in aqueous media. RG shows a broad substrate specificity in the synthesis of 1,4-disubstituted 
1,2,3-triazole products for small and bulky azido and/or alkyne substrates. Also, it was found that 
RG was a capable catalyst in the di-CuAAC, substitution and one-pot CuAAC reactions in water 
affording the desired product in excellent yield within a short period of time. 
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3.5. Experimental section 
General information 
1H- and 13C-NMR spectra were recorded on a Bruker DRX-250, a Inova 400 and a Varian 
DD-500 spectrometers. Sample concentrations were about 10 % (w/v) in CDCl3 and DMSO-d6 
and the J values are given in Hz. 
Materials 
All reagents were used with no further purification unless otherwise specified. Compounds 
20, 21, RG and triazoles (6c, 7c, 10c, 12c & 19c-33c) are reported for the first time.  
 
Synthesis of resorcin[4]arene glycoconjugate (RG) 
Ocat-propargyl resorcin[4]arene (20): Compound 1 (5 g, 5.7 mmol) was dissolved in 
110 mL acetone. Potassium carbonate (6.26 g, 45 mmol) was added into the solution and allowed 
to stir for 10 min at room temperature. Propargyl bromide (8.1 mL, 90 mmol) was then added and 
the reaction mixture was refluxed overnight. After completion, the reaction mixture was cooled at 
room temperature and the salt was filtered out followed by the concentration of acetone. The 
product was purified by column chromatography using (1:9) ethyl acetate/hexane as a pale yellow 
solid in 5.91 g (88 %) yield. 1H NMR (250 MHz, CDCl3) δ 0.85 (t, J = 6.5 Hz, 12H), 1.25-1.36 
(m, 16H), 1.36 (m, 16H), 1.82-1.94 (m, 8H), 2.25 (s, 12H), 2.50 (t, J = 2.4 Hz, 4H), 4.11 (d, J = 
15.3Hz, 8H), 4.25 (d, J = 15.3Hz, 8H), 4.45 (t, J = 7.1 Hz, 4H), 6.39 (s, 4H); 13C NMR (62.5 MHz, 
CDCl3) δ 11.1, 14.0, 22.7, 28.5, 29.5, 31.9, 34.9, 38.3, 60.3, 74.8, 79.5, 124.3, 124.3, 133.9, 154.0; 
HRMS [M + Na]+ calcd for C80H96O8Na 1207.7003, found 1207.7034. 
Octa-sugar acetate resorcin[4]arene (21): Compound 20 (1 g, 0.84 mmol) was dissolved 
in 30 mL chloroform. CuI (32 mg, 0.17 mmol) and DIPEA (0.88 mL, 5 mmol) were then added to 
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the solution. Sugar azide 12 (5.6 g, 13.5 mmol) was then added to the solution. The reaction 
mixture was then refluxed overnight. After completion, the reaction was worked up using 
ammonium hydroxide solution and the organic phase was extracted and dried using Na2SO4. 
Chloroform was evaporated and the product was purified by column chromatography using (1:19) 
MeOH/DCM in order to separate the product from the excess sugar azide. The product 21 was 
collected as a yellow oil that solidified slowly to a pale yellow solid in 3.48 g (91 %) yield. 1H 
NMR (500 MHz, CDCl3) δ 0.80 (t, J = 6.6 Hz, 12H), 1.15-1.35 (m, 32H), 1.78-1.85 (bs, 12H), 
1.88 (s, 12H), 1.93 (s, 12H), 1.98 (s, 24H), 2.04 (s, 12H), 2.04 (s, 12H), 2.07-2.16 (bs, 12H), 2.37 
(bm, 8H), 3.71-3.77 (m, 8H), 3.91-4.00 (m, 8H), 4.06-4.14 (m, 8H), 4.22 (t, J = 2.9 Hz, 8H), 4.25 
(dd, J = 2.9, 4.4 Hz, 4H), 4.49 (bs, 16H), 4.55 (d, J = 8.1 Hz, 8H), 4.58 (t, J = 8.1 Hz, 4H), 4.93 
(t, J = 7.7 Hz, 8H), 5.03 (ddd, J = 3.3, 9.5, 13.2 Hz, 8H), 5.13 (q, J = 9.9 Hz, 8H), 7.69 (s, 8H); 
13C NMR (125 MHz, CDCl3) δ 10.7, 14.0, 20.3, 20.4, 20.4, 20.6, 22.7, 28.6, 29.6, 31.8, 35.2, 38.0, 
49.5, 61.6, 65.9, 67.5, 68.1, 70.7, 71.7, 72.4, 100.4, 123.7, 124.1, 124.2, 144.3, 144.5, 169.3, 170.0, 
170.5; HRMS [M + 2Na]2+ calcd for C208H280N24O88Na2 2283.8984, found 2283.8955. 
Resorcin[4]arene Glycoconjugate (RG): Acetylated sugar resorcin[4]arene 21 (1 g) was 
dissolved in (0.1 M) sodium methoxide solution. The reaction mixture was allowed to stir at room 
temperature for 4 hrs. After completion, the reaction mixture was neutralized with Dowex 50W-
X8. This was followed by filtration and concentration of methanol with no furthermore purification 
to afford RG as a pale yellow solid in 92 %; 1H NMR (500 MHz, DMSO-d6) δ 0.79 (t, J = 6.6 Hz, 
12H), 1.14-1.36 (m, 32H), 2.27 (bm, 8H), 2.27 (bs, 12H), 2.98 (t, J = 8.1 Hz, 8H), 3.05 (ddd, J = 
3.3, 9.2, 18.3 Hz, 8H), 3.11-3.19 (m, 16H), 3.41-3.47 (m, 8H), 3.67 (d, J = 10.6 Hz, 8H), 3.89 (bs, 
8H), 4.07 (bs, 8H), 4.24 (d, J = 7.0 Hz, 8H), 4.53 (bs, 24H), 4.63 (bs, 16H), 7.93-8.39 (bs, 12H); 
13C NMR (125 MHz, DMSO-d6) δ 11.1, 14.0, 22.2, 28.1, 29.1, 31.4, 34.8, 37.8, 49.6, 61.1, 65.4, 
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67.3, 70.0, 73,3, 76.6, 77.0, 102.9, 123.8, 124.3, 124.7, 142.9, 143.1; HRMS [M + 2Na]2+ calcd 
for C144H216N24O56Na2 1611.7294, found 1611.7374. 
 
General procedure for optimizing and scoping the CuAAC in water using RG. 
Azido substrates 1a-4a (1.0 mmol) and aryl/alkyl alkyne 1b-4b (1.05 equiv.) were added 
to a solution of copper(II) sulfate pentahydrates, Na-ascorbate and RG (1:3:1 mol%) in 10 mL 
water. The reaction mixture was then heated to 80 0C for 15-65 min. After completion, the reaction 
mixture was then extracted with DCM (2 x 5 mL). The combined organic layer was collected and 
dried over MgSO4. DCM was then concentrated and 
1H-NMR was taken in CDCl3.  
 
General procedure for CuAAC reactions of o-azidophenol derivatives in water using RG. 
Azidophenol derivative 5a-9a (1.0 mmol) and phenylacetylene 1b (1.05 equiv.) were 
added to a solution of copper(II) sulfate pentahydrates, Na-ascorbate and RG (1:3:1 mol%) in 10 
mL de-ionized distilled water. The reaction mixture was then heated to 80 0C for 20-45 min. After 
completion, the products were filtered through Buchner funnel and dried in vacuum over at 60 0C 
and NMR was taken in CDCl3 or DMSO-d6. 
 
General procedure for di-CuAAC using RG. 
Di-propargyl benzene 5b-7b (1.0 mmol) and benzyl azide derivatives 1a-4a (2.1 equiv.) 
were added to a solution of copper(II) sulfate pentahydrates, Na-ascorbate and RG (1:3:1 mol%) 
in 10 mL de-ionized distilled water. The reaction mixture was then heated to 80 0C for 45-60 min. 
After completion, the products were filtered through a Buchner funnel and dried in a vacuum oven 
at 60 0C and an NMR spectrum was taken in CDCl3 or DMSO-d6. 
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General procedure for one-pot CuAAC using RG. 
Phenylacetylene 1b (1.0 mmol) and bromide substrates (1.05 equiv.) with sodium azide 
(1.1 equiv) were added to a solution of copper(II) sulfate pentahydrates, Na-ascorbate and RG 
(1:3:1 mol%) in 10 mL de-ionized distilled water. The reaction mixture was then heated to 80 0C 
for 20-55 min. After completion, the products were filtered through a Buchner funnel and dried in 
vacuum oven at 60 0C and an NMR spectrum was taken in CDCl3 or DMSO-d6 
Triazole (1c): Beige solid (98 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.54 (s, 2H), 7.26-
7.41 (m, 8H), 7.68 (s, 1H), 7.79 (d, J = 7.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 54.0, 125.6, 
127.91, 128.0, 128.6, 128.7, 129.0, 130.4, 134.6. 
Triazole (2c): White solid (98 %) yield; 1H NMR (400 MHz, CDCl3) δ 4.57 (s, 2H), 4.65 
(s, 2H), 5.50 (s, 2H), 7.25-7.36 (m, 10H), 7.45 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 54.1, 63.6, 
72.5, 122.4, 127.7, 127.8, 128.1, 128.3, 128.7, 129.0, 134.43, 137.7, 145.5. 
Triazole (3c): Pale yellow solid (99 %) yield; 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 
7.4 Hz, 3H), 1.28-1.37 (m, 2H), 1.56-1.63 (m, 2H), 2.66 (t, J = 7.4 Hz, 2H), 5.46 (s, 2H), 7.17 (s, 
1H), 7.21-7.24 (m, 2H), 7.29-7.35 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 13.7, 22.3, 25.3, 31.4, 
53.9, 120.5, 127.9, 128.5, 128.9, 134.9. 
Triazole (4c): White solid (95 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.79 (s, 1H), 4.69 
(s, 2H), 5.44 (s, 2H), 7.21-7.22 (m, 2H), 7.30-7.33 (m, 3H), 7.45 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 54.1, 55.9, 128.0, 128.9, 129.0, 134.4. 
Triazole (5c): White solid (99 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.28 (s, 3H), 5.54 
(s, 2H), 7.16-7.22 (m, 3H), 7.28 (t, J = 7 Hz, 2H), 7.36 (t, J = 7 Hz, 2H), 7.53 (s, 1H), 7.76 (d, J = 
7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 18.9, 52.3, 125.6, 126.59, 128.0, 128.7, 129.1, 129.3, 
130.5, 131.0, 132.5, 136.9. 
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Triazole (6c): White solid (98 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.25 (s, 3H), 4.55 
(s, 2H), 4.62 (s, 2H), 5.48 (s, 2H), 7.11-7.13 (m, 1H), 7.15-7.21 (m, 2H), 7.24 (d, J = 7.0 Hz, 2H), 
7.29 (m, 4H), 7.33 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 18.9, 52.2, 63.6, 72.4, 126.5, 127.7, 
127.8, 128.3, 129.0, 129.4, 130.9, 132.3, 136.8, 137.6. 
Triazole (7c): White solid (90 %) yield; 1H NMR (400 MHz, CDCl3) δ 0.87 (t, J = 7 Hz, 
3H), 1.27-1.36 (m, 2H), 1.54-1-61 (m, 2H), 2.23 (s, 3H), 2.64 (t, J = 7.8 Hz, 2H), 5.45 (s, 2H), 
7.15-7.18 (m, 2H) 7.22-7.26 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 13.7, 18.9, 22.2, 25.3, 31.4, 
51.0, 120.2, 126.5, 128.8, 129.1, 130.8, 132.7, 136.8. 
Triazole (8c): White solid (95 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.21 (s, 3H), 3.49 
(s, 1H), 4.66 (s, 2H), 5.44 (s, 2H), 7.07-7.09 (m, 1H), 7.14-7.16 (m, 2H), 7.20-7.23 (m, 1H), 7.31 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 18.9, 52.3, 56.1, 126.6, 129.1, 129.4, 130.9, 132.26. 
Triazole (9c): Pale yellow solid (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 2H), 
5.48 (s, 2H), 6.80 (s, 1H), 6.84 (m, 2H), 7.24 (m, 2H), 7.36 (t, J = 7.0 Hz, 2H), 7.72 (bs, 1H), 7.78 
(d, J = 6.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 54.1, 55.2, 113.5, 114.1, 120.1, 125.5, 128.0, 
128.7, 130.1, 130.4, 136.0, 160.0. 
Triazole (10c): Brown oil (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.71 (s, 2H), 4.54 
(s, 2H), 4.62 (s, 2H), 5.40 (s, 2H), 6.77 (s, 1H), 6.79-6.85 (m, 2H), 7.20-7.26 (m, 2H), 7.28-7.30 
(m, 3H), 7.47 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 53.6, 54.9, 63.3, 72.1, 113.4, 113.7, 119.9, 
122.3, 127.4, 127.5, 128.0, 135.8, 137.5, 145.1, 159.7. 
Triazole (11c): Brown oil (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 0.78 (t, J = 7.3 Hz, 
3H), 1.19-1.28 (m, 2H), 1.46-1.54 (m, 2H), 2.56 (t, J = 7.7 Hz, 2H), 3.61 (s, 3H), 5.31 (s, 2H), 
6.66 (s, 1H), 6.71 (t, J = 9.0 Hz, 2H), 7.12 (t, J = 7.9 Hz, 1H), 7.19 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 13.3, 21.8, 24.9, 31.0, 53.2, 54.7, 113.0, 113.4, 119.6, 120.3, 129.5, 136.2, 148.2, 159.5. 
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Triazole (12c): White solid (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 3H), 4,22 
(bs, 2H), 4.71 (bs, 2H), 5.40 (s, 2H), 6.74 (s, 1H), 6.80 (m, 2H), 7.22 (t, J = 8.2 Hz, 1H), 7.59 (bs, 
1H); 13C NMR (100 MHz, CDCl3) δ 54.2, 55.2, 55.8, 113.7, 114.1, 120.3, 130.1, 135.7, 160.0. 
Triazole (13c): Pale yellow solid (99 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.45 (s,2H), 
7.10 (d, J = 7.1 Hz, 2H), 7.21-7.28 (m, 1H), 7.32-7.36 (m, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.66 (s, 
1H), 7.74 (d, J = 7.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 53.5, 122.8, 125.6, 128.2, 128.8, 
129.6, 130.3, 132.2, 133.6.  
Triazole (14c): Pale yellow solid (92 %) yield; 1H NMR (400 MHz, CDCl3) δ 4.54 (s, 2H), 
4.61 (s, 2H), 5.41 (s, 2H), 7.08 (d, J = 7.1 Hz, 2H), 7.21-7.28 (m, 6H) 7.43 (d, J = 7.4 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 53.5, 63.6, 72.6, 122.9, 127.8, 127.9, 128.4, 129.7, 132.3, 133.5, 137.6. 
Triazole (15c): White solid (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 0.85 (t, J = 7.4 
Hz, 3H), 1.26-1.35 (m, 2H), 1.54-1.62 (m, 2H), 2.63 (t, J = 7.4 Hz, 2H), 5.39 (s, 2H), 7.05 (d, J = 
7.1 Hz, 2H), 7.21 (s, 1H), 7.42 (d, J = 7.4 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 13.7, 22.6, 
25.3, 31.4, 53.4, 122.7, 129.5, 132.2, 133.9. 
Triazole (16c): Dark beige solid (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.94 (s, 1H), 
4.75 (s, 2H), 5.42 (s, 2H), 7.08 (d, J = 7.1 Hz, 2H), 7.44 (d, J = 7.4 Hz, 2H), 7.56 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 53.7, 122.9, 129.7, 132.3, 133.4. 
Triazole (17c): Pale red solid (94 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 7.01 (t, J = 
7.0 Hz, 1H), 7.15 (d, J = 7.2 Hz, 1H), 7.36 (d, J = 7.4 Hz, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.62 (d, J 
= 7.6 Hz, 1H), 7.95 (d, J = 7.9 Hz, 2H), 8.95 (s, 1H), 10.57 (s, 1H); 13C NMR (100 MHz, DMSO-
d6) δ 117.1, 119.5, 123.1, 124.6, 125.4, 125.6, 128.0, 128.9, 130.4, 130.6, 142.2, 150.1. 
Triazole (18c): Yellow solid (97 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.83 (s, 3H), 
7.02-7.07 (m, 2H), 7.27-7.31 (m, 1H), 7.34-7.41 (m, 3H), 7.76 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.9 
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Hz, 2H), 8.28 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 55.9, 121.2, 121.8, 125.4, 125.8, 126.2, 
128.0, 128.8, 130.1, 130.6. 
Triazole (19c): White solid (98 %) yield; 1H NMR (400 MHz, CDCl3) δ 1.37 (t, J = 6.9 
Hz, 3H), 4.08 (q, J = 6.9 Hz, 2H), 7.04 (m, 2H), 7.34 (m, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.81 (d, J 
= 7.8 Hz, 1H), 7.89 (d, J = 7.6 Hz, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 14.5, 64.6, 
113.2, 121.0, 121.6, 125.0, 125.6, 126.3, 127.9, 128.7, 129.8, 130.7, 147.0, 150.1. 
Triazole (20c): White solid (98 %) yield; 1H NMR (400 MHz, CDCl3) δ 0.93 (t, J = 6.8 
Hz, 3H), 1.40-1.47 (m, 2H), 1.72-1.78 (m, 2H), 4.05 (t, J = 6.3 Hz, 2H), 7.08 (t, J = 8.9 Hz, 2H), 
7.32-7.39 (m, 2H), 7.44 (t, J = 8.0 Hz, 2H), 7.83 (d, J = 7.8 Hz, 1H) 7.88 (d, J = 8.1 Hz, 2H), 8.36 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 13.7, 19.2, 31.0, 68.7, 113.2, 121.0, 121.7, 125.2, 125.7, 
126.4, 128.0, 128.8, 129.9, 130.7, 147.0, 150.4. 
Triazole (21c): Beige solid (99 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.13 (s, 2H), 7.08-
7.13 (m, 2H), 7.31 (m, 5H), 7.36-7.41 (m, 2H), 7.78 (d, J = 7.8 Hz, 2H), 7.85 (d, J = 7.8 Hz, 1H), 
8.33 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 71.1, 114.0, 121.7, 121.8, 125.2, 125.7, 126.8, 127.1, 
128.0, 128.3, 128.7, 128.8, 129.9, 130.6, 135.8, 149.9. 
Triazole (22c): White solid (95 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.15 (s, 4H), 5.44 
(s, 4H), 6.85-6.90 (m, 2H), 6.95-7.00 (m, 2H), 7.19 (d, J = 1.9 Hz, 2H), 7.20 (d, J = 3.8 Hz, 2H), 
7.30 (d, J = 1.9 Hz, 3H), 7.31 (d, J = 1.7 Hz, 2H), 7.58 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 
54.1, 63.5, 115.7, 122.2, 128.0, 128.7, 129.0, 134.5, 148.4. 
Triazole (23c): White solid (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.21 (s, 6H), 5.12 
(s, 4H), 5.43 (s, 4H), 6.83-6.87 (m, 2H), 6.93-6.98 (m, 2H), 7.03 (d, J = 7.6 Hz, 2H), 7.11-7.16 
(m, 4H), 7.20-7.24 (m, 2H), 7.47 (bs, 2H); 13C NMR (100 MHz, CDCl3) δ 18.8, 63.4, 115.6, 122.0, 
126.4, 128.9, 129.1, 130.8, 132.4, 136.6, 148.3. 
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Triazole (24c): White solid (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 6H), 5.12 
(s, 4H), 5.41 (s, 4H), 6.74 (s, 2H), 6.78 (m, 4H), 6.88 (bs, 2H), 6.98 (bs, 4H), 7.22 (t, J = 8.4 Hz, 
2H), 7.71 (bs, 2H); 13C NMR (100 MHz, CDCl3) δ 54.3, 55.1, 63.5, 113.5, 113.9, 115.4, 120.1, 
121.9, 129.9, 135.7, 148.2, 159.7. 
Triazole (25c): Yellow solid (96 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.16 (s, 4H), 
5.45 (s, 4H), 6.90-6.93 (m, 2H), 6.99-7.02 (m, 2H), 7.09 (d, J = 8.7 Hz, 4H), 7.44 (d, J = 7.7 Hz, 
4H), 7.70 (bs, 2H); 13C NMR (100 MHz, CDCl3) δ 53.5, 115.6, 122.2, 122.7, 129.6, 132.1, 133.5, 
148.4. 
Triazole (26c) Yellow solid (94 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.11 (s, 4H), 5.61 
(s, 4H), 6.61 (d, J = 2.2 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 6.71 (t, J = 2.3 Hz, 1H), 7.18 (t, J = 8.2 
Hz, 1H), 7.30-7.40 (m, 10H), 8.28 (s, 2H);13C NMR (100 MHz, CDCl3) δ 52.8, 61.1, 101.6, 107.3, 
124.6, 127.9, 128.1, 128.7, 135.9, 159.2. 
Triazole (27c): White solid (92 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.24 (s, 6H), 5.08 
(s, 4H), 5.49 (4H), 6.52-6.55 (m, 3H), 7.09-7.13 (m, 3H), 7.16-7.20 (m, 4H), 7.23-7.27 (m, 2H), 
7.40 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 18.9, 52.3, 62.0, 102.1, 107.5, 126.6, 129.1, 129.4, 
129.9, 130.9, 132.3, 136.8, 159.3. 
Triazole (28c): White solid (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.73 (s, 6H), 5.11 
(s, 4H), 5.46 (s, 4H), 6.54 (m, 3H), 6.76 (s, 2H), 6.83 (t, J = 7.5 Hz, 1H), 7.25 (m, 2H) 7.58 (bs, 
2H); 13C NMR (100 MHz, CDCl3) δ 54.1, 55.2, 61.8, 101.9, 107.5, 113.6, 114.1, 120.1, 129.9, 
130.1, 135.8, 159.3, 159.9. 
Triazole (29c): Yellow solid (96 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 5.07 (s, 4H), 
5.56 (s, 4H), 6.57 (d, J = 2.3 Hz, 1H), 6.59 (d, J = 2.3 Hz, 1H), 6.67 (t, J = 2.5 Hz, 1H), 7.14 (t, J 
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= 7.9 Hz, 1H), 7.22-7.26 (m, 4H), 7.51-7.55 (m, 4H), 8.28 (s, 2H); 13C NMR (100 MHz, DMSO-
d6) δ 52.5, 61.5, 102.1, 107.8, 121.9, 125.2, 130.6, 132.1, 135.8, 143.5, 159.7. 
Triazole (30c): Yellow solid (92 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.06 (s, 4H), 
5.60 (s, 4H), 6.95 (s, 4H), 7.30 (m, 2H), 7.32-7.33 (m, 3H), 7.34 (d, J = 1.8 Hz, 1H), 7.35-7.36 (m, 
2H), 7.37-7.40 (m, 2H), 8.25 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 52.8, 61.6, 115.6, 124.5, 
127.9, 128.1, 128.73, 135.9, 143.2, 152.3. 
Triazole (31c): White solid (93 %) yield; 1H NMR (400 MHz, CDCl3) δ 2.24 (s, 6H), 5.06 
(s, 4H), 5.49 (s, 4H), 6.83 (s, 4H), 7.10-7.11 (m, 2H), 7.16-7.19 (m, 4H), 7.23-7.27 (m, 2H), 7.41 
(bs, 2H); 13C NMR (100 MHz, CDCl3) δ 18.9, 52.4, 62.6, 115.8, 126.6, 129.1, 129.3, 130.9, 132.3, 
136.8, 152.7. 
Triazole (32c): White solid (92 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 6H), 5.09 
(bs, 4H), 5.46 (s, 4H), 6.75 (s, 2H), 6.81-6.86 (m, 8H), 7.24 (m, 2H), 7.67 (bs, 2H); 13C NMR (100 
MHz, CDCl3) δ 54.3, 55.2, 62.4, 113.6, 114.1, 115.7, 120.1, 130.0, 135.7, 152.6, 159.9. 
Triazole (33c): Yellow solid (92 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 5.07 (s, 4H), 
5.60 (s, 4H), 6.95 (s, 4H), 7.26 (d, J = 8.6 Hz, 4H), 7.57 (d, J = 8.6 Hz, 4H), 8.26 (s, 2H); 13C NMR 
(100 MHz, DMSO-d6) δ 52.1, 61.5, 115.6, 121.4, 124.6, 130.2, 131.7, 135.4, 143.3, 152.3. 
Triazole (34c): Yellow solid (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 5.67 (s, 2H), 
7.24-7.32 (m, 1H), 7.34-7.41 (m, 3H), 7.48-7.70 (m, 2H), 7.69 (s, 1H), 7.74-7.85 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 54.3, 119.7, 125.6, 125.8, 126.6, 127.3, 127.7, 127.8, 128.1, 128.7, 
128.8, 129.1, 130.3, 131.9, 133.1. 
Triazole (35): Pale yellow solid (92 %) yield; 1H NMR (400 MHz, DMSO-d6) δ 6.26 (s, 
2H), 7.35 (m, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.63 (t, J = 7.5 Hz, 2H), 7.75 (m, 1H), 7.87 (d, J = 7.6 
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Hz, 2H), 8.09 (d, J = 7.8 Hz, 2H), 8.52 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 56.0, 123.0, 
125.2, 128.2, 127.9, 128.2, 128.9, 130.7, 134.3, 146.3, 192.2. 
Triazole (36): Pale yellow solid (95 %) yield; 1H NMR (400 MHz, CDCl3) δ 3.84 (s, 3H), 
5.77 (s, 2H), 6.93 (d, J = 6.9 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.37 (t, J = 7.8 Hz, 2H), 7.90 (s, 
1H), 7.92 (d, J = 7.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 55.2, 114.4, 125.8, 126.9, 128.8, 
130.6, 164.6, 188.6. 
Triazole (37): White solid (93 %) yield; 1H NMR (400 MHz, CDCl3) δ 1.22 (t, J = 6.4 Hz, 
3H), 4.18 (q, J = 7.1 Hz, 2H), 5.12 (s, 2H), 7.25-7.29 (m, 1H), 7.36 (t, J = 7.4 Hz, 2H), 7.77 (d, J 
= 7.1 Hz, 1H), 7.88 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 13.9, 50.9, 62.3, 125.7, 128.2, 128.7, 
130.3, 166.2. 
Triazole (38c): White solid (91 %) yield; 1H NMR (400 MHz, CDCl3) δ 4.92 (t, J = 1.7 
Hz, 1H), 4.94 (t, J = 1.7 Hz, 1H), 5.23-5.31 (m, 2H), 5.93-6.03 (m, 1H), 7.23-7.29 (m, 1H), 7.33-
7.38 (m, 2H), 7.73 (s, 1H), 7.76-7.79 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 52.2, 119.5, 119.9, 
125.5, 127.9, 128.6, 130.4, 131.1. 
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Chapter 4 
Resorcin[4]arene Cavitand-based Carcerands (RCCs) via Tandem CuAAC 
 
4.1. Introduction 
The remarkable structure of resorcin[4]arenes and the chalice shaped structures 
“cavitands”,1 the ease of chemical modification on their upper rims,2 manipulation of their cavity 
sizes,3 and the inherent spatial directionality on their upper rim,4 led synthetic chemists to explore 
their utilities in the synthesis of grand sized assemblies, dendrimer, and supramolecular capsules.5 
In particular, designing and constructing of resorcin[4]arene/cavitand capsules by joining two 
resorcin[4]arenes or cavitands together have become significant using three typical approaches, 
namely; self-assemble hydrogen bonding6-12, self-assemble metal complexation13-16 and through 
stable covalently bond bridges in the synthesis of carcerands and/or hemicarcerands.17 
Resorcin[4]arenes as mentioned previously in Chapter 1 are capable of forming 
supramolecular structures (hexamer and dimer) via self-assemble H-bonding (see Chapter 1, 
Figure 1.5 & Figure 1.6) in the presence of water molecules or in the existence of an appropriate 
H-bond acceptor organic bridges.6-10 In addition, with respect to cavitands, the formation of 
dimeric assemblies via self-assemble H-bonding was established by Rebek and coworkers in the 
synthesis of cylindrical-type capsule using modified donor/acceptor H-bonding 
pyrazinedicarboximide-bridged cavitand with an estimated cavity size of approximately 14.7 Å by 
5.7 Å.11 Similarly, a tubular-shaped capsule composing of 2-bezimidazole linkers have been 
reported by Ebbing and coworkers (Figure 4.1).12 
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Figure 4.1. Cylindrical-type structure cavitand via self-assemble H-bonding. 
 
Numerous functionalized cavitands with metal coordinating ligands on their upper rims or 
between the neighboring phenols (-OHs), form self-assembled metal-coordination cages with 
metals such as Pd, Pt, Ag, Fe and Co (Figure 4.2).13-16 
 
Figure 4.2. Cavitand cages via self-assembled metal complexation. 
 
Molecular cages (carcerands/hemicarcerands) provide a nanometer size cavity in which 
small organic molecules or reactive species could be trapped inside and are therefore also known 
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as nanoscale reactors.17 The concept of carceplex was first proposed by Donald Cram18 in 1982 
and after three years, Cram reported the construction of the first carceplex upon joining two 
modified resorcin[4]arene cavitand subunits through their upper rims via multiple sulfur linkers 
which was then fully characterized later in 1989 (Scheme 4.1).19,20 
 
Scheme 4.1. Synthesis of the first carceplex. 
 
A number of covalently bonded cavitand cages (carcerands and hemicarcerands) have been 
described by coupling the two cavitands together with covalent linkers, e.g.,; sulfur,21 alkyl,22,23 
imine, amine,24 lactone, lactam,25 biphenyl, o-oxylyl26 and mono-, bis-acetylene27  (Figure 4.3). 
As well, mono-, di- and tetra-linkers among two cavitands through their bridges between the 
adjacent phenols (-OHs) have been reported.28 Additionally, resorcin[4]arene cages via four 
piperazine units between two resorcin[4]arene molecules have been reported in literature.29 
 
Figure 4.3. Structure of carcerands and hemicarcerands. 
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Carcerand formation, requiring the assembly of tandem multiple covalent bonds, heavily 
depends on chemical transformations that reliably connect two building blocks in the presence of 
other functional groups and across a wide range of reaction conditions. The Cu(I)-catalyzed azide-
alkyne cycloaddition (CuAAC)30 reaction is among the recently discovered transformations that 
has emerged as the premier example of click chemistry (CC). The Cu(I)-catalyzed reaction 
transforms organic azides and terminal alkynes exclusively into the corresponding 1,4-
disubstituted 1,2,3-triazoles and is incredibly fast (7 to 8 orders of magnitude relative to the thermal 
process31) making it a convenient coupling reaction. Numerous applications of the CuAAC 
reaction reported during the last several years have been regularly reviewed, and are continually 
enriched by investigators in many fields but no report of its use in synthesis of carcerand has been 
reported.32 
In this Chapter, the synthesis of resorcin[4]arene cavitand-based carcerands (RCCs) by 
coupling tetra-alkyne (5a-d) and tetra-azido (8a-d) cavitands through their C-2 position on the 
upper rims via four 1,4-disubstituted 1,2,3-triazole units using the CuAAC reaction is described. 
Many covalently linked resorcin[4]arene based carcerands/hemicarcerands have been reported as 
mentioned previously, however, high dilution condition is often required in order to avoid any 
cross-linking or polymer formation. Owing to the unique characteristic of the CuAAC reaction, it 
is worth exploring its efficiency in the synthesis of carcerands.  
The strategy for the carcerand formation could be considered to be composed of two 
distinct events, the first being the intermolecular CuAAC between one azido and one alkyne from 
each cavitand halves resulting in the first 1,2,3-triazole linker that holds the two cavitands (and via 
infra the complimentary azide/alkyne groups) in close proximity, while the second event is the 
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multiple (three) intramolecular CuAAC reactions leading up to the stitching of the two halves 
together to form the carcerand (Scheme 4.2). 
 
Scheme 4.2. The synthetic strategy for the synthesis of RCCs. 
 
4.2. Design and the synthesis of RCCs 
4.2.1. The design strategy 
For synthesis of the carcerands, it is advantageous to start with a preformed spatially 
directional cavity and resorcin[4]arene cavitands with their rigid ‘chalice’ shape fit the bill 
perfectly. Resorcin[4]arenes are known to adopt different conformations as mentioned previously 
(see Chapter 1, section 1.1) but only the crown (C4v) conformation is suitable for the carcerands 
synthesis. The synthetic protocol began with the synthesis of the octa-hydroxy resorcin[4]arene 
(1a-1d)2-4 with different length aliphatic alkane chains on their lower rims, i.e. methyl, propyl, 
hexyl and nonyl using a standard experimental protocol; resorcin[4]arenes (2a-d)2-4 prefer the 
crown conformation.2-4 The crown (C4v) conformation was further locked into a rigid ‘chalise’ 
shape by bridging the adjacent phenolic (-OH) groups with methylene linkers to obtained cavitands 
(2a-2d) in high yields. Free-radical bromination installed the Br on the benzylic C-2 position (3a-
d)2-4, which upon treatment with NaN3 or propargyl alcohol resulted in the corresponding tetra-
azido (4a-d)33 and tetra-alkyne (5a-d)33 cavitands, respectively (Scheme 4.3). 
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Scheme 4.3. Synthesis of cavitand intermediates 4 and 5. 
 
4.2.2. Synthesis of cavitands intermediates (4 & 5) 
The bridged cavitands (2a-d) were synthesized from the reaction of 1a-d with 
dibromomethane in presence of potassium carbonate in hot DMF. Free-radical bromination on the 
benzylic C-2 position of cavitands (2a-d) using NBS/AIBN in hot benzene afforded the bromo-
cavitands 3a-d in gram quantities (>85 %). The azido-cavitands 4a-d were prepared by treating 
3a-d with NaN3 in DMF at room temperature (>90 % isolated yields), while tetra-alkyne 
intermediates 5a-d were obtained in high yields (>80 %) upon the reaction of 3a-d with propargyl 
alcohol in the presence of NaH (60 %) in dry THF. 
All compounds were characterized from their respective NMR spectra. In their 1H-NMR 
spectra (400 & 250 MHz, CDCl3), for example, compounds 4a and 4c, the benzylic protons (-
CH2N3, Ha) were at 4.31 and 4.34 ppm, respectively. The methylene bridge protons (-OCH2O-, 
Hc,c’) were observed as two doublets at 4.38 and 5.93 ppm (J = 7.1 Hz) in 4a and at 4.39 and 5.95 
ppm (J = 7.1 Hz) in 4c. In their 
13C-NMR spectra, the benzylic carbons (-CH2N3, Ca) were at 44.9 
ppm (Figure 4.4). 
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Figure 4.4. Partial 1H- and 13C-NMR spectrum of (a) 4a and (b) 4c. 
 
Similarly, in the 1H-NMR spectra (400 & 250 MHz, CDCl3) of compound 5a and 5c the 
benzylic protons (-CH2OCH2CCH, Ha) were around ~4.45 ppm and the methylene bridge protons 
(-OCH2O-, Hc,c’) were observed as two doublets at 4.44 and 5.88 ppm (J = 7.2 Hz) in 5a and at 
4.42 and 5.87 ppm (J = 7.3 Hz) in 5c. The terminal alkyne protons (-CCH, Hf) in cavitand 5a 
showed as a triplet at 2.46 (J = 2.1 Hz) while it was found at 2.45 (J = 2.2 Hz) ppm in cavitand 5c. 
The methyleneoxy protons (-CH2OCH2CCH, He) were observed as a doublet at 4.13 ppm (J = 2.4 
Hz). Further, in the 13C-NMR spectra of compounds 5a and 5c, the alkyne carbons Cf and Cg were 
at 74.3 and 79.8 ppm in 5a and at 74.4 and 80.0 ppm in 5c. The propargyl methylene carbons (-
CH2OCH2CCH, Ce) were found at around 57.6 (5a) and 57.7 (5c) ppm and the benzylic methylene 
carbons (-CH2OCH2CCH, Ca) around 61.5 (5a) and 61.7 (5c) ppm (Figure 4.5). 
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Figure 4.5. Partial 1H- and 13C-NMR spectrum of (a) 5a and (b) 5c. 
 
4.2.3. Optimizing the CuAAC reaction 
After successfully synthesizing the tetra-azido (4) and tetra-alkyne (5) cavitand 
intermediates, the CuAAC was investigated and reaction condition was optimized. For example, 
all compounds were subjected to investigate the CuAAC reaction for modeling the 
resorcin[4]arene cavitand carcerands (RCC 1-4). Cavitands 4a-d compose of four benzyl azide 
monomers, while cavitands 5a-d contain four 3-benzeloxy-1-propyne units. Thus, compounds 4a-
d (0.1 mmol) were treated with 3-benzeloxy-1-propyne (8.0 equiv.), while compounds 5a-d (0.1 
mmol) were coupled with benzyl azide (8.0 equiv.) for the synthesis of cavitands 6a-d and 7a-d, 
respectively. All CuAAC reactions were carried out in 40 mL refluxed chloroform (2.5 mM 
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concentration with respect to the number of moles of azido/alkyne cavitands) in the presence of 
catalytic amount of CuI (10 mol%) and DIPEA (6.0 equiv.) (Scheme 4.4). 
 
Scheme 4.4. Synthesis of cavitands 6a-d & 7a-d. 
 
It was found that all reactions were completed within 6 hrs affording cavitands 6a-d and 
7a-d in high yield (>90 % isolated yield). The structures of the resulted compounds were 
established from their respective 1H and 13C NMR data (400 MHz, CDCl3). For example, in the 
1H-NMR spectra of cavitands 6a and 6c, the benzylic methylene protons (-CH2-N, Ha) were at 
5.23 ppm in 6a and at 5.29 ppm in 6c. The new singlet at 4.65 ppm in 6a and at 4.72 ppm in 6c 
were for the benzylic ether protons (ph-CH2-OCH2, Hh). The resonances, singlets, at 7.54 and 7.61 
ppm were attributed to the triazole protons (Hf) with respect to 6a and 6c. Further, in their 13C 
NMR spectra, the triazole carbons (Cf & Cg) were observed at ~121 and 150.0 ppm (Figure 4.6). 
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Figure 4.6. Partial 1H- and 13C-NMR spectra of (a) 6a and (b) 6c. 
 
Likewise, it was observed the disappearance of the terminal alkyne protons (-C CH, Hf) 
in the 1H-NMR spectra (400 MHz, CDCl3) for both 7a and 7c. The resonances, singlets, around 
~5.53 ppm were ascribed to the benzylic methylene protons (-CH2-N, He) and the triazole protons 
(Hf) were found at 7.62 ppm. In their 13C NMR, the triazole carbons (Cf & Cg) were observed at 
~123 and 145.0 ppm (Figure 4.7). 
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Figure 4.7. Partial 1H- and 13C-NMR spectra of (a) 7a and (b) 7c. 
 
4.2.4. Synthesis of resorcin[4]arene cavitand-based carcerand RCC1-4 
With the reaction conditions optimized, azido (4a-d) and alkyne (5a-d) cavitand 
intermediates were subjected for the synthesis of the carcerand via the CuAAC reaction but to our 
disappointment no carcerand formation occurred even after 7 days at 5 mM concentration and the 
unreacted starting materials were recovered (Scheme 4.5). Repeating the reaction at higher 
cavitand concentrations (10 and 20 mM) led to no appreciable carcerand construction but the 
formation of polymeric material was detected. 
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Scheme 4.5. Synthesis of RCC1-4. 
 
Researching the failed reaction, it appeared that the steric bulk of the substrate may play a 
critical role in this coupling reaction; the large steric bulk of the two cavitands halves may hinder 
the intramolecular coupling reaction. Specifically, we suspected that close proximity of the azido 
groups to the cavitand core prevented its addition to the activated Cu-alkyne complex (a key step 
in the Cu(I)-catalyzed azide-alkyne coupling), resulting in a failed coupling. While sterics play a 
critical role in the intramolecular CuAAC reaction no such limitation is placed for the 
intermolecular coupling in which sideways approach is preferred and is evident in the polymer 
formation observed at higher concentrations. (Scheme 4.6). 
 
Scheme 4.6. Proposed mechanism for the CuAAC of cavitands 4a-d and 5a-d. 
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To test this hypothesis, tetra-azido cavitands (8a-d) were synthesized from the 
corresponding bromo cavitands (3a-d) upon nucleophilic substitution with 2-azidoethanol in the 
presence of NaH in dry THF (Scheme 4.7). In the azido-cavitands the added ethylene linker moves 
the azido functionality further away from the cavitand core, thus, reducing the steric bulk during 
the coupling reaction. 
 
Scheme 4.7. Synthesis of tetra-azido cavitands 8a-d. 
 
Tetra-azido cavitands (8a-d) were characterized from their respective 1H- (400 MHz, 
CDCl3) and 
13C-NMR spectra (100 MHz, CDCl3). For cavitand 8a and 8c, it was observed the 
presence of two triplet corresponded for the ethylene protons (-OCH2CH2N3, Hh) and (-
OCH2CH2N3, Hi) around 3.36-3.39 (J = 4.7, 5.2 Hz) and 3.60-3.62 (J = 4.8 Hz), respectively. Also, 
the ethylene carbons (-OCH2CH2N3, Ch) and (-OCH2CH2N3, Ci) were observed around 63.1 and 
~44.9-50.5 ppm, respectively (Figure 4.8). 
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Figure 4.8. Partial 1H- and 13C-NMR spectra of (a) 8a and (b) 8c. 
 
4.2.5. Synthesis of resorcin[4]arene cavitand-based carcerand RCC5-8 
The flexible azido intermediates (8a-d) were then treated with the alkyne cavitands (5a-d) 
for the formation of the carcerands (RCC 5-8). The CuAAC reaction of the new azido-cavitands 
(8) with the complementary alkyne (5) cavitands in 5 mM solution in refluxed chloroform with 
catalytic amount of CuI (10 mol%) and DIPEA (6.0 equiv.) gave the desired RCC5-8 in good to 
excellent yield (Table 4.1). 
The formation of the carcerand in excellent yield with the sterically less demanding tetra-
azido (8), lends support to the hypothesis that the steric bulk indeed was a determining factor in 
the failed intramolecular CuAAC coupling between cavitands 4 and 5. Interestingly, it was 
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observed that the length of the alkyl group on the lower rim of the cavitands also influenced the 
efficiency of the carcerand formation. Notably, the isolated yield of the carcerand increased, 32 % 
to 95 %, with the increasing chain length from a CH3 to n-C9H19 group (Entries 1 & 10). Although 
it is difficult to speculate on the origin of this effect but the enhanced solubility and greater 
hydrophobicity of the alkyl chains may allow for better association for the intramolecular CuAAC 
reaction. 
 
Table 4.1. Synthesis of RCC5-8 via CuAAC. 
 
Entry Azido Alkyne Conc. (mM) Time (day) Product Yielda 
1   5 2  32 % 
2 8a 5a 10 1 RCC5 ~10 % 
3   20 0.25  N/A 
4   5 2  39 % 
5 8b 5b 10 1 RCC6 ~10 % 
6   20 0.25  N/A 
7   5 2  89 % 
8 8c 5c 10 1 RCC7 69 % 
9   20 0.25  54 % 
10   5 2  95 % 
11 8d 5d 10 1 RCC8 82 %b 
12   20 0.25  66 %b 
a Isolated yield. N/A= Polymeric material was obtained. 
 
At 5 mM the substrate concentration is much higher than that reported for the synthesis of 
covalently linked resorcin[4]arane cavitands in literature4 suggesting that the fast CuAAC 
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reactions are ideally suited for assembly of the carcerand molecules via multiple covalent bonds. 
Reactions at much higher concentration of 10 and 20 mM (Table 4.1), at which the intermolecular 
reaction resulting in the polymeric material is more likely, the isolated yield of the carcerand, to 
our surprise, was quite good (Table 4.1, entries 9 and 12); though some polymerization was also 
observed. 
The isolated carcerands (RCC5-8) were subjected to NMR, FT-IR and high resolution 
mass spectral characterization to confirm their structure. In a representative 1H-NMR (600 MHz, 
CHCl3) spectrum (Figure 4.9), for carcerand RCC7, the absence of alkyne protons (-CCH, Hf 
observed in 5c, see Figure 4.5b) and the downfield shift in resonances of the ethylene protons (-
OCH2CH2-) Hh and Hi (3.37 and 3.61 ppm, respectively, in 8c, see Figure 4.8b) to ~ 4.25-5 ppm 
confirmed the azide alkyne coupling; the triazole protons (1H, bs) was observed at 7.87 ppm. 
Similarly, in the 13C-NMR (150 MHz, CHCl3) spectrum of RCC7, the alkyne Cf and Cg 
resonances were missing (Figure 4.9).  
 
Figure 4.9. 1H- and 13C-NMR spectra of RCC7. 
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Attempts to acquire NMR spectra with sharper resonances did not materialize despite 
acquisitions on different magnets (250, 400, 500 MHz), at varying sample concentrations (20 mM 
to 2 mM), and at different probe temperatures (25 and 40 oC), which could be because of the high 
molecular mass of the carcerands and slower molecular motions due to the rigid core. 
Next, the formation of all four 1,2,3-triazole units was investigated using FT-IR, i.e.; the 
disappearance of both terminal alkyne (-C≡C- stretch 2260-2100 cm-1 & -C≡C-H stretch 3330-
3270 cm-1) and terminal azido (-N=N+=N- 2100 cm-1) signals and the appearance of the triazole 
around 1600 cm-1. For example, it was determined from the FT-IR spectra of RCC7 the 
disappearance of the terminal alkyne peaks from (-CC- stretch ~2116 cm-1 & the -CC-H stretch 
~3290 cm-1) and the terminal azido (-N3 ~2100 cm
-1) signals supported the carcerand formation 
(RCC7, Figure 4.10). 
 
Figure 4.10. FT-IR spectra (3500-800 cm-1) of (a) 5c; (b) 8c; (c) RCC7. 
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The HRMS (ESI-Q-TOF) of the carcerand confirmed its chemical composition; for RCC1 
m/z (ESI-Q-TOF): observed 1854.7045 (M*)+, calculated 1854.7130 (M*)+ ; for RCC2 m/z (ESI-
Q-TOF): observed 2078.9533 (M*)+, calculated 2078.9634 (M*)+; for RCC3 m/z (ESI-Q-TOF): 
observed 2414.3211 (M+H)+ calculated 2414.3233 (M+H)+; for RCC4 m/z (ESI-Q-TOF): 
observed 1375.8552 (M+2)+2, calculated 1375.8573 (M+2)+2. 
To understand the kinetics of the reaction, the progress of the coupling reaction during 
formation of RCC7 was monitored with time; aliquots were withdrawn at 4, 12, 24, 36 and 48 hrs. 
The reaction was slow and after 4 hrs only 18 % product was formed and the reaction progressively 
became slower resulting in 89 % yield in 48 hrs. The progressively slower rate was a consequence 
of the declining substrates concentration. Importantly, there was no isolation of the partially 
bridged hemi-carcerand (1, 2 or 3 bridges), in fact the 1H-NMR of the product after 4 hrs at 18 % 
yield was identical to the one obtained after 48 hrs, confirming the formation of the carcerand 
RCC7 with four triazole linkages. The isolation of RCC7, the lack of the hemi-carcerand 
formation and the concentration dependency of the reaction rate suggest that, in the carcerand 
formation, the intermolecular CuAAC (resulting in the first 1,2,3-triazole linker between the 
cavitand halves, Scheme. 4.2) is the rate limiting step. The second event, the multiple (three) 
tandem intramolecular CuAAC reactions leading up to the stitching of the two halves together to 
form the carcerand is fast and is a testament to the fast reaction kinetics of the CuAAC coupling. 
 
4.3. Conclusions 
In conclusion, four novel resorcin[4]arene cavitand based-carcerands (RCCs) have been 
synthesized, for the first time, using the azido/alkyne cavitands via the CuAAC reaction. Unlike 
the most reports of covalently linked carcerand synthesis accomplished at very dilute 
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concentration, the fast kinetics of the CuAAC enabled carcerand synthesis at much higher 
concentration. The carcerand formation is believed to involve two distinct events, the 
intermolecular (slower, rate limiting step) and intramolecular (fast, three couplings) CuAAC 
reactions. The length of the alkyl chains, on the lower rim of the resorcin[4]arene cavitand, 
influenced the carcerand formation, i.e., higher yield with longer alkyl chain. Importantly, the 
formation of the covalently linked carcerands was accomplished in good to excellent yield in up 
to 20 mM concentrations. The carcerand now can be synthesized in gram quantities and are being 
evaluated for their inclusion and materials properties. 
 
4.4. Experimental section 
General information 
1H- and 13C-NMR spectra were recorded on a Bruker DPX-250, a Inova 400 and a Varian 
DD-500 spectrometers. Sample concentrations were about 10 % (w/v) in CDCl3 and DMSO-d6 
and the J values are given in Hz. The mass spectral analyses were performed on an Aligent 
Technologies 6540 UHD Accurate-Mass Q-TOF LC/MS. 
Materials 
All reagents were used with no further purification unless otherwise specified. 2-Methyl 
resorcinol (98 %) was purchased from Acros Organics Chemical Company. Azobisisobutylonitrile 
(AIBN) was re-crystallized from hot ethanol. N-Bromosuccinimide (NBS) was re-crystallized 
from hot water. THF was distilled by drying it over sodium metal in the presence of benzophenone 
as an indicator and stored under nitrogen. Compounds 2d, 3d, 4b, 4d, 5b, 5d, 6a-d, 7a-d, 8a-d 
and RCC5-8 are reported for the first time. 
 
120 
 
General procedure for the synthesis of octa-hydroxy resorcin[4]arenes (1a-d) 
2-Mehtyl resorcinol (10.0 mmol) was dissolved in 80 mL of ethanol and 18.5 mL of 37 % 
aqueous HCl. The solution was cooled in ice bath and aldehyde (10.0 mmol) was added slowly in 
10 min period of time. The reaction mixture was stirred at 0 0C for 5 min which was then refluxed 
for 12 hrs. An orange coloured compound was precipitated from the reaction mixture. The 
precipitated compound was filtered out using a Buchner funnel and washed several times with cold 
ethanol and distilled water. The product was then collected and dried in a vacuum oven at 40 0C. 
Octa-hydroxy resorcin[4]arene (1a): Pale yellow solid (84 %) yield. 1H NMR (400 MHz, 
DMSO-d6) δ 1.69 (d, J = 6.8 Hz, 12H), 1.94 (s, 12H), 4.41 (q, J = 6.3 Hz, 4H), 7.38 (s, 4H), 8.67 
(s, 8H); 13C NMR (100 MHz, DMSO-d6) δ 10.1, 20.2, 28.7, 111.6, 120.9, 125.8, 148.7. 
Octa-hydroxy resorcin[4]arene (1b): Pale yellow solid (79 %) yield. 1H NMR (400 MHz, 
DMSO-d6) δ 0.95 (t, J = 7.1 Hz, 12H), 1.22-1.27 (m, 8H), 1.97 (s, 12H), 2.24-2.27 (m, 8H), 4.26 
(d, J = 7.6 Hz, 4H), 7.32 (s, 4H), 8.68 (s, 8H); 13C NMR (100 MHz, DMSO-d6) δ 10.1, 13.9, 20.8, 
33.8, 35.0, 111.6, 121.3, 124.8, 149.0. 
Octa-hydroxy resorcin[4]arene (1c): Pale yellow solid (80 %) yield. 1H NMR (250 MHz, 
DMSO-d6) δ 0.89 (t, J = 6.5 Hz, 12H), 1.25-1.38 (m, 32H), 1.99 (s, 12H), 2.15-2.29 (m, 8H), 4.25 
(t, J = 7.6  Hz, 4H), 7.23 (s, 4H), 8.69 (s, 8H); 13C NMR (62.5 MHz, DMSO-d6) δ 10.1, 13.9, 22.2, 
28.0, 29.0, 31.6, 34.3, 111.7, 120.7, 124.7, 149.1. 
Octa-hydroxy resorcin[4]arene (1d): Pale yellow solid (83 %) yiled. 1H NMR (400 MHz, 
DMSO-d6) δ 0.87 (t, J = 6.1 Hz, 12H), 1.15-1.37 (m, 56H), 1.96 (s, 12H), 2.11-2.17 (m, 8H), 4.21 
(t, J = 7.1 Hz, 4H), 7.09 (s, 4H), 8.66 (s, 8H); 13C NMR (100 MHz, DMSO-d6) δ 10.0, 13.9, 22.2, 
28.0, 29.2, 29.3, 29.4, 31.5, 33.5, 34.2, 111.6, 120.3, 124.4, 149.2. 
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General procedure for the synthesis of resorcin[4]arene cavitands (2a-d) 
Octa-hydroxy resorcin[4]arene 1 (5.0 mmol) was dissolved in 66 mL DMF. Potassium 
carbonate (40.0 mmol) was added into the solution and allowed to stir for 10 min at room 
temperature. Dibromomethane (80.0 mmol) was then added and the reaction mixture was heated 
to 70 0C overnight. After completion, the reaction mixture was cooled at room temperature and 
the salt was filtered out using Buchner funnel. The reaction mixture was then extracted using ethyl 
acetate or chloroform (100 mL) and water (3 x 50 mL). The organic phase was collected and dried 
over Na2SO4 and the solvent was evaporated. The product was purified by column chromatography 
ethyl acetate/hexane or chloroform/hexane. 
Bridge resorcin[4]arene cavitand (2a): Pale yellow solid (85 %) yield. 1H NMR (400 
MHz, CDCl3) δ 1.79 (d, J = 7.2 Hz, 12H), 2.03 (s, 12H), 4.32 (d, J = 6.7 Hz, 4H), 5.03 (q, J = 7.0, 
Hz, 4H), 5.94 (d, J = 6.7 Hz, 4H), 7.17 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 10.3, 16.1, 31.2, 
98.4, 116.9, 123.5, 138.8, 152.8. 
Bridge resorcin[4]arene cavitand (2b): Pale yellow solid (90 %) yield. 1H NMR (400 
MHz, CDCl3) δ 1.04 (t, J = 7.3 Hz, 12H), 1.41 (q, J = 7.4, 14.8 Hz, 8H), 1.99 (s, 12H), 2.21 (q, J 
= 7.8 Hz, 8H), 4.27 (d, J = 6.9 Hz, 4H), 4.81 (t, J = 8.1 Hz, 4H), 5.89 (d, J = 6.9 Hz, 4H), 7.01 (s, 
4H); 13C NMR (100 MHz, CDCl3) δ 10.2, 14.1, 20.9, 32.1, 36.5, 98.5, 117.6, 127.6, 137.9, 153.2. 
Bridge resorcin[4]arene cavitand (2c): Pale yellow solid (89 %) yield. 1H NMR (250 
MHz, CDCl3) δ 0.90 (t, J = 6.5 Hz, 12H), 1.27-1.49 (m, 32H), 1.98 (s, 12H), 2.15-2.27 (m, 8H), 
4.25 (d, J = 7.0 Hz, 4H), 4.76 (t, J = 7.9 Hz, 4H), 5.88 (d, J = 7.0 Hz, 4H), 6.98 (s, 4H); 13C NMR 
(62.5 MHz, CDCl3) δ 10.3, 14.0, 22.6, 27.9, 29.5, 30.1, 31.9, 36.9, 98.4, 117.5, 123.6, 137.9, 153.2. 
Bridge resorcin[4]arene cavitand (2d): Pale orange oil (83 %) yield. 1H NMR (400 MHz, 
CDCl3) δ 0.90 (t, J = 6.3 Hz, 12H), 1.26-1.43 (m, 56H), 1.99 (s, 12H), 2.14-2.28 (m, 8H), 4.27 (d, 
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J = 6.8 Hz, 4H), 4.78 (t, J = 7.9 Hz, 4H), 5.89 (d, J = 6.8 Hz, 4H), 7.00 (s, 4H); 13C NMR (100 
MHz, CDCl3) δ 10.3, 14.1, 22.7, 27.9, 29.4, 29.7, 29.8, 30.1, 32.0, 36.9, 98.5, 117.6, 123.6, 137.9, 
153.2. 
 
General procedure for the synthesis of tetra-bromo cavitands (3a-d) 
Cavitand 2 (5.0 mmol) and AIBN (0.5 mmol) were dissolved in 100 mL benzene. NBS 
(22.0 mmol) was then added and the reaction mixture was refluxed for 4 hrs. After completion, 
the reaction mixture was allowed to cool in ice for 5 min. The crystallizine salt was then filtered 
out using a Buchner funnel and washed with chloroform or DCM. The solvent mixture was 
concentrated by rotovaporation and the product was re-crystallized from chloroform/hexane (3:7) 
or acetone.  
Tetra-bromo cavitand (3a): Pale yellow solid (89 %) yield. 1H NMR (400 MHz, CDCl3) 
δ 1.77 (d, J = 7.6 Hz, 12H), 4.33, (s, 8H), 4.43 (d, J = 6.9 Hz, 4H), 5.01 (q, J = 7.4 Hz, 4H), 5.95 
(d, J = 7.1 Hz, 4H), 7.29 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 16.0, 22.9, 31.1, 98.9, 120.4, 
124.3, 138.9, 153.1. 
Tetra-bromo cavitand (3b): Pale yellow solid (88 %) yield. 1H NMR (400 MHz, CDCl3) 
δ 1.04 (t, J = 7.2 Hz, 12H), 1.38 (q, J = 7.3 Hz, 8H), 2.21 (q, J = 7.7 Hz, 8H), 4.43 (s, 8H), 4.55 
(d, J = 6.9 Hz, 4H), 4.82 (t, J = 8.0 Hz, 4H), 6.02 (d, J = 6.9 Hz, 4H), 7.16 (s, 4H); 13C NMR (100 
MHz, CDCl3) δ 14.0, 20.8, 22.9, 32.0, 36.5, 99.0, 121.0, 124.5, 138.0, 153.5. 
Tetra-bromo cavitand (3c): White solid (93 %) yield. 1H NMR (250 MHz, CDCl3) δ 0.90 
(t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 2.15-2.27 (m, 8H), 4.43 (s, 8H), 4.55 (d, J = 7.0 Hz, 4H), 
4.79 (t, J = 7.9 Hz, 4H), 6.02 (d, J = 7.0 Hz, 4H), 7.14 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 
13.9, 22.5, 27.7, 29.4, 30.0, 31.7, 98.9, 120.8, 124.3, 137.8, 153.6. 
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Tetra-bromo resorcin[4]arene cavitand (3d): Pale orange oil (88 %) yield. 1H NMR (400 
MHz, CDCl3) δ 0.89 (t, J = 6.2 Hz, 12H), 1.25-1.43 (m, 56H), 2.17-2.28 (m, 8H), 4.42 (s, 8H), 
4.54 (d, J = 6.6 Hz, 4H), 4.79 (t, J = 7.6 Hz, 4H), 6.02 (d, J = 6.6 Hz, 4H), 7.14 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 14.1, 22.7, 22.9, 27.8, 29.3, 29.6, 31.9, 36.7, 99.0, 121.0, 124.5, 138.0, 153.5. 
 
General procedure for the synthesis of tetra-azido cavitands (4a-d) 
To a solution of tetra-bromo cavitand 3 (5.0 mmol) in 50 mL DMF, NaN3 (40.0 mmol) was 
added and the reaction mixture was allowed to stir at room temperature for 4-6 hrs. After 
completion, the salt was filtered out using Buchner funnel and the reaction mixture was extracted 
using 50 mL DCM and water (3 x 100 mL). The organic phase was collected and dried over 
Na2SO4. DCM was concentrated by rotovaporation and the product was re-crystallized using (2:3) 
acetone/MeOH. 
Tetra-azido cavitand (4a): White solid (90 %) yield. 1H NMR (250 MHz, CDCl3) δ 1.77 
(d, J = 7.4 Hz, 12H), 4.33 (s, 8H), 4.40 (d, J = 7.1 Hz, 4H), 5.01 (q, J = 7.4 Hz, 4H), 5.95 (d, J = 
7.1 Hz , 4H), 7.30 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 15.9, 31.1, 44.9, 99.6, 120.2, 122.1, 
138.9, 153.2. 
Tetra-azido cavitand (4b): White solid (95 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.04 
(t, J = 7.3 Hz, 12H), 1.36-1.45 (m, 8H), 2.24 (q, J = 7.8 Hz, 8H), 4.34 (s, 8H), 4.40 (d, J = 7.1 Hz, 
4H), 4.83 (t, J = 8.1 Hz, 4H), 5.95 (d, J = 7.1 Hz , 4H), 7.19 (s, 4H); 13C NMR (100 MHz, CDCl3) 
δ 13.9, 20.8, 32.0, 36.5, 45.0, 99.7, 120.7, 138.0, 153.6. 
Tetra-azido cavitand (4c): White solid (98 %) yield. 1H NMR (250 MHz, CDCl3) δ 0.91 
(t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 2.19-2.28 (m, 8H), 4.34 (s, 8H), 4.39 (d, J = 7.1 Hz, 4H), 
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4.80 (t, J = 7.9 Hz, 4H), 5.95 (d, J = 7.1 Hz , 4H), 7.17 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 
13.9, 22.5, 27.7, 29.3, 29.9, 31.7, 36.7, 44.9, 99.6, 120.6, 122.1, 137.9, 153.5. 
Tetra-azido cavitand (4d): Orange oil (94 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.90 
(t, J = 6.4 Hz, 12H), 1.25-1.43 (m, 56H), 2.15-2.29 (m, 8H), 4.34 (s, 8H), 4.39 (d, J = 6.6 Hz, 4H), 
4.77 (t, J = 7.9 Hz, 4H), 5.94 (d, J = 6.6 Hz, 4H), 7.16 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 
14.1, 22.7, 27.8, 29.6, 29.7, 31.9, 36.8, 45.1, 99.7, 120.8, 122.2, 138.1, 153.7. 
 
General procedure for the synthesis of tetra-alkyne cavitands (5a-d) 
NaH (60 %) (40.0 mmol) was added slowly to 50 mL ice cold THF and allowed to stir for 
5 min. Propargyl alcohol (40.0 mmol) was then added dropwise and the solution was allowed to 
stir for more 5-10 min. A solution of tetra-bromo cavitand 3 (5.0 mmol) in 10 mL of THF was 
added dropwise and the reaction mixture was refluxed overnight. After completion, the reaction 
mixture was quenched using MeOH followed by concentration of the solvent mixture over 
rotovapor. The crude mixture was extracted using 50 mL DCM and water (2 x 100 mL). The 
organic layer was collected and dried over Na2SO4 followed by the concentration of DCM. The 
product was re-crystallized from (2:3) DCM/MeOH. 
Tetra-alkyne cavitand (5a): White solid (80 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.75 
(d, J = 7.6 Hz, 12H), 2.46 (t, J = 2.4 Hz, 4H), 4.13 (d, J = 2.5 Hz, 8H), 4.43 (d, J = 7.4 Hz, 4H), 
4.45 (s, 8H), 5.02 (q, J = 7.3 Hz, 4H), 5.88 (d, J = 7.4 Hz, 4H), 7.35 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 16.0, 31.0, 53.4, 57.6, 61.5, 74.3, 79.8, 99.8, 119.9, 123.3, 138.6, 153.7. 
Tetra-alkyne cavitand (5b): White solid (83 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.03 
(d, J = 7.3 Hz, 12H), 1.35-1.44 (m, 8H), 2.21 (q, J = 7.8 Hz, 8H), 2.45 (d, J = 2.0 Hz, 4H), 4.13 
(d, J = 2.0 Hz, 8H), 4.43 (d, J = 7.3 Hz, 4H), 4.45 (s, 8H), 4.84 (t, J = 8.0 Hz, 4H), 5.87 (d, J = 
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7.3 Hz, 4H), 7.15 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 20.8, 32.1, 36.4, 57.7, 61.7, 74.4, 
79.9, 99.9, 120.7, 123.5, 137.8, 154.2. 
Tetra-alkyne cavitand (5c): White solid crystals (92 %) yield. 1H NMR (250 MHz, 
CDCl3) δ 0.90 (t, J = 6.5 Hz, 12H), 1.25-1.49 (m, 32H), 2.15-2.26 (m, 8H), 2.45 (t, J = 2.2 Hz, 
4H), 4.13 (d, J = 2.4 Hz, 8H), 4.42 (d, J = 7.3 Hz, 4H), 4.45 (s, 8H) 4.81 (t, J = 7.9 Hz, 4H), 5.87 
(d, J = 7.3 Hz, 4H), 7.14 (s, 4H); 13C NMR (62.5 MHz, CDCl3) δ 14.0, 22.6, 27.8, 29.4, 30.1, 31.8, 
36.8, 57.7, 61.7, 74.4, 80.0, 99.9, 120.6, 123.4, 137.8, 154.1. 
Tetra-alkyne cavitand (5d): Pale yellow viscous oil (88 %) yield. 1H NMR (400 MHz, 
CDCl3) δ 0.90 (t, J = 6.1 Hz, 12H), 1.25-1.43 (m, 56H), 2.18-2.24 (m, 8H), 2.45 (t, J = 2.2 Hz, 
4H), 4.13 (d, J = 2.4 Hz, 8H), 4.42 (d, J = 6.6 Hz, 4H), 4.45 (s, 8H), 4.78 (t, J = 7.6 Hz, 4H), 5.87 
(d, J = 6.6 Hz, 4H), 7.13 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 27.9, 29.3, 29.6, 31.9, 
36.7, 57.7, 61.7,  99.8, 120.6, 123.5, 137.8, 154.2. 
 
General procedure for the synthesis of cavitands (6a-d) 
Cavitand 4 (0.1 mmol) and 3-benzeloxy-1-propyne (0.8 mmol) were dissolved in 40 mL 
chloroform. CuI (0.01 mmol) and DIPEA (0.6 mmol) were then added and the reaction mixture 
was refluxed for 6 hrs. After completion, the reaction mixture was washed with ammonium 
hydroxide solution and the organic layer was collected and dried over Na2SO4. Chloroform was 
concentrated and the product was purified by column chromatography using (1:19) MeOH/DCM. 
Tetra-(1-benzyl-4-methyl benzoloxy-1H-1,2,3-triazole) cavitand (6a): Pale yellow 
solid (93 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.73 (d, J =  6.6 Hz, 12H), 4.24 (d, J = 7.1 Hz, 
4H), 4.54 (s, 8H), 4.62 (s, 8H), 4.94 (q, J = 6.8 Hz, 4H), 5.20 (s, 8H), 5.76 (d, J = 7.1 Hz, 4H), 
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7.23-7.32 (m, 24H), 7.51 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 16.0, 31.1, 43.9, 63.6, 72.5, 99.3, 
120.4, 120.8, 122.8, 127.7, 127.8, 128.3, 137.6, 138.9, 144.9, 153.2. 
Tetra-(1-benzyl-4-methyl benzoloxy-1H-1,2,3-triazole) cavitand (6b): Pale yellow 
solid (91 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.07 (t, J =  7.2 Hz, 12H), 1.37-1.45 (m, 8H), 
2.26 (q, J = 7.7 Hz, 8H), 4.30 (d, J = 7.2 Hz, 4H), 4.62 (s, 8H), 4.70 (s, 8H), 4.83 (t, J = 8.0 Hz, 
4H), 5.27 (s, 8H), 5.32 (d, J = 8.0 Hz, 4H), 7.31-7.38 (m, 24H), 7.59 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 14.0, 20.8, 32.0, 36.5, 43.9, 83.7, 72.5, 99.4, 120.6, 121.3, 122.8, 122.9, 127.7, 128.3, 
137.7, 138.0, 145.0, 153.7. 
Tetra-(1-benzyl-4-methyl benzoloxy-1H-1,2,3-triazole) cavitand (6c): Pale yellow 
solid (91 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.96 (t, J = 6.6 Hz, 12H), 1.37-1.50 (m, 32H), 
2.26-2.31 (m, 8H), 4.31 (d, J = 7.2 Hz, 4H), 4.64 (s, 8H) 4.72 (s, 8H), 4.81 (t, J = 7.9 Hz, 4H), 
5.21 (s, 8H), 5.84 (d, J = 7.2 Hz, 4H), 7.30-7.40 (m, 24H), 7.61 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 13.9, 22.5, 27.7, 29.3, 30.1, 31.7, 36.8, 43.9, 63.6, 72.5, 99.4, 120.5, 121.3, 122.9, 127.7, 
127.8, 128.3, 137.7, 138.0, 144.9, 153.7. 
Tetra-(1-benzyl-4-methyl benzoloxy-1H-1,2,3-triazole) cavitand (6d): Pale orange 
solid (94 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.90 (t, J = 6.1 Hz, 12H), 1.25-1.43 (m, 56H), 
2.18-2.24 (m, 8H), 4.23 (d, J = 6.6 Hz, 4H), 4.57 (s, 8H), 4.65 (s, 8H), 4.73 (t, J = 7.6 Hz, 4H), 
5.22 (s, 8H), 5.76 (d, J = 6.6 Hz, 4H), 7.19 (s, 4H), 7.26-7.33 (m, 20H), 7.54 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 14.1, 22.7, 27.8, 29.3, 29.6, 31.9, 36.9, 44.0, 63.7, 72.6, 99.4, 120.6, 122.8, 
123.5, 127.8, 128.3, 137.7, 138.1, 145.0, 153.7. 
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General procedure for the synthesis of cavitands (7a-d) 
Cavitand 5 (0.1 mmol) and benzyl azide (0.8 mmol) were dissolved in 40 mL chloroform. 
CuI (0.01 mmol) and DIPEA (0.6 mmol) were then added and the reaction mixture was refluxed 
for 6 hrs. After completion, the reaction mixture was washed with ammonium hydroxide solution 
and the organic layer was collected and dried over Na2SO4. Chloroform was concentrated and the 
product was purified by column chromatography using (1:19) MeOH/DCM. 
Tetra-(1-methyl benzyloxy-4-benzyl-1H-1,2,3-triazole) cavitand (7a): Pale yellow 
solid (91 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.68 (d, J = 7.3 Hz, 12H), 4.21 (d, J = 7.3 Hz, 
4H), 4.30 (s, 8H) 4.57 (s, 8H), 4.92 (q, J = 7.2 Hz, 4H), 5.54 (s, 8H), 5.56 (d, J = 7.3 Hz, 4H), 
7.17 (s, 4H), 7.28-7.31 (m, 8H), 7.33-7.37 (m, 12H), 7.62 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 
16.0, 30.9, 54.0, 62.0, 63.7, 99.4, 119.9, 123.2, 123.5, 128.1, 129.0, 134.8, 138.6, 145.0, 153.6. 
Tetra-(1-methyl benzyloxy-4-benzyl-1H-1,2,3-triazole) cavitand (7b): Pale yellow 
solid (92 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.00 (t, J = 7.2 Hz, 12H), 1.31-1.40 (m, 8H), 
2.13 (q, J = 7.9 Hz, 8H), 4.21 (d, J = 7.3 Hz, 4H), 4.30 (s, 8H), 4.58 (s, 8H), 4.35 (t, J = 8.1 Hz, 
4H), 5.54 (d, J = 7.3 Hz, 4H), 5.56 (s, 8H), 7.06 (s, 4H), 7.27-7.38 (m, 20H), 7.64 (s, 4H); 13C 
NMR (100 MHz, CDCl3) δ 14.1, 20.8, 32.0, 36.2, 54.0, 62.0, 63.8, 99.5, 120.4, 123.2, 123.6, 128.1, 
128.6, 129.0, 134.8, 137.6, 145.0, 154.0. 
Tetra-(1-methyl benzoloxy-4-benzyl-1H-1,2,3-triazole) cavitand (7c): Pale yellow 
solid (94 %) yield. 1H NMR (400 MHz, CDCl3) δ 1.12 (t, J = 6.4 Hz, 12H), 1.52-1.63 (m, 32H), 
2.34-2.44 (m, 8H), 4.42 (d, J = 7.2 Hz, 4H), 4.52 (s, 8H), 4.81 (s, 8H), 4.94 (t, J = 7.9 Hz, 4H), 
5.76 (d, J = 7.2 Hz, 4H), 5.78 (s, 8H), 7.49-7.58 (m, 24H), 7.87 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 13.9, 22.6, 27.8, 29.4, 30.1, 31.8, 36.7, 54.0, 62.0, 63.8, 99.5, 120.4, 123.6, 128.1, 128.6, 
128.9, 134.8, 137.6, 144.9, 153.9. 
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Tetra-(1-methyl benzyloxy-4-benzyl-1H-1,2,3-triazole) cavitand (7d): Pale yellow oil 
(93 %) yield. 1H NMR (400 MHz, CDCl3) δ 0.89 (t, J = 6.1 Hz, 12H), 1.21-1.44 (m, 56H), 2.10-
2.24 (m, 8H), 4.20 (d, J = 6.6 Hz, 4H), 4.30 (s, 8H), 4.59 (s, 8H), 4.71 (t, J = 7.6 Hz, 4H), 5.54 (d, 
J = 6.6 Hz, 4H), 5.56 (s, 8H), 7.04 (s, 4H), 7.28-7.41 (m, 20H), 7.67 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 14.1, 22.7, 27.9, 29.3, 29.6, 31.9, 36.7, 62.1, 63.9, 99.5, 120.4, 123.6, 128.1, 128.6, 
129.0, 134.8, 137.7, 154.0. 
 
General procedure for the synthesis of tetra-azido cavitands (8a-d) 
NaH (60 %) (40.0 mmol) was added slowly to 50 mL ice cold THF and allowed to stir for 
5 min. 2-azidoethanol (40.0 mmol) was then added dropwise and the solution was allowed to stir 
for more 5-10 min. A solution of tetra-bromo cavitand 3 (5.0 mmol) in 10 mL THF was added 
dropwise and the reaction mixture was then allowed to reflux overnight. After completion, the 
reaction mixture was quenched using MeOH followed by the concentration of solvent mixture 
over rotovapor. The crude mixture was extracted using 50 mL DCM and water (2 x 100 mL). The 
organic layer was collected and dried over Na2SO4 followed by the concentration of DCM. The 
product was re-crystallized out from (2:3) DCM/MeOH. 
Tetra-azido resorcin[4]arene cavitand (8a): White solid (91 %) yield. 1H NMR (400 
MHz, CDCl3) δ 1.73 (d, J = 7.4 Hz, 12H), 3.36 (t, J = 4.7 Hz, 8H), 3.60 (t, J = 4.8 Hz, 8H), 4.37 
(s, 8H), 4.41 (d, J = 7.3 Hz, 4H), 4.99 (q, J = 7.1 Hz, 4H), 5.86 (d, J = 7.1 Hz, 4H), 7.25 (s, 4H); 
13C NMR (100 MHz, CDCl3) δ 15.9, 31.1, 44.9, 99.6, 120.2, 122.1, 138.9, 153.2. 
Tetra-azido resorcin[4]arene cavitand (8b): White solid (89 %) yield. 1H NMR (400 
MHz, CDCl3) δ 1.04 (t, J = 7.2 Hz, 12H), 1.35-1.44 (m, 8H), 2.23 (q, J = 7.8, 14.9 Hz, 8H), 3.39 
(t, J = 5.1 Hz, 8H), 3.63 (t, J = 5.0 Hz, 8H), 4.39 (s, 8H), 4.42 (d, J = 7.3 Hz, 4H), 4.83 (t, J = 8.0 
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Hz, 4H), 5.88 (d, J = 7.3 Hz, 4H), 7.16 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 20.8, 32.1, 
36.5, 50.5, 63.1, 68.9, 99.8, 120.7, 123.5, 137.8, 154.1. 
Tetra-azido resorcin[4]arene cavitand (8c): White solid (92 %) yield. 1H NMR (400 
MHz, CDCl3) δ 0.91 (t, J = 6.5 Hz, 12H), 1.26-1.44 (m, 32H), 2.19-2.25 (m, 8H), 3.39 (t, J = 5.2 
Hz, 8H), 3.62 (t, J = 4.8 Hz, 8H), 4.39 (s, 8H), 4.42 (d, J = 7.3 Hz, 4H), 4.80 (t, J = 7.9 Hz, 4H), 
5.88 (d, J = 7.3 Hz, 4H), 7.14 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 13.9, 22.6, 22.8, 29.4, 30.1, 
31.8, 36.8, 50.5, 63.1, 68.8, 99.8, 120.6, 123.4, 137.8, 154.0. 
Tetra-azido resorcin[4]arene cavitand (8d): Pale yellow oil (84 %) yield. 1H NMR (400 
MHz, CDCl3) δ 0.90 (t, J = 6.1 Hz, 12H), 1.25-1.43 (m, 56H), 2.18-2.24 (m, 8H), 3.39 (t, J = 4.4 
Hz, 8H), 3.64 (t, J = 4.4 Hz, 8H), 4.39 (s, 8H), 4.42 (d, J = 6.6 Hz, 4H), 4.78 (t, J = 7.2 Hz, 4H), 
5.88 (d, J = 6.6 Hz, 4H), 7.14 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 27.9, 29.3, 29.6, 
31.9, 36.7, 50.5, 63.2, 68.9, 99.9, 120.7, 123.5, 137.8, 154.1. 
 
General procedure for the synthesis of RCC 5-8 via CuAAC. 
Alkyne cavitand 5 (0.1 mmol) and azido-cavitand 8 (0.1 mmol) were dissolved in 40 mL 
of chloroform. CuI (10 mol%) and DIPEA (0.6 mmol) were then added to the solution. The 
reaction mixture was refluxed for 2 days until the disappearance of the starting materials was 
observed by TLC. After completion, the reaction mixture was washed with ammonium hydroxide 
solution and the organic layer was collected and dried over Na2SO4. Chloroform was then 
evaporated and the product was purified by column chromatography using (1:19) MeOH/DCM 
solvent mixture. 
Resorcin[4]arene cavitand based carcerand 5 (RCC 5): Pale yellow solid (32 %) yield. 
Resorcin[4]arene cavitand based carcerand 6 (RCC 6): Pale yellow solid (39 %) yield. 
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Resorcin[4]arene cavitand based carcerand 7 (RCC 7): Pale yellow solid (89 %) yield. 
Resorcin[4]arene cavitand based carcerand 8 (RCC 8): Pale yellow solid (95 %) yield. 
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Appendix A 
Spectroscopic data for compounds of Chapter 1 
 
 
Figure A.1. 1H and 13C-NMR spectra of compound 1. 
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Figure A.2. 1H and 13C-NMR spectra of compound 2. 
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Figure A.3. 1H and 13C-NMR spectra of compound 3. 
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Figure A.4. 1H and 13C-NMR spectra of compound 4. 
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Figure A.5. 1H and 13C-NMR spectra of compound 5. 
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Figure A.6. 1H and 13C-NMR spectra of compound 6. 
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Figure A.7. 1H and 13C-NMR spectra of compound 7. 
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Figure A.8. 1H and 13C-NMR spectra of compound 8. 
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Figure A.9. 1H and 13C-NMR spectra of compound 9. 
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Figure A.10. 1H and 13C-NMR spectra of compound 10. 
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Figure A.11. 1H and 13C-NMR spectra of compound 11. 
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Figure A.12. 1H and 13C-NMR spectra of compound 12. 
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Figure A.13. 1H and 13C-NMR spectra of compound 13. 
 
 
Figure A.14. 1H and 13C-NMR spectra of compound 14. 
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Figure A.15. 1H and 13C-NMR spectra of compound 15. 
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Figure A.16. 1H and 13C-NMR spectra of compound 16. 
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Figure A.17. 1H and 13C-NMR spectra of compound 17. 
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Figure A.18. 1H and 13C-NMR spectra of compound 18. 
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Figure A.19. 1H and 13C-NMR spectra of compound 19. 
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Figure A.20. 1H and 13C-NMR spectra of RCG1. 
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Figure A.21. 1H and 13C-NMR spectra of RCG2. 
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Figure A.22. 1H and 13C-NMR spectra of RCG3. 
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Figure A.23. 1H and 13C-NMR spectra of RCG4. 
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Figure A.24. 1H and 13C-NMR spectra of RCG5. 
158 
 
 
 
Figure A.25. 1H and 13C-NMR spectra of compound X.
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Appendix B 
Spectroscopic data for compounds of Chapter 2 
 
 
Figure B.1. 1H and 13C-NMR spectra of thiazole 1b. 
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Figure B.2. 1H and 13C-NMR spectra of thiazole 2b. 
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Figure B.3. 1H and 13C-NMR spectra of thiazole 3b. 
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Figure B.4. 1H and 13C-NMR spectra of thiazole 4b. 
163 
 
 
 
Figure B.5. 1H and 13C-NMR spectra of thiazole 5b. 
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Figure B.6. 1H and 13C-NMR spectra of thiazole 6b. 
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Figure B.7. 1H and 13C-NMR spectra of thiazole 7b. 
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Figure B.8. 1H and 13C-NMR spectra of thiazole 8b. 
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Figure B.9. 1H and 13C-NMR spectra of thiazole 9b. 
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Figure B.10. 1H and 13C-NMR spectra of thiazole 14b. 
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Figure B.11. 1H and 13C-NMR spectra of thiazole 18b. 
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Figure B.12. 1H and 13C-NMR spectra of thiazole 19b. 
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Figure B.13. 1H and 13C-NMR spectra of thiazole 20b. 
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Figure B.14. 1H and 13C-NMR spectra of thiazole 21b. 
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Figure B.15. 1H and 13C-NMR spectra of thiazole 22b. 
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Figure B.16. 1H and 13C-NMR spectra of thiazole 23b. 
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Figure B.17. 1H and 13C-NMR spectra of thiazole 24b. 
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Figure B.18. 1H and 13C-NMR spectra of thiazole 25b.
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Appendix C 
Spectroscopic data for compounds of Chapter 3 
 
 
Figure C.1. 1H- and 13C-NMR spectra of compound 20. 
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Figure C.2. 1H- and 13C-NMR spectra of compound 21. 
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Figure C.3. 1H- and 13C-NMR spectra of RG. 
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Figure C.4. 1H- and 13C-NMR spectra of triazole 1c. 
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Figure C.5. 1H- and 13C-NMR spectra of triazole 2c. 
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Figure C.6. 1H- and 13C-NMR spectra of triazole 3c. 
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Figure C.7. 1H- and 13C-NMR spectra of triazole 4c. 
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Figure C.8. 1H- and 13C-NMR spectra of triazole 5c. 
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Figure C.9. 1H- and 13C-NMR spectra of triazole 6c. 
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Figure C.10. 1H- and 13C-NMR spectra of triazole 7c. 
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Figure C.11. 1H- and 13C-NMR spectra of triazole 8c. 
188 
 
 
 
Figure C.12. 1H- and 13C-NMR spectra of triazole 9c. 
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Figure C.13. 1H- and 13C-NMR spectra of triazole 10c. 
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Figure C.14. 1H- and 13C-NMR spectra of triazole 11c. 
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Figure C.15. 1H- and 13C-NMR spectra of triazole 12c. 
192 
 
 
 
Figure C.16. 1H- and 13C-NMR spectra of triazole 13c. 
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Figure C.17. 1H- and 13C-NMR spectra of triazole 14c. 
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Figure C.18. 1H- and 13C-NMR spectra of triazole 15c. 
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Figure C.19. 1H- and 13C-NMR spectra of triazole 16c. 
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Figure C.20. 1H- and 13C-NMR spectra of triazole 17c. 
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Figure C.21. 1H- and 13C-NMR spectra of triazole 18c. 
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Figure C.22. 1H- and 13C-NMR spectra of triazole 19c. 
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Figure C.23. 1H- and 13C-NMR spectra of triazole 20c. 
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Figure C.24. 1H- and 13C-NMR spectra of triazole 21c. 
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Figure C.25. 1H- and 13C-NMR spectra of triazole 22c. 
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Figure C.26. 1H- and 13C-NMR spectra of triazole 23c. 
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Figure C.27. 1H- and 13C-NMR spectra of triazole 24c. 
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Figure C.28. 1H- and 13C-NMR spectra of triazole 25c. 
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Figure C.29. 1H- and 13C-NMR spectra of triazole 26c. 
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Figure C.30. 1H- and 13C-NMR spectra of triazole 27c. 
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Figure C.31. 1H- and 13C-NMR spectra of triazole 28c. 
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Figure C.32. 1H- and 13C-NMR spectra of triazole 29c. 
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Figure C.33. 1H- and 13C-NMR spectra of triazole 30c. 
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Figure C.34. 1H- and 13C-NMR spectra of triazole 31c. 
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Figure C.35. 1H- and 13C-NMR spectra of triazole 32c. 
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Figure C.36. 1H- and 13C-NMR spectra of triazole 33c. 
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Figure C.37. 1H- and 13C-NMR spectra of triazole 34c. 
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Figure C.38. 1H- and 13C-NMR spectra of triazole 35c. 
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Figure C.39. 1H- and 13C-NMR spectra of triazole 36c. 
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Figure C.40. 1H- and 13C-NMR spectra of triazole 37c. 
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Figure C.41. 1H- and 13C-NMR spectra of triazole 38c. 
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Appendix D 
Spectroscopic data for compounds of Chapter 4 
 
 
Figure D.1. 1H and 13C-NMR spectra of compound 1a. 
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Figure D.2. 1H and 13C-NMR spectra of compound 1b. 
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Figure D.3. 1H and 13C-NMR spectra of compound 1c. 
221 
 
 
 
Figure D.4. 1H and 13C-NMR spectra of compound 1d. 
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Figure D.5. 1H and 13C-NMR spectra of compound 2a. 
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Figure D.6. 1H and 13C-NMR spectra of compound 2b. 
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Figure D.7. 1H and 13C-NMR spectra of compound 2c. 
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Figure D.8. 1H and 13C-NMR spectra of compound 2d. 
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Figure D.9. 1H and 13C-NMR spectra of compound 3a. 
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Figure D.10. 1H and 13C-NMR spectra of compound 3b. 
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Figure D.11. 1H and 13C-NMR spectra of compound 3c. 
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Figure D.12. 1H and 13C-NMR spectra of compound 3d. 
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Figure D.13. 1H and 13C-NMR spectra of compound 4a. 
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Figure D.14. 1H and 13C-NMR spectra of compound 4b. 
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Figure D.15. 1H and 13C-NMR spectra of compound 4c. 
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Figure D.16. 1H and 13C-NMR spectra of compound 4d. 
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Figure D.17. 1H and 13C-NMR spectra of compound 5a. 
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Figure D.18. 1H and 13C-NMR spectra of compound 5b. 
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Figure D.19. 1H and 13C-NMR spectra of compound 5c. 
237 
 
 
 
Figure D.20. 1H and 13C-NMR spectra of compound 5d. 
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Figure D.21. 1H and 13C-NMR spectra of compound 6a. 
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Figure D.22. 1H and 13C-NMR spectra of compound 6b. 
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Figure D.23. 1H and 13C-NMR spectra of compound 6c. 
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Figure D.24. 1H and 13C-NMR spectra of compound 6d. 
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Figure D.25. 1H and 13C-NMR spectra of compound 7a. 
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Figure D.26. 1H and 13C-NMR spectra of compound 7b. 
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Figure D.27. 1H and 13C-NMR spectra of compound 7c. 
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Figure D.28. 1H and 13C-NMR spectra of compound 7d. 
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Figure D.29. 1H and 13C-NMR spectra of compound 8a. 
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Figure D.30. 1H and 13C-NMR spectra of compound 8b. 
248 
 
 
 
Figure D.31. 1H and 13C-NMR spectra of compound 8c. 
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Figure D.32. 1H and 13C-NMR spectra of compound 8d. 
250 
 
 
 
Figure D.33. 1H and 13C-NMR spectra of RCC5. 
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Figure D.34. 1H and 13C-NMR spectra of RCC6. 
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Figure D.35. 1H and 13C-NMR spectra of RCC7. 
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Figure D.36. 1H and 13C-NMR spectra of RCC8. 
